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ABSTRACT
Colonic epithelium represents an important interface between the host and external 
environment serving both as a surface for absorption and a defence against ingested 
pathogens. Colonic epithelial cells may play an important role in inflammatory and immune 
reactions and participate in the communication between inflammatory and immune cells, 
probably via the generation of inflammatory mediators. The potential of human colonic 
epithelial cells to produce inflammatory mediators such as chemokines and nitric oxide and 
the modulation of this production were examined.
Colonic epithelial cells HT-29 were found to produce nitric oxide (NO) after stimulation with 
specific combinations of the pro-inflammatory cytokines IL-la, TNF-a and IFN-y. This NO 
generation was via the induction of the inducible nitric oxide synthase (iNOS), since iNOS 
mRNA and protein expression were observed after stimulation with cytokines. The T cell 
derived anti-inflammatory cytokines, IL-4 and IL-13 reduced significantly this NO generation 
and iNOS expression, while the other T cell derived cytokine, IL-10, had not a similar effect. 
Immunohistochemical study of human colonic biopsies revealed iNOS expression in colonic 
epithelial cells from patients with ulcerative colitis (UC) and infectious colitis, while the iNOS 
expression was absent in normal colonic mucosa or in colonic mucosa from infectious colitis 
patients in total remission.
Pro-inflammatory cytokines were found to induce chemokine expression in HT-29 cells. 
Stimulated cultures of HT-29 cells produced the CXC chemokine, IL-8 , and the CC 
chemokines MCP-1 and RANTES and expressed IL-8 , MCP-1, and RANTES mRNA. IL- 
13 and IL-4 were found to have a differential effect on CXC and CC chemokine generation 
by HT-29 cells, reducing significantly the MCP-1 and RANTES, but not the IL- 8  
expression and production. In addition, in immunohistochemical studies the neutrophil 
chemoattractant IL- 8  was found expressed in colonic epithelial cells and lamina propria 
cells in inflamed mucosa from UC and infectious colitis patients, while IL- 8  expression was 
not found in normal colonic mucosa.
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1.1 IMMUNOLOGICAL ROLE OF COLONIC EPITHELIUM
Colonic mucosa is the innermost layer of the large bowel wall. It consists of the colonic 
epithelium, which covers the absorptive surface and the crypts, and of the lamina propria, 
which is found immediately beneath the epithelium. Colonic epithelium is composed of 
colonic epithelial cells, that represent the main population, mucus secreting goblet cells 
and endocrine epithelial cells. Intraepithelial lymphocytes infiltrate throughout the 
epithelium. The primary function of the intestinal epithelium is the absorption of 
nutrients, water and electrolytes from the lumen to the body. However, during the last 
decades it has been realised that the epithelium itself is involved in various 
immunological and inflammatory processes.
The discovery of the molecular basis of how IgA antibodies function on the surface of 
epithelial cells demonstrated a new role of the intestinal mucosa. Tomasi in 1970 showed 
that mucosal IgA was synthesized by plasma cells as a dimer, which combine with 
secretory component (SC), a glycopeptide product of epithelial cells, to form secretory 
IgA (SIgA) (Tomasi, 1970). SC is a transmembrane polypeptide, which is preferentially 
expressed on the basolateral aspects of intestinal epithelial cells. This peptide protects the 
IgA dimer from luminal proteolysis (Mostov et al. 1984). In 1973 Brandtzaeg reported 
that IgM was also adapted to function at mucosal surfaces by binding SC to form 
secretory IgM (Brandtzaeg, 1973). The functional importance of SIgA was first shown in 
children vaccinated by the oral Sabin poliovirus vaccine. The intestinal epithelium 
represents an important interface between the host and external environment serving both as 
a surface for absorption and a defence against ingested pathogens (McKay & Perdue, 1993a; 
McKay & Perdue, 1993b). Both non-immune and immune mechanism protect the 
privileged environment of the lamina propria from challenge by foreign antigens.
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Intestinal motility, commensal microflora and mucous coat or glycocalyx comprise some 
of the non-specific protective barriers. The immune mechanisms may operate within the 
lumen of the gut, at the mucosal surface or within the lamina propria (Abreumartin & 
Targan, 1996). The intestinal epithelial cells constitute a barrier between the environment 
and the host tissue and they are the first cells to come in contact with many pathogens. From 
this position intestinal epithelial cells might play a crucial role as an outpost of the immune 
system located in the underlying intestinal mucosa and soluble mediators produced by these 
cells might function as an early signal to neighbouring immune cells and are involved in the 
recruitment of cells during the inflammatory response. Finally, the interplay between the 
colonic epithelial cells and intraepithelial lymphocytes (IEL) may complete the 
immunological role of colonic mucosa.
It is thought that IEL may play a central role in local intestinal immunity and are likely to 
be important in immunity to gastrointestinal neoplasms and rejection responses to gut 
allografts. However, the biology of IEL and their unusual immunological 
microenvironments in the gastrointestinal mucosa are little understood (Croitoru & 
Ernest, 1992; Cerf-Benussan & Gay-Grand, 1991). The IEL comprise two populations. 
The predominant group is the CD8 + suppressor-cytolytic subset of T lymphocytes (Ts) 
which display the cx/p T cell receptor (TCR) and show evidence of activation. The second 
group of T cells bears the y/ 8  form of TCR. These T cells are mostly CD4\ Most of the 
lamina propria T lymphocytes belong to the CD4+ helper-inducer subset (Th) and y/5 cells 
are rare (Trejdosiewicz, 1992).
A role for colonic epithelial cells in inflammatory and immune reactions is increasingly 
recognised. These cells present antigens via class II molecule expression and act as antigen 
presenting cells to T cells (Mayer et al. 1991; Lowes et al. 1992). Class II MHC 
determinants are expressed on normal small intestinal epithelial cells but not on colon 
epithelial cells unless the colon is inflamed (Selby et al. 1983). Colonic epithelial cells in
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Gai-deficient mice with colitis were found by immunohistochemistry to express 
increased levels of both MHC class I and class II antigens (Homquist et al. 1997). 
Expression of Class II antigens may be modulated by IFN-y produced by activated CD8 + 
T cells in the epithelium (Cerf-Bensussan et al. 1984). The expression of HLA molecules 
by colonic epithelial cells was found to activate CD3+/CD8+ IEL (Hoang et al. 1992). 
Colonic epithelial cells express adhesion proteins such as intercellular adhesion molecule-1 
(Kaiserlian et al. 1991; Kvale & Brandtzaeg, 1995) and generate soluble inflammatory 
mediators e.g. arachidonic acid derivatives (Gustafson & Tagesson, 1990; Dias et al. 1992), 
platelet activating factor (Ferraris et al. 1993), cytokines (Hedges et al. 1992; Eckmann et 
al. 1993; Schuerer-Maly et al. 1994; Kolios & Nakos, 1995; Gross et al. 1995), and 
chemokines (Mazzucchelli et al. 1994; Jung et al. 1995), all of which contribute to the 
communication between inflammatory cells and cells of the immune system (Sartor, 1994). 
Colon epithelial cells appear to be programmed to provide a set of signals for the 
activation of the mucosal inflammatory response in the earliest phases after microbial 
invasion (Jung et al. 1995). The involvement of colonic epithelial cells in immune and 
inflammatory reactions in inflammatory bowel disease is discussed below in detail.
1. 2 INFLAMMATORY BOWEL DISEASE
The term inflammatory bowel disease (IBD) describes two major pathological conditions 
involving the gastrointestinal tract, ulcerative colitis (UC) and Crohn’s disease (CD). In 
UC the inflammatory disorder is superficial in the mucosa and submucosa and limited to 
the large bowel, affecting the rectum and a variable extend of the colon. Histologically, 
the disease is characterised by an infiltration of both acute and chronic inflammatory cells 
in the lamina propria and the crypts forming microabscesses. The deeper layers of the 
intestinal wall are characteristically not involved. CD is a transmural inflammation that 
may occur anywhere throughout the alimentary tract from the mouth to the anus. The 
disease can affect the deeper layers of the bowel wall producing superficial and deep
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ulceration and also leading to collagen deposition and fibrosis. The cellular infiltration 
consists of lymphocytes and macrophages and the presence of granulomas is a 
predominant feature of the disease. Both of these diseases are characterised by chronic 
relapses and associated with many extraintestinal manifestations.
Despite extensive investigation over the last decades the aetiology and pathogenesis of 
both major forms of IBD remains unknown. Increasing evidence suggests that these two 
disorders are partly and possibly wholly distinct in their initial aetiological event, but they 
share important common pathogenetic mechanisms. It is likely that the aetiology of IBD 
is not a single cause and effect relationship and probably represents an interaction 
between various agents. A number genetic predisposing factors, exogenous and 
endogenous triggers and modifying factors is involved and their interaction is an 
inflammatory process, in which tissue injury seem to be mediated by the immune system 
(Shanahan, 1993). The prognosis of ulcerative colitis and Crohn's disease is much 
improved over the years, but an aetiologic cure has not yet been found, re-emphasising 
the need for further investigation of these challenging diseases. Until the cause of these 
diseases has been clearly identified therapeutic strategies for these conditions must be 
based on interrupting the immunopathogenetic mechanisms involved and inhibiting the 
gut inflammation; hence the widespread use of immunosuppressives in their treatment 
(MacDonald & Murch, 1994). In the following section, I review the recent clues in 
aetiology and pathogenesis of IBD, concentrating mostly on immunological mechanisms, 
since the local immune response probably causes the tissue damage in these diseases.
1.2.1 Aetiology of IBD
The cause of IBD is likely to be multifactorial. Although the aetiology of IBD remains 
obscure, a number of genetic, environmental, microbial, and immunologic factors 
responsible for the cause of this disorder have been suggested and multiple aetiological 
theories have been proposed.
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Genetics. Genetic influence in the susceptibility to IBD is suggested by racial, ethnic, and 
familial aggregation of disease (Pena et al. 1993). Both CD and UC are familial. Between 
10% and 20% of close relatives may also be affected. Patients with CD have a stronger 
family history than patients with UC. Further support for a stronger genetic influence in 
Crohn’s disease has come from studies of twins (Ellis, 1995). Increased concordance for 
IBD in monozygotic compared with dizygotic twins suggests that genetic rather than 
environmental factors are primarily responsible for the familial aggregation. The 
concordance rate of monozygotic twins with CD is higher than of twins with UC (Tysk et 
al. 1988). Although these observations suggest the existence of genetic factors in the 
aetiology of IBD they do not support a simple mendelian pattern of inheritance. The 
search for a specific genetic marker has been disappointing. At present, HLA class II 
antigens are most in focus, but also genetic markers such as the antineutrophil- 
cytoplasmic-autoantibodies (p-ANCA) are strongly associated with UC and may represent 
an indicator of genetic susceptibility to UC (Jamerot, 1996). The well recognised 
association of HLA antigens with diseases, as for example the ankylosing spondylitis and 
sclerosing cholangitis, that occur in association or as complications with IBD is indirect 
evidence for a genetic relation of these antigens with IBD. Many studies have reported an 
association of IBD with HLA-DR (Asakura et al. 1982; Kobayashi et al. 1990; Toyoda et 
al. 1993) and one of them found an even stronger association with DWQ1 (Kobayashi et 
al. 1990). Genes of the major histocompatibility complex are implicated as important 
inherited determinants of susceptibility to UC and may also influence the pattern of 
disease. In CD, important susceptibility genes are likely to exist outside the HLA region 
(Satsangi et al. 1996). Recently, it has been have shown that the TNF-a 2blc2d4el allelic 
combination is the strongest genetic risk factor described in CD and, with HLA class II 
alleles, defines a group of markers on chromosome 6  that extends from HLA class II to 
upstream of the TNF-beta gene (Plevy et al. 1996). The IL-lra gene is a marker for 
genetic susceptibility and severity in UC and contributes to the definition of the
i
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immunogenetic heterogeneity of the disease (Bioque et al. 1995; Bioque et al. 1996). 
Future studies using molecular biologic technology with highly informative polymorphic 
genetic markers should permit successful identification of possible IBD-susceptibility 
genes.
Diet. It is reasonable to propose that dietary factors, for example acting as antigens, play a 
role in the initiation of intestinal inflammation, but there is less evidence to support this 
hypothesis in UC than in CD. In UC, a minority of patients improve on avoidance of 
cow’s milk, but intravenous feeding, which would be expected to prove beneficial, was 
not found effective, on the other hand, in patients with CD, elemental diets appear to have 
a therapeutic effect, although the mechanism by which this occurs is uncertain (O'Morain 
et al. 1984; Mishkin, 1997). The role of dietary antigens in the aetiology of CD is 
controversial. Controlled studies have suggested that elemental diets may be as effective as 
corticosteroids in inducing a remission in patients with acute CD (Okeefe, 1996), however, 
corticosteroids are more effective than enteral nutrition in the treatment of active CD 
(King, 1995). Favourable reports of the value of exclusion diets (Riordan et al. 1993), or 
specific diets (Campbell et al. 1997) have not been confirmed by other workers. Patients 
with elevated yeast antibodies tended to develop a higher CD activity. These results 
suggest that dietary yeast may affect the activity of CD, but does not necessarily implicate 
them as aetiological factors (Barclay et al. 1992). A population-based case-control study of 
IBD and dietary habits has shown that the relative risk of CD was increased for subjects 
who had a high intake of sucrose and was decreased for subjects who had a high intake of 
fibre (Persson et al. 1992). UC patients also consumed more total protein than controls 
(Tragnone et al. 1995). Recently, an enteric-coated preparation of fish oil has been shown 
to be effective in patients with CD, and it seem prudent to promote a diet rich in fish oil in 
patients with CD (Kim, 1996).
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Infection. A wide variety of infective agents has been suspected to initiate, and/or trigger 
relapse of IBD. Relapse of UC has been documented in association with proven infection 
with shigella (Felsen, 1936), salmonella (Lindeman et al. 1967), Campylobacter jejuni 
(Newman & Lambert, 1990), Clostridium difficile (Bolton et al. 1980), aeromonas 
(Willoughby et al. 1989) entamoeba histolytica (Rampton et al. 1983) and 
cytomegalovirus (Berk et al. 1985). Pathological resemblances between CD , tuberculosis 
and John’s disease in cattle, which is caused by Mycobacterium paratuberculosis, have 
evoked intense study of the possible aetiological role of the latter organism (Ciclitira, 
1993; Mishina et al. 1996), but data from other studies do not support a role for M. 
paratuberculosis in Crohn's disease (Dumonceau et al. 1996; Suenaga et al. 1995; 
Rowbotham et al. 1995). Recently a paramixovirus, possibly measles, have been identified 
in the vascular endothelium of CD intestine (Ciclitira, 1993; Wakefield et al. 1993). 
Recent epidemiological data support the idea that early exposure to measles virus in 
childhood is a risk factor for the later development of CD (Wakefield, 1995; Thompson et 
al. 1995b; EJcbom et al. 1994), but also of UC (Thompson et al. 1995a). Furthermore data 
indicate that exposure of mothers to measles virus in utero is a risk factor for CD in their 
children (Ekbom et al. 1996). These data are consistent with the possibility that CD may 
be a chronic granulomatous vasculitis in reaction to a persistent infection with measles 
virus within the vascular endothelium (Wakefield et al. 1995; Wakefield et al. 1997), but 
this hypothesis merits further study. Detection of organisms in IBD patients does not of 
course necessarily establish them as primary aetiological factors. The delicate balance 
between luminal microbial constituents and protective mucosal forces can be disturbed by 
genetically determined immunoregulatory abnormalities and environmental triggers, 
leading to chronic, relapsing intestinal inflammation (Sartor et al. 1996b). Furthermore, it 
seems unlikely that a specific infection could alone explain the chronically relapsing and 
remitting natural history of IBD. More probably, one or more infective agents, or their 
products, trigger IBD, as a hit and run event, by stimulation of an inappropriately hyper- 
responsive mucosal immune system (MacPherson etal. 1996).
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Mucus. The oligosaccharide side chains of mucus glycoproteins are shorter in patients 
with UC than controls, and show altered binding patterns with monoclonal antibodies and 
lectins (Stevens et al. 1992; Podolsky & Fournier, 1988; Rhodes et al. 1988). Compared 
with healthy subjects, the different biochemical features of the mucin obtained from whole 
gut lavage fluid from IBD patients appear to reflect mucosal pathological changes 
associated with the disease (Saitoh et al. 1996). MUC2 is the predominant mucin in the 
human colon responsible for the protective mucus layer. MUC2 precursor biosynthesis 
and total MUC2 levels were significantly decreased in UC patients with active 
inflammation compared to controls, and returned to control values during remission of the 
inflammation (Tytgat et al. 1996). Colonic mucin is heavily sulphated and it has been 
shown that enzymatic desulphation by faecal bacterial sulphatases greatly increases its 
susceptibility to degradation by faecal glycosidases. The increased faecal mucin sulphatase 
activity in UC could be the result of greater intraluminal substrate (mucin) availability 
leading to bacterial enzyme induction, but would probably result in more rapid degradation 
of secreted mucin and represents a potential target for treatment (Tsai et al. 1995). The 
striking increase in mucin synthesis that results when butyrate is added to standard nutrient 
medium in colonic biopsy cultures, suggests that this may be an important mechanism 
affecting the rate of mucin synthesis in vivo and may also explain the therapeutic effect of 
butyrate in colitis (Finnie et al. 1995). Nicotine, and possibly smoking, may affect colitis 
by an action on mucosal eicosanoids and on adherent surface mucus increased secretion in 
the rectum and large bowel (Cohen & Hanauer, 1996; Zijlstra et al. 1994). The marked 
stimulation of mucin synthesis by corticosteroids suggests that this may account, at least in 
part, for their therapeutic effect in UC (Finnie et al. 1996).
Mucosal permeability. Blood lactulose concentration in patients with IBD were found 
significantly increased over the controls, representing an increase of intestinal permeability 
in patients with IBD. This increase of blood lactulose may represent a disturbance of the 
intestinal barrier function due to mucosal changes such as erosion, ulceration, and oedema
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(Hollander, 1992). Patients with CD have increased mucosal permeability to small 
molecular weight probes such as Cr-EDTA (Bjamason & Peters, 1987). Lindberg et al 
using a group of monozygotic twin pairs concordant and discordant for CD were found no 
differences in the absorption of polyethylene glycols between the study groups (Lindberg 
et al. 1995). These results give no support to the hypothesis of a genetically determined 
intestinal leakiness in CD. In another study the intestinal permeability and the immune 
response to enteric bacterial antigens in patients with inactive CD were significantly 
increased over those in the controls as well as in patients with inactive UC (Oriishi et a l
1995). Whether increased gut permeability in CD is a primary abnormality predisposing to 
increased mucosal access of luminal pathogenic factors, or is simply a consequence of 
mucosal damage induced by other mechanisms is not yet resolved.
Colonocyte energy metabolism. Over the past decade it has become evident that normal 
colonic epithelium depends largely on short chain fatty acids (SCFA) derived from 
luminal bacterial metabolism for its energy supply. The principal SCFAs, acetate, 
propionate, and butyrate, are formed by bacterial fermentation of unabsorbed 
carbohydrates (Cummings & MacFarlane, 1991) and tend to be present in colonic contents 
in relatively constant concentrations and proportions (Mortensen et al. 1991). SCFAs are 
absorbed from the colonic lumen (Ruppin et al. 1980), and once inside the colonocytes, 
the cellular oxidation of SCFAs is considered to be the major energy source for the 
epithelial cells (Roediger, 1980b). In UC, colonocytes appear less able to utilise butyrate 
as an energy source and low luminal SCAF levels in severe UC may exacerbate this defect 
(Roediger, 1980a). SCFA are potentially valuable as a topical therapy for distal UC. 
Treatment with SCFA enemas were found to have therapeutic benefit in patients with 
distal UC (Breuer et al. 1997). The mechanism of action is unknown, but evidence that 
butyrate oxidation is impaired in colonocytes isolated from patients with UC has led to the 
hypothesis that failure of fatty acid oxidation in UC is an expression of an energy 
deficiency disease of the colonic mucosa (Breuer et al. 1991). Isolated human colonocytes
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were found capable of utilising each of the three major SCFAs. Kinetic studies on 
colonocyte metabolism have shown a specific role of butyrate as an energy source for the 
colonic mucosa in both health and UC without support for either a pathogenic role for 
defective metabolism of butyrate in UC (Clausen & Mortensen, 1995) or to define whether 
abnormal colonic epithelial SCFA utilisation in UC is a primary or secondary 
phenomenon.
Cigarette smoking. UC is primarily a disease of non-smokers (Harries et al. 1982). The 
risk of developing disease after cessation of smoking is 'dose-related' by pack-years, and 
former smokers may be at higher risk than non smokers. In marked contrast CD is less 
favourable in smokers than in non-smokers (Breuerkatschinkski et al. 1996) and patients 
with CD should be dissuaded from smoking (Lindberg et al. 1992). Nicotine in chewing 
gum and transdermal patches has been shown to improve clinical symptoms and 
endoscopic appearance in patients with active UC, although no maintenance benefit has 
been seen (Cohen & Hanauer, 1996; Pullan et al. 1994), while topical administration of 
nicotine may be useful treatment for distal UC (Green et al. 1997). Proposed mechanisms 
for the 'protective' effect of nicotine in ulcerative colitis include modulation of the humoral 
and cellular immune response, increase mucus (Finnie et al. 1996), decreased mucosal 
eicosanoid levels (Zijlstra et al. 1994), alteration of rectal mucosal blood flow, decreased 
intestinal permeability, release of endogenous glucocorticoids (Cope & Heatley, 1992). 
Nicotine was found to cause a significant inhibition of IL-2 and TNF-alpha production 
(Vandijk et al. 1995; Madretsma et al. 1996), and an inhibitory effect on Th2 cell function 
as measured by inhibition of IL-10 production (Madretsma et al. 1996). The beneficial 
effects of smoking and nicotine in CD could be attributed to this inhibition, however, why 
UC and CD have such different relationship to smoking is at present a mystery.
Drugs NSAIDs have been associated with initiation and relapse of IBD, changes in 
eicosanoid metabolism and gut permeability being two possible mechanisms (Rampton,
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1987). Although the confounding effects of concurrent smoking are difficult to exclude 
altogether (Katschinski et al. 1993), there appears to be an increased risk of CD in users of 
the oral contraceptive pill (Lesko et al. 1985; Boyko et al. 1994), perhaps as a result of the 
prothrombotic effects of the drug. This increased risk for IBD seem to be due to the 
thromboembolic disorders and intestinal ischaemia caused by the oral contraceptives, 
which trigger a chain of events that culminate in clinical IBD (Koutroubakis et al. 1996). 
Anecdotal reports relate antibiotic usage to relapse of IBD, but this could be due to 
changes in colonic bacterial flora or colonic ischaemia.
Psychological factors Although most physicians and some patients consider psychosocial 
factors important in aggravating already existing IBD and patients often comment that 
emotional stress triggers relapse, formal studies have not shown any influence of stressful 
life events on the natural history of IBD (North et al. 1991), while studies have shown that 
there are substantial personality differences between patients with CD and UC (Barrett et 
al. 1996). Stress is associated with alterations in both humoral and cellular immune 
mechanisms in humans and in experimental animals and mind-gut interactions affect 
salivation, gastric secretion, gastric motility and colonic motility, as well as numerous 
other gastrointestinal functions. While psychosocial factors may not initiate inflammation 
in IBD, it is possible that they lead to alterations in the immune response and thereby alter 
disease activity (Bayless, 1995). In the 1970s and early 1980s, several studies accurately 
identified that the cause of IBD was not psychosomatic, but rather that patients with these 
diseases had higher levels of stress and anxiety as a result of the diagnosis of a chronic 
disease (Talal & Drossman, 1995).
1 .2 .2  Pathogenesis of IBD
Although the primary aetiological agents in IBD is still elusive, we now know that disease 
activation involves an early increase in expression of surface adhesion molecules on
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vascular endothelial cells, with consequent diapedesis and activation of circulating 
leukocytes in gut mucosa (Schuermann et a l 1993; Koizumi et a l 1992), and an increased 
synthesis and release of a wide range of inflammatory mediators and cytokines likely to 
contribute to the clinicopathological features of IBD. The sources of these mediators 
include not only resident and newly recruited mucosal inflammatory cells such as 
neutrophils, macrophages and mast cells, but also platelets, colonic epihelial cells, 
vascular endothelial cells, fibroblasts, smooth muscle cells and enteric neurons 
(MacDonald & Murch, 1994).
Prostaglandins. Eicosanoids seem to be implicated in the pathophysiology of IBD (Yang, 
1996), as concentrations of all eicosanoids and soluble Fc gamma receptors (sFc gamma 
RlUb) were found significantly increased in gut lavage fluid from patients with IBD 
(Hommes et a l 1996). Efforts have been made to inhibit the production of potentially 
damaging eicosanoids. Diets with fish oil changes intestinal eicosanoid synthesis, 
however, its utility in patients with active or inactive inflammatory disease is controversial 
(Casellas & Guamer, 1996). Historically, the prostaglandins (PG) were the first 
eicosanoids to be studied in IBD, their increased production in active disease being shown 
by a variety of methods including in vitro culture of colorectal biopsies and in vivo rectal 
dialyses (Rampton & Hawkey, 1984; Lauritsen et al 1989; Baumeister et a l 1996). 
Luminal release of PGE2 was found significantly higher in patients with CD than in 
control subjects. Furthermore, there was a modest, but significant increase in luminal 
PGE2 in first-degree relatives and suggested that this increased synthesis of prostaglandins 
may constitute a response to altered genetic mucosal characteristics (Ahrenstedt et a l 
1994). The increased PGE2 production found in the inflamed mucosa in active UC may be 
caused by a fraction of activated eosinophils and macrophages (Raab et al 1995). 
Theoretically at least, increased prostaglandin synthesis in IBD could account for 
diarrhoea, by inducing mucosal secretion of water and electrolytes and through effects on 
intestinal motility (Schmitz et a l 1996), it could also have a mucoprotective effect by
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increasing mucus release, altering mucosal blood flow and suppressing immune and 
inflammatory cell function (Rampton & Hawkey, 1984; Lauritsen et al. 1989; Rampton & 
Collins, 1993). 5-aminosalysilate (5-ASA), which is successfully used in the treatment of 
IBD, did not affect the PGE2 production in colonic mucosa, but decreased the LTB4 
synthesis in a dose related fashion (Schmidt et al. 1996). In addition the adverse effects of 
NSAIDs in IBD could be related to inhibition of prostaglandin synthesis (Davies, 1995).
Leukotrienes Leukotrienes are involved in the inflammatory processes of intestinal 
lesions. Many studies, both in vitro and in vivo, have shown increased mucosal production 
of leukotrienes in patients with active IBD (Rampton & Hawkey, 1984; Lauritsen et al. 
1989; Cole et al. 1996; Baumeister et al. 1996). Colonic biopsies from untreated patients 
with active IBD showed a significant increase in LTB4  synthesis compared with healthy 
controls. However, in patients receiving steroids, sulphasalazine or 5-aminosalicylic acid, 
LTB4 was markedly decreased. Drugs effective in the treatment of these diseases may 
exert their pharmacological action by normalising these pathological findings (Schmidt et 
al. 1995). These compounds are likely to contribute to mucosal inflammation principally 
by their effects on the recruitment and activation of neutrophils. Inflamed colonic mucosa 
was found to release more neutrophil movement inducing bioactivity than uninflamed 
mucosa, and to have greater LTB4  dependent activity (Cole et al. 1996). Selective 
leukotriene inhibitors and receptor antagonists are currently under evaluation in the 
treatment of IBD (Roberts et al. 1997) and Zileuton, a 5-lipoxygenase inhibitor, was found 
beneficial in IBD (Hawkey et al. 1997). This effect may be related to an increased and 
maintained production of PGE2 together with inhibition of LTB4  synthesis (Bertran et al.
1996). Importantly, the reported experience to date has shown that the leukotriene 
inhibitors do not have the same side-effects as the current therapies, promising that both 
safe and effective treatment may be derived from this approach (Harris et al. 1997).
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Thromboxanes. Thromboxanes are produced in excess not only in inflamed mucosa, but 
also in CD by uninflamed bowel and by isolated intestinal and peripheral blood 
mononuclear cells (Rampton & Collins, 1993). Their pro-inflammatory effects are both 
direct (diapedesis and activation of neutrophils, mucosal ulceration, reduction of 
suppressor T-cell activity) and indirect (vasoconstriction, platelet activation) (Rampton & 
Collins, 1993). Indeed, multifocal microvascular infraction has been proposed as an early 
pathogenic factor in CD (Wakefield et al. 1989), in which increased platelet aggregation 
and activation is common (Collins et al. 1994), and it is possible that enhanced 
thromboxane production contributes to these phenomena. Low dose aspirin will 
selectively inhibit a proportion of rectal thromboxane and may have prophylactic 
therapeutic potential in IBD (Cole et al. 1994). Selective thromboxane synthesis inhibitors 
and receptor antagonists such as picotamide and ridogrel are available for use in man and 
each has been found promising in studies in IBD (Casellas et al. 1995; Collins et al. 1996). 
The classical therapeutic drugs used in IBD, namely corticosteroids and derivatives of 
sulfasalazine, have significant effects on eicosanoid synthesis, providing evidence for their 
role in IBD. In the future, specific subgroups of patients with IBD may benefit from new 
eicosanoid inhibitors (Casellas & Guamer, 1996).
Platelet activating factor Recent data shows increased synthesis and content of platelet 
activating factor (PAF) in the colorectal mucosa of patients with UC and correlated to 
local injury and inflammation (Guimbaud et al. 1995; Wardle et al. 1996). In contrast, 
other studies did not find high concentrations of PAF in the rectal mucosa of patients with 
active UC compared with patients in remission or controls, and they suggested that PAF 
has not an important role as a mediator of inflammation of UC (Aimer et al. 1996). PAF 
stimulates mucosal chloride secretion and inhibits sodium chloride absorption (Bern et al. 
1989), so it could contribute to the production of diarrhoea in UC. The PAF receptor 
antagonist lexipafant (BB-882) shows efficacy in treating inflammation in an animal 
model of acute colitis as evidenced by a dose-dependent fall in macroscopic mucosal
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damage, neutrophil infiltration and reduced generation of inflammatory mediators 
(Meenan et al. 1996). However, there have been no published reports of the effects of PAF 
antagonists in human IBD, and the pathogenic importance of this mediator remain 
uncertain.
Biogenic amines Patients with UC have increased rectal mucosal release of histamine 
(Rampton et al. 1980). In recent studies, histamine content and secretion were found to be 
significantly increased particularly in affected mucosa of CD and UC than in unaffected 
tissue or in healthy controls. These findings give strong evidence that mast cell mediators 
like histamine play a role in the pathogenesis of these diseases (Raithel et al. 1995). This 
increased histamine secretion could contribute to vasodilatation, increased vascular 
permeability, sensory nerve activation, smooth muscle contraction and mucosal fluid and 
electrolyte secretion in intestinal inflammation.
Kinins Increased secretion of kinins occurs in animal models of colitis but has not been 
reported in IBD (Lauritsen et al. 1989). Kinins have many biological effects, including 
vasodilatation, increased vascular permeability, mobilisation of blood cells and mucosal 
fluid secretion, that appear to be mediated by eicosanoids. The kallikrein-kinin (K-K) 
system has suggested to be directly involved in the pathogenesis of the acute phase of 
experimental acute intestinal inflammation (Stadnicki et al. 1996). Activation of the K-K 
system plays an important role in experimental models of inflammation, suggesting that 
activation of this system may play a role in the pathogenesis of IBD and suggests that this 
pathway is one determinant of genetic susceptibility to granulomatous enterocolitis and 
systemic complications (Delacadena et al. 1991; Sartor et al. 1996a).
Proteases Studies of the tissue levels of phagocyte-derived proteases have given 
conflicting results. Acid proteases derived from the secondary granules of neutrophils are 
present in increased amounts in IBD mucosa (Kane & Vincenti, 1979; O'Morain et al.
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1983), but levels of the constituents of primary granules (elastase, cathepsin D, 
chymotrypsin) are increased (Seitz et al. 1995), normal or decreased (Kane & Vincenti, 
1979). In a rabbit model of chronic colitis, collagenase was found to be associated with the 
acute phase of ulcer formation, whereas stromelysin and gelatinase are predominant during 
healing (Anthony et al. 1994). Gastrointestinal epithelium contains a powerful protease 
inhibitor called pancreatic secretory trypsin inhibitor (PSTI). Reduction in mucosal PSTI 
in UC patients may be related with changes in mucus structure suggestive of increased 
proteolysis (Playford et al. 1995). While direct measurements of tissue concentrations of 
proteases can be complicated by autoactivation, it is conceivable that enzyme activity 
contributes to mucosal damage in IBD by degradation of elastin, collagen and other 
connective tissue proteins. The effects of protease inhibitors in human IBD has not been 
assessed.
Reactive oxygen species The production of reactive oxygen species (ROS) was found 
increased in inflamed tissue, peripheral blood monocytes and isolated intestinal 
macrophages from patients with IBD (Simmonds & Rampton, 1993; Grisham, 1994). 
Levels of endogenous antioxidants, such as superoxide dismutase, metallothionein and 
glutathione peroxidase, were found reduced (Lihbrody et al. 1996). Activation of 
granulocytes and monocytes/macrophages at the site of inflammation increases the 
production of reactive oxygen metabolites both in animal models of experimental 
intestinal injury, and in IBD (Gross et al. 1994). Evidence of ROS-mediated tissue damage 
comes from detection of lipid peroxidation in mucosal biopsies in active UC (Anhfelt- 
Ronne et al. 1990). ROS have a wide range of pro-inflammatory actions which are likely 
to contribute to the pathogenesis of IBD, a conclusion made more credible by preliminary 
reports of the beneficial effects of antioxidant agent such as superoxide dismutase (Emerit 
et al. 1989), allopurinol and dimethylsulphoxide (Salim, 1992), and tirilazad mesylate 
(Yue et al. 1996) in IBD. Some of the anti-inflammatory actions of aminosalicylates have 
been ascribed to their capability to scavenge superoxide radicals directly or to inhibit its
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production in stimulated neutrophils (Allgayer et al. 1994). Oxidation and inhibition of 
essential protein function by inflammatory cells is a potential mechanism of tissue injury 
that may contribute to the pathogenesis of the disease and supports the exploration of 
compounds with antioxidant activity as new therapies for IBD (McKenzie et al. 1996). If 
confirmed, such treatment could reduce the risk of colon cancer in patients with UC by 
preventing oxidative DNA damage (Simmonds & Rampton, 1993).
Complement. Immunohistochemical studies have detected deposits of terminal 
complement complex in the muscularis mucosa and submucosal blood vessels in inflamed 
gut wall in IBD (Halstensen et al. 1989) and on the brush border of colonic epithelial cells 
from UC patients (Halstensen et al. 1990). Increased secretion of C3 and C4 has been 
reported into the lumen of uninvolved jejunum in patients with CD apparently confined to 
the terminal ileum (Ahrenstedt et al. 1990) and C3b on the brush border of colonocytes in 
patients with active UC (Halstensen et al. 1990). Deposition of the C3 fragments occurs in 
inflamed colonic mucosa of diverse aetiologies, including UC, but to define a role of the 
deposition in the development of mucosal injury in UC awaits further study (Ueki et al.
1996). As well as participating in neutrophil-endothelial cell interactions, complement 
components may contribute to intestinal inflammation by stimulating release of histamine, 
eicosanoids, PAF and IL-1 (Lauritsen et al 1989; Halstensen etal. 1990).
Neuropeptides: Regulatory neuropeptides are widely distributed in the gastrointestinal 
tract, where they play an important role in motility, secretion, immune and inflammatory 
responses (Sanahan & Anton, 1988). Recent studies suggest that substance P (SP), and 
vasoactive intestinal polypeptide (VIP) play a role in inflammatory processes of the bowel. 
An increase in the density of SP-immunoreactive nerve fibres has been found in inflamed 
ileal pouch mucosa of clinically asymptomatic pouchitis patients (Keranen et al. 1996), 
while decreased tissue levels of VIP reported in chronic colonic inflammation could be 
due to diminished gene expression of VIP observed in UC (Schultebockholt et al. 1995).
Introduction 18
In another study, in active UC, VIP- and SP-nerves decreased in severe inflammatory 
lesions and VIP-nerves were almost absent particularly around crypt abscesses. In the 
uninvolved mucosa of UC, they did not change their distribution. In CD, the distribution 
abnormality of both nerves resembled that of UC (Kimura et al 1994). The expression of 
receptors for somatostatin (SOM) in veins of inflamed intestines suggests an active 
involvement of this peptide in the pathophysiology of IBD (Reubi et al. 1994). The 
content of immunoreactive-SOM was decreased in UC patients, especially in those with 
persistent disease activity, while the levels of immunoreactive-SP, beta-endorphin (BE), 
and thyrotropin-releasing hormone (TRH) were increased in such patients (Yamamoto et 
al. 1996). The pro-inflammatory effects of SP suggest that it may play a role in the 
pathogenesis of IBD and the report that lidocaine enemas are efficacious in proctitis 
(Bjorck et al. 1989) is of interest. However, topical anaesthetics may not act solely through 
interference with enteric nerve function since they have recently been shown to inhibit 
neutrophil ROS, leukotriene B4 and IL-1 production directly in vivo (Sinclair et al 1993).
Cytokines, Cytokines are a large family of structurally diverse proteins of 8-30 kD, which 
are produced by most nucleated cells, particularly but not exclusively immune cells. These 
proteins probably play a key role in intestinal inflammation via inducing and suppressing 
inflammatory process. In addition they have a role in the regulation of healing and repair 
(Dieleman et a l 1996) by activating effector cells (Pallone & Montelleone, 1996), by 
increasing their proliferation and providing chemotactic messages. Individual cytokines 
modulate the secretion not only of others, but also other mediators. Thus cytokines may be 
responsible for many of the symptoms in patients with IBD via their local and systematic 
effects or inducing the production of other mediators and initiating a cascade of effects 
(Fiocchi etal. 1994).
II^l has a large range of biological activities, including the induction of cytokines, 
chemokines, adhesion molecules, enzymes (cyclo-oxygenase, soluble phospholipases,
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collagenases) and it is regarded now as a major pro-inflammatory cytokine (Dinarello, 1996). 
In active IBD, isolated peripheral blood mononuclear cells were found to produce increased 
levels of I H  compared to controls (Grottrupwolfers et al 1996), but reverted to control 
levels in the inactive stages and they found significant correlation between the IL-1 (3 
production and the activity index of the diseases (Nakamura et al 1992). IL-lp mRNA was 
found in colonic biopsies from patients with infectious and ischaemic colitis. These results 
suggest that production of IL-lp is not unique to active IBD but is also increased in intestinal 
inflammation (Isaacs et al 1992). Organ cultures of involved IBD mucosa spontaneously 
produced increased amounts of IL-lp compared to normal mucosa (Reimund et a l 1996). 
The increased IL-1 production at the mucosal level in patients with active IBD is probably 
derived from the presence of increased number of cells capable of synthesising IL-1 in the 
inflamed intestinal mucosa (Grottrupwolfers et al 1996). Macrophages have been suggested 
as the major source of IL-1 in IBD mucosa (Mahida et al 1989). However, there may be 
other cell types than macrophages involved in IL-1 production. Finally, levels of IL-1 ra were 
markedly increased in patients with IBD and an imbalance in the ratio of tissue IL-1 and 
interleukin-1 receptor antagonist (IL-lra) levels in the intestinal mucosa of patients with 
IBD has been proposed (Kam et al 1995).
IL-2, the first of a series of lymphocytotropic hormones to be recognised and completely 
characterised, is pivotal for the generation and regulation of the immune response (Smith, 
1988). In the investigation of IL-2 in IBD conflicting data have been published (Radford- 
Smith & Jewell, 1996). Decreased or absent IL-2 production by blood mononuclear cells 
(Ebert et al 1984), mucosal mononuclear cells or both (Fiocchi, 1989) has been reported in 
IBD. Although T lymphocytes are numerous in normal bowel mucosa and their number 
increases in CD and UC, abnormalities of IL-2 production and response have been reported 
in IBD (Ebert et al 1984). In other studies, using ELISA, increased concentrations of IL-2 
have been demonstrated in both plasma and endoscopic biopsies from bowel mucosa of 
patients with active IBD, or using polymerase chain reaction (PCR), presence of increased
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mucosal T-cell IL-2 mRNA transcripts has been detected in IBD patients (Mullin et al
1992). It has been suggested that the increased production of the soluble form of the JL-2 
receptor (sIL-2R), observed in IBD, causes the insignificant change in IL-2 production 
trapping of the free IL-2 (Mueller et al. 1990). An explanation for these contradictory results 
may be that the IL-2 production varies with the degree or the type of the inflammation and 
the stage of the disease. 1 1 ^ 2  production by intestinal lamina propria mononuclear cells in an 
animal experimental model has been found decreased in an early stage (acute phase) and 
increased in a later stage (chronic phase) (Gurbindo et al 1993). Recent studies of IL-2 
deficient mice revealed that IL-2 has a key function in intestinal immune homeostasis and 
might play a crucial role in the pathogenesis of IBD (Ehrhardt et al 1997).
Elevated levels of DL- 6  in serum and bowel mucosa have been demonstrated in IBD. This is 
confirmed by the detection of IL- 6  mRNA transcripts in actively inflamed tissues from IBD 
patients (Isaacs et al 1992). IL- 6  positive IBD specimens were also found positive for IL-16 
and it has been suggested that the expression of IL- 6  may provide an additional mediator in 
IBD (Grottrupwolfers et al 1996) that, in common with IL-1 (3, and other mediators leads to 
the inflammatory response characteristic of IBD, or IL- 6  play a protective role by inducing 
hepatic acute phase proteins (Stevens et al 1992). Organ cultures of involved IBD mucosa 
spontaneously produced increased amounts of IL- 6  compared to normal mucosa (Reimund 
et a l 1996). A significant relationship between serum IL- 6  antigen and platelet count has 
been reported in IBD (Hyams et al 1993). It has been suggested that IL- 6  may stimulate 
megacaryocyte activity and result in thrombocytosis in disease characterised by chronic 
inflammation (Hollen et al 1991). Taken together these reports suggest that elevated serum 
IL- 6  levels may be associated with elevated platelet counts frequently seen as part of the 
acute phase response in IBD patients.
Studies on TNF-a production have detected no significant differences in serum or mucosal 
specimens between IBD patients and normal controls (Greenfield et al 1993), whereas organ
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cultures of involved IBD mucosa were found to produce increased amounts of TNF-a 
compared to normal mucosa (Reimund et a l 1996). Tissue levels of TNF-a mRNA were 
not found increased in IBD specimens using PCR amplification (Isaacs et al. 1992) and it 
has been suggested that the increase of IL- 6  in IBD, which inversely regulates TNF-a 
production, may be responsible for the apparent decrease expression of TNF-a in intestinal 
inflammation (Isaacs et al 1992). The systemic levels of TNF-a were not found to be 
elevated in an experimental model of chronic colitis compared to controls and it has been 
suggested that other pro-inflammatory mediators with biological properties parallel to those 
of TNF-a - as IL-1 - may be responsible for the systemic manifestations of chronic colitis 
(Mack et al. 1992). In another study the amount of TNF-a in the stools has been referred as a 
marker of intestinal inflammation (Braegger et al 1992). TNF-a has a large range of 
biological activities, most similar with those of IL-1, including the induction of cytokines 
and enzymes that are involved in the generation of inflammatory mediators (Beutler & 
Cerami, 1995). In addition, TNF-a has been found to increase adhesion molecule expression 
on the cell membranes of monocytes and granulocytes and it has been suggested that this 
cytokine might be responsible for leukocytes recruitment into the bowel wall in IBD 
(Greenfield et al 1993; Lo et al 1989).
Although IFN-y was originally defined as an agent with direct antiviral activity, now we 
know that the properties of this lymphokine include regulation of several aspects of the 
immune response (Boehm et al 1997). The reports about IFN-y production in IBD are 
contradictory (Radford-Smith & Jewell, 1996). Serum levels of IFN-y have been found 
elevated in patients with active disease (Simon et al 1983; Stalnikowicz et al 1985) and 
increased spontaneous release of IFN-y by cultured mucosal mononuclear cells from CD 
patients has been reported, whereas peripheral blood mononuclear cells release IFN-y after 
stimulation (Fais et al 1991). In other reports, the production of IFN-y in peripheral blood 
mononuclear leukocytes of patients with IBD was found to be the same as that in controls 
(Nakamura et al 1992), mitogen activation of peripheral blood mononuclear cells from IBD
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patients showed normal or decreased levels of IFN-y (Miura & Hiwatashi, 1985; 
Stalnikowicz et al. 1985; Mutchnick et al. 1988) and stimulated intestinal mononuclear cells 
from both CD and UC patients have been detected to produce decreased levels of IFN-y as 
compared to the normal controls (Lieberman et al. 1988). However, in experimental models, 
inflamed colonic mucosa from Goci2-deficient mice with colitis exhibited increase in IFN-y 
and an important role for this lymphokine in IBD has been suggested (Homquist et al. 1997).
The pathogenesis of IBD may be associated with changes in the production of T-cell- 
derived cytokines IL-4, IL-10, and IL-13 (Kucharzik et al. 1997). These T-cell derived 
cytokines have all been proposed as anti-inflammatory cytokines. For example IL-13 is a 
potent suppressor of cytokine and chemokine expression by activated monocytes and 
macrophages (Minty et al. 1993; McKenzie et al. 1993; Zurawski & De Vries, 1994; De 
Waal Malefyt et al. 1993), and endothelial cells (Marfaing-Koka et al. 1995). In addition ILr 
13 induces the production of IL-1 receptor antagonist (Muzio et al. 1994) and modulates the 
expression of cell surface proteins such as class II MHC antigens (De Waal Malefyt et al.
1993). Similar biological activities are also displayed by IL-4, in addition both cytokines are 
potent stimulators of B-cell IgE production, while IL-4 alone has an effect on human T-cells 
(Zurawski & De Vries, 1994). Interleukin-10 is produced by a variety of cells including 
activated human T-cells, and it is also a potent suppressor of cytokine and chemokine 
generation by activated monocytes/macrophages (Moore et al. 1993; Hsu et al. 1990; Vieira 
et al. 1991; de Waal Malfyt et al. 1991; Fiorentino et al. 1991) and polymorphonuclear cells 
(Kasama et al. 1994). IL-4 mRNA expression is decreased in intestinal tissue from CD 
patients, while IL-10 mRNA expression is decreased in majority of UC patients, 
suggesting different immunopathogenesis of the two diseases (Nielsen et al. 1996). IL-10 
was found able to down-regulate all proinflammatory cytokines in active IBD as well as in 
controls (Kucharzik et al. 1996) and IL-10 deficient mice were found to develop chronic 
enterocolitis (Kahn et al. 1993; Rennick et al. 1997). Activated monocytes with increased 
expression of proinflammatory cytokines play a major role in IBD. Immunoregulatory
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cytokines such as IL-4 and IL-10 can effectively suppress the proinflammatory response of 
activated monocytes (Kucharzik et al. 1997). With regard to IL-13 and IL-4, there was no 
significant suppression of TNF-a and IL- 6  in patients with active IBD (Kucharzik et al.
1996). By contrast, IL-10 was able to down-regulate all proinflammatory cytokines in 
active IBD as well as in controls (Kucharzik et al. 1996; Murata et al. 1995). In vivo 
topical application of IL-10 induces down-regulation of proinflammatory cytokine 
secretion both systemically and locally (Schreiber et al. 1995). The results about the IL-13 
production in IBD patients are contradictory so far (Radford-Smith & Jewell, 1996). The 
inhibitory effect of IL-13 on TNF-a and IL- 6  production in differentiated macrophages 
was diminished in IBD patients and the anti-inflammatory activity of IL-13 was found 
partially reduced in patients with active IBD (Kucharzik et al. 1996), while IL-13 has been 
found to inhibit nitric oxide production in activated colonic epithelial cells (Kolios et al.
1997).
The aetiology of IBD appears to be immunologically mediated and cytokines with their 
inflammatory and regulatory properties appear to play a role in pathogenesis of UC and CD. 
These molecules have simultaneous protective effects that are important in the resistance to 
infectious agents and possibly in the healing phase of inflammation and the relative balance 
of the inflammatory and protective properties of the cytokine network may determine the 
chronicity of inflammation and the tendency of reactivation of these diseases.
Conclusions. The aetiology of IBD remains obscure. It seems most likely that 
environmental factors, for example dietary or microbial, trigger an inappropriate mucosal 
inflammatory response in individuals having genetically abnormal immune system, gut 
permeability, mucus and/or colonocyte metabolism. Although the pathogenesis of IBD is 
gradually being elucidated, we remain ignorant of the mechanisms underlying the
Table 1. Soluble inflammatory mediators in ESP
_________Group______
Eicosanoids
















Elastase, cathepsin, collagenase, 
chymotrypsin
Superoxide anion, hydrogen 
peroxide, perhydroxyl radical
C3, C3b, C4
IL-1 a, IL-1 (3, IL-2, IL-4, IL-6 , IL- 
10, IL-13, TNF-a, IFN-y




Regulation of electrolyte secretion, diarrhoea, transmigration and 
activation of neutrophils, platelet activation, vasoconstriction
Regulation of sodium chloride secretion, diarrhoea
Vasodilatation, vascular permeability, smooth muscle contraction
Intestinal secretion, activation of prostaglandin formation
Mucosal damage, degradation of connective tissue proteins
Tissue damage, cellular toxicity, oxidative DNA damage, mutation, 
development of neoplastic disorders
Stimulation of histamine, eicosanoids, PAF, IL-1 formation
Activation of effector cells, cell proliferation and communication, 
induction and suppression of inflammatory responses
Transmigration and activation of specific leukocyte populations
Cytotoxicity, vasodilatation, peroxynitrate formation, protective 
effects
Substance P, somatostatin, Regulation of motility and secretion, protective effects
vasoactive intestinal polypeptide______________________________________________
(See text for references)
Introduction 25
chronicity of mucosal inflammation and relapse of quiescent disease in patients with IBD. 
For example, is chronicity due to persistence of an exogenous stimulus of inflammation, or 
to genetically defective down-regulation of the immune response (Podolsky, 1991)? 
Answers to these questions are a priority if we are to make major strides in our 
understanding of the pathogenesis of IBD, and in its treatment.
1.3 CHEMOKINES
The discovery of IL- 8  in 1987 revealed the existence of a superfamily of inducible, 
proinflammatory cytokines (Baggiolini et al. 1989; Rollins, 1997). The members of this 
family are small, mostly 8-14 kD, heparin-binding polypeptides, that are involved in 
attracting effector cells to the site of inflammation and also participate in activation of 
specific leukocytes (Lindley et al. 1993). The production of chemokines is not limited to 
immune cells, but a wide spectrum of tissue cells e.g. fibroblasts, endothelial cells and 
mesangial cells, expresses and secretes these cytokines upon appropriate stimulation, e.g. 
IL-1, TNF, IFN-y, LPS (Baggiolini et al. 1994). These proteins are structurally related by 
possessing four conserved cysteine residues that form two disulphide bonds and establish 
the tertiary structure of the protein. The key feature of chemokines is their ability to attract 
subsets of leukocytes in a relatively specific manner and they are divided into sub-families 
based on the arrangement of the conserved cystein residues in the molecule (Oppenheim et 
al. 1991). Four groups of chemokines have now been defined.
The C-X-C or a  sub-family (see Table 2), with IL- 8  the prominent member, has an 
intervening aminoacid residue between the first two cysteine residues and attract and 
activate neutrophils (Baggiolini et al. 1989). The C-C (see Table 3) or (3 sub-family in 
which the first two cysteine residues are adjacent, which include monocyte chemotactic 
protein-1 (MCP-1) and Regulated on Activation, Normal T cell Expressed and Secreted
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Table 2. CXC Chemokines
Name Target cells
ERL
IL- 8 Neutrophils, lymphocytes, basophils, angiogenesis 
(?endothelial cells)
GRO-a(MGSA) Neutrophils, melanoma cells, (?endothelial cells)
GRO-p(MIP-2a) Neutrophils, (?endothelial cells)









Platelet factor 4 Fibroblasts, endothelial cells
IP-10 Activated T lymphocytes, TIL, ?endothelial cells, 
NK cells
MIG Activated T lymphocytes




Table 3. CC Chemokines
Name Target cells
MCP-1 Monocytes, memory T lymphocytes, basophils, NK cells, 
hematopoietic progenitors, ?dendritic cells
MCP-2 Monocytes, memory and naive T lymphocytes, basophils, 
NK cells, eosinophils
MCP-3 Monocytes, memory T lymphocytes, basophils, NK cells, 
dendritic cells, eosinophils
MCP-4 Monocytes, T lymphocytes, eosinophils
MCP-5 Monocytes, T lymphocytes, eosinophils
M IP-la Monocytes, T lymphocytes, basophils, NK cells, 
dendritic cells, eosinophils, hematopoietic progenitors
MIP-lp Monocytes, T lymphocytes, NK cells, dendritic cells, 
hematopoietic progenitors
MIP-ly (mouse only) Resting and activated T lymphocytes




HCC-1 Monocytes, hematopoietic progenitors
TARC T lymphocytes
CIO (mouse only) ?





(RANTES)) and preferentially act on mononuclear cells. MCP-1 is a potent 
chemoattractant for monocytes/macrophages (Leonard & Yoshimura, 1990), for CD4+ and 
CD8 + T lymphocytes (Loetscher et al. 1994; Taub et al. 1995), and for tumour-associated 
macrophages (Mazzucchelli et al. 1996b). In addition to monocytes, RANTES is a 
selective chemotactic agent for CD45RO/CD4+ T cells (memory T cells) (Schall et al. 
1990; Turner et al. 1995) and eosinophils (Kameyoshi et al. 1992). The discovery of 
lymphotactin (Kelner et al. 1994) has suggested the existence of a third group named C or 
y subfamily which lacks two (the first and third) of the four conserved cysteine residues. 
Lymphotactin is a chemotactic cytokine for lymphocytes, but not neutrophils and 
monocytes and it is produced abundantly by CD8 + T cells (Kennedy et al. 1995). Finally, 
the recently defined CX3C chemokine (also referred to as “fractalkine” or “neurotactin”), 
that is an integral membrane protein with a chemokine domain in its N-terminus (Bazan et 
al. 1997), has established a new chemokine group. This subfamily differs from the other 
chemokines by the presence of three amino-acids intervening between the first two 
cysteins (Rollins, 1997).
The C-X-C subfamily can be further divided into proteins which contain or lack an ELR 
motif. This motif consists of three aminoacids Glu-Leu-Arg that precede the first cysteine 
residue in the molecule near the amno terminus and it plays a crucial role in receptor- 
ligand interactions on neutrophils. Chemokines with the ELR motif act primarily on 
neutrophils as chemoattractants and activators, inducing neutrophil degranulation. On the 
other hand the C-X-C chemokines, which lack the ELR domain have no neutrophil 
chemotactic activity. In addition, the ELR containing CXC chemokines (IL-8 , Groa, Gro(3, 
Groy, ENA-78 and NAP) are angiogenic agents, while non ELR expressing chemokines 
(MIG, IP 10 and PF-4) are angiostatic (Strieter et al. 1995). The chemokine subfamilies 
have a distinguished chromosomal location of their genes. C-X-C chemokines are 
localised on human chromosome 4 (ql2-q21), while the C-C chemokines are clustered on
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human chromosome 17 (Donlon et al. 1990). The gene encoding the C chemokine, 
lymphotactin is located on human chromosome 1 (Kennedy et al. 1995).
A conceptual leap in the field of cell migration has been the realisation that extravascular 
leukocyte accumulation is a multi-step process and requires a series of co-ordinated 
signals, including the expression and activation of cellular adhesion molecules as well as 
the generation of chemotactic gradients by the cells of the extravascular compartment 
(Huber et al. 1991; Adams & Shaw, 1994). Chemokines participate at several levels of the 
multi-step process that regulates leukocyte migration into injured tissue. This process is 
defined by four sequential steps: rolling, triggering, adhesion and migration (Adams & 
Shaw, 1994). In an initial step, leukocytes become attached to the endothelial layer but are 
still allowed to roll in a slower flow along the vessel wall. Rolling is mediated by 
selectins, which are expressed in both endothelium and leukocytes. However, without a 
further triggering factor leukocytes can still disengage from the vessel wall (Springer,
1994). Chemokines are important to enhance integrin adhesiveness, and to promotes 
strong adhesion (Vaddi & Newton, 1994). In the next step of extravasation, stimulated 
leukocytes spread and firmly attached to the endothelial layer through the interaction of 
integrins on the leukocytes with adhesion molecules on the endothelial cells (Adams & 
Shaw, 1994). IL- 8  is an important example of a neutrophil triggering factor (Rot, 1992), 
while both RANTES and MIP-1(3 can activate the T cell integrins, VLA-4 ( Very Late 
Antigen 4 ) and LFA-1 ( Leucocyte Function antigen-1 ) (Gilat et al. 1994). After strong 
adhesion to the endothelium, leukocytes migrate into the underlying tissue along a 
chemotactic gradient. Migration of certain subsets of leukocytes into tissue depends on the 
type of integrin expressed on the leukocytes and on the interaction with a specific 
endothelial adhesion molecule, of which the expression depends on the type of 
endothelium and on the stimulating chemokine. This complex mechanism helps to migrate 
the correct leukocyte to a specific site (Kubes & Wallace, 1995).
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Chemokines mediate their activities by binding to an array of shared and specific receptors 
on blood leukocytes (Schall, 1994; Sozzani et al. 1995) that belong to the family of 
heterotrimeric G protein-coupled receptors, which process seven transmembrane domains. 
To date four C-X-C chemokine receptors (CXCR-1 to 4) and eight C-C chemokine 
receptors (CCR-1 to 8 ) have been cloned and expressed (Power & Wells, 1996). CXCR-1 
previously known as IL-8 RA or IL- 8  receptor type I is specific for IL-8 , while CXCR-2 
(IL-8 RB or EL- 8  receptor type II) also binds other C-X-C chemokines, including 
melanocyte growth stimulating activity/gro (MGSAIgro), epithelial-derived neutrophil 
attractant-78 (ENA-78) and neutrophil activating protein-2 (NAP-2) with high affinity 
(Holmes et al. 1991; Murphy & Tiffany, 1991). CXCR-3, also known as the IP-10/Mig 
receptor is a highly expressed by IL-2-activated T lymphocytes, B lymphocytes, 
monocytes and granulocytes, and binds IP-10 and Mig, but not PF4. This receptor does not 
bind the C-X-C chemokines that contain the ELR domain (Loetscher et al. 1996). CXCR- 
4 receptor also known as fusin is a necessary co-factor for entry of T cell tropic HIV 
viruses into CD4+ cells (Feng et al. 1996) and is the specific receptor for SDF-1. Receptor 
binding studies indicate the existence of multiple receptors for C-C chemokines, which 
differ mainly in their NH2-terminal part that might explain the different specificity of the 
C-C chemokines for particular receptor interactions.
An additional factor which may enhance this specificity may be the cellular distribution of 
the receptors (Sozzani et al. 1995). CCR-1 has been cloned, and binds MIP-lcx, RANTES, 
MCP-3 with high affinity and MIP-lp and MCP-1 with lower affinity (Neote et al. 1993). 
CCR-2, which is specific for MCP-1, MCP-2, MCP-3 and MCP-4, has two forms (type A 
and B) that differ in their alternatively spliced carboxyl terminus and are probably spliced 
variants of a single gene (Charo et al. 1994). CCR-3 is a high affinity receptor for eotaxin, 
RANTES and MCP-3 (Kitaura et al. 1996; Daugherty et al. 1996). CCR-4 binds 
RANTES, MIP-lcx, MCP-1, and has been shown to be expressed in T cells, B cells and 
monocytes (Power et al. 1995; Hoogewerf et al. 1996). CCR-5 is expressed in monocytes,
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macrophages, and T cells and mediates the activities of RANTES, MIP-la, and MIP-lp. 
Recently they found that this receptor is a co-receptor on CD4+ target cells for infection 
with primary, monocyte-tropic HIV-1 viruses (Samson et al. 1996; Dragic et al. 1996). 
Furthermore, the Duffy blood group antigen, has been detected to be an erythrocyte 
chemokine receptor that can bind C-X-C and C-C chemokines (Neote et al. 1994). The 
Duffy antigen receptor for chemokines (DARC) present on human erythrocytes and 
endothelial cells may play a role in leucocyte transmigration by concentrating chemokines 
at the cell surface for presentation to target leukocytes and seem to be identical to the 
receptor for the invasion of the malarial parasite, Plasmodium vivax (Schall, 1994; Sozzani 
et al. 1995). An isoform of this receptor has also been localised on endothelial cells lining 
post-capillary venules in the kidney (Hadley et al. 1994).
Chemokines, together with adhesion molecules, cytokines and proteases are essential for 
the directional migration of leukocytes during normal and inflammatory processes (Proost 
et al. 1996). However, the degree of leucocyte specificity they possess, which contrasts 
with the non-specific action of the classical chemotactic factors such as C5a, platelet 
activating factor (PAF) and leukotriene B4 , may explain in part, the time-dependent 
accumulation of specific leucocyte populations during the course of acute and chronic 
inflammation (Adams & Shaw, 1994). Finally, chemokines are important not only in acute 
and chronic inflammation, but they have also been implicated in lymphocyte trafficking 
during T cell development and maturation, coagulation, haemopoiesis, angiogenesis, 
wound healing, autoimmune diseases, allergy, and malignancy (Proost et al. 1996).
1.3.1 The role of chemokines in IBD
The study of chemokine expression and production in IBD is still in its beginning with the 
majority of published data focusing on IL-8 , during the course of this study. The movement 
of neutrophils into the colonic mucosa in UC is thought to be induced mainly by IL- 8  and
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leukotriene B-4 (Cole et al. 1996). Significantly higher levels of IL- 8  have been found in 
macroscopically and histologically inflamed and non inflamed colonic mucosa from UC and 
CD patients than in controls (Daig et al. 1996) and in both the proximal and distal regions 
of the colonic mucosa of UC patients there was a more than 10-fold increase in IL- 8  
levels over that in control subjects (Izzo et al. 1992), an observation which might indicate 
more extensive disease than indicated by endoscopic and histological examination (Izzo et 
al. 1992). IL- 8  mRNA has found in colonic biopsies from IBD patients, using PCR 
amplification and in situ hybridisation (Isaacs et al. 1992; Daig et al. 1996). Colonic 
epithelial cell lines have been reported as a source of IL 8  after stimulation by the pro- 
inflammatory cytokines IL-1 a  and TNF-a or lipopolysaccharide (Schuerer-Maly et al. 1994; 
Gross etal. 1995).
Freshly isolated human colon epithelial cells were found to express IL- 8  (Jung et al. 
1995) and it has been suggested that colonic epithelial cells may contribute to neutrophil 
extravasation and tissue infiltration in intestinal inflammation (Kelly et al. 1994). 
Furthermore, it has been found that increased levels of IL 8  in mucosal samples from UC 
patients was associated with increased levels of myeloperoxidase in corresponding regions of 
the colonic mucosa (Izzo et al. 1992). In situ hybridisation with IL- 8  anti-sense RNA 
probes revealed strong and specific signals in the histologically affected mucosa in active 
IBD, but not in the mucosa of uninvolved bowel segments and in normal control mucosa. 
Tissue specimens from two patients with acute appendicitis displayed IL-8 -expressing 
cells in the mucosa. These results suggest that IL 8  is not specific in the pathogenesis of 
IBD, but it is involved in the intestinal inflammation (Mazzucchelli et al. 1994). The role 
of IL- 8  in IBD is unknown, though this cytokine is likely to induce the neutrophil 
chemotaxis and the accumulation of the large number of neutrophils in the intestinal 
inflamed mucosa in IBD (Brynskov et al. 1992; Kelly et al. 1994).
Introduction 33
Peripheral blood monocytes are recruited from the circulation to the inflamed mucosa of 
IBD. Monocyte chemoattractant protein-1 (MCP-1) a chemokine with potent monocyte 
attracting and activating properties has been detected in large bowel mucosa from IBD 
patients. Freshly isolated human colon epithelial cells were found to express MCP-1 
(Jung et al. 1995). MCP-1 transcripts were found generally increased in the intestinal 
mucosa of patients with IBD compared with controls, and MCP-1 gene expression in the 
mucosa was restricted to the lamina propria. Compared with controls, a significant 
increase of MCP-l-expressing cells was observed in tissue specimens from patients with 
IBD, in endothelial cells of venules, and in cells present in the lumen of intestinal vessels 
(Mazzucchelli et al. 1996a). In another study they found MCP-1 mRNA expression and 
MCP-1 protein in macrophages, some of which had been recently recruited from the as 
well as in smooth muscle and endothelial cells in inflamed mucosa. By contrast minimal 
MCP-1 mRNA expression and protein were found in histologically normal mucosa 
(Grimm etal. 1996).
RANTES, another monocyte attracting chemokine was found increased in the intestinal 
mucosa of patients with IBD compared with controls. The gene coding for RANTES was 
expressed in intraepithelial lymphocytes and in the lamina propria (Mazzucchelli et al. 
1996a). Using in situ hybridisation, another study demonstrated that the monocyte 
attracting chemokines, RANTES, MIP-la, MIP-lp, and y-interferon-inducible protein-10 
were expressed by macrophages, T lymphocytes, and endothelial cells in actively inflamed 
tissue but rarely expressed in uninflamed sections from IBD. The frequency of chemokine- 
expressing cells was significantly greater in severely inflamed than in moderately or mildly 
inflamed tissue. RANTES was expressed by T lymphocytes in normal colon lamina 
propria, although infrequently (Grimm & Doe, 1996). The increased number of MCP-1 
and RANTES mRNA-expressing cells in mucosa from patients with IBD suggests that 
these cytokines play a role in the recruitment of peripheral blood monocytes and the 
expression of the MCP-1 gene in vessel-associated cells may indicate its involvement in
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mechanisms regulating the adhesion of blood monocytes to endothelial cells 
(Mazzucchelli et al. 1996a).
Eotaxin is a directly chemoattractant cytokine for eosinophils, but not mononuclear cells 
or neutrophils. Eotaxin messenger RNA was found markedly accumulated in the lesions of 
patients with IBD, but not in the lesions of patients with diverticulitis. These results now 
provide a mechanism involving eotaxin to explain the eosinophil infiltration seen in IBD 
(Garciazepeda et al. 1996).
These data indicate an implication of colonic epithelial cells in chemokine production and 
from their post may be of paramount importance in the early recruitment of inflammatory 
and immune cells in intestinal inflammation.
1.4. NITRIC OXIDE
In recent years, nitric oxide (NO), a gas previously considered a potentially toxic chemical, 
has become established as a diffusible universal messenger mediating cell-cell 
communication throughout the body (Moncada et al. 1991; Whittle, 1995). This molecule 
is a highly reactive free radical with a multitude of organ specific regulatory functions. NO 
is synthesised from the amino acid L-arginine by a family of enzymes (Figure 1) generally 
referred to as the nitric oxide synthases (NOSs). The oxidation of a terminal nitrogen of 
the amino acid L-arginine produces NO and L-citrulline. NO is a short-lived molecule and 
decomposes into other nitrogen oxides such as nitrite (N02-) and nitrate (N03-), and in 
the presence of superoxide anion to the potent oxidising agent peroxynitrite (ONOO-) 
(Fukuto & Chaudhuri, 1995). Three isoforms have been identified. Two of NOS are 
continuously present and are termed constitutive NOS (cNOS), while a third isoform is 
expressed after induction by certain cytokines, microbes, and bacterial products, thus it is 





haem, FAD, FMN, BH
NADPH
Figure 1. Nitric Oxide (NO) production from the aminoacid L arginine by the family of 
enzymes named Nitric Oxide Synthases (NOS)
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isoforms of NOS require reduced nicotinamide adenine dinucleotide (NADH), flavine 
dinucleotide (FAD), flavine mononucleotide (FMN) and tetrahydrobiopterine (BH4) as 
cofactors, but vary in their dependency for Ca2+ and calmodulin. Brain NOS, and 
endothelial NOS, which were cloned from rat cerebellum (Bredt et al. 1991), bovine and 
human vascular endothelial cells (Lamas et al. 1992; Janssens et al. 1992), respectively, 
are the constitutive enzymes (cNOS) and they are calcium and calmodulin dependent. 
Brain NOS and endothelial NOS share -60% homology at the amino acid level. The third 
isoform, which is calcium and calmodulin independent was cloned from murine 
macrophages and it is -50% homologous at the amino acid level to endothelial NOS 
(Lowenstein et al. 1992).
Constitutive NOS produce small amounts of NO and are involved in homeostatic processes 
(Moncada et al. 1991), while the inducible NOS is responsible for the main NO production 
in tissues and it is highly regulated by the action of cytokines (Moncada & Higgs, 1993). The 
soluble constitutive isoforms of NOS are activated by Ca2+/calmodulin and no activity is 
observed in the absence of Ca2+/calmodulin. NO production by cNOS is small, nM 
quantities, short lasting, it is controlled by Ca2+ mobilising agents in a very transient and 
highly controlled fashion, and fully inhibited by calmodulin antagonists (Stuehr & Griffith,
1992). In marked contrast iNOS synthesises NO in large QiM) amounts and is regulated at 
the transcriptional level (Morris & Billiar, 1994), although at the start of my study very 
little was known about human iNOS and the pM amounts of NO referred to rodent iNOS. 
NO production by iNOS is delayed by several hours following stimulation, but once 
induced, is active for hours and days. The gap between stimulation and enzyme generation 
might suggest the requirement of de novo synthesis of a co-factor, e.g. tetrahydrobiopterin 
(Stuehr & Griffith, 1992; Nussler et al. 1992) for maximal activity (Figure 1). iNOS is 
sensitive to inhibitors of DNA transcription and protein synthesis, such as actinomycin D 
and cycloheximide. Glucocorticoids (Radomski et al. 1990; Pfeilschifter, 1991) and 
cytokines such as TGFp, PDGF, IL-8 , IL-4 and IL-10 (Oswald et al. 1992; McCall et al.
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1992; Ding et al. 1990; Cunha et al. 1992) have been found to inhibit iNOS activity, 
without affecting cNOS.
Based on early studies showing that Nw-methyl-L-arginine blockedmacrophage mediated 
L-arginine-dependent tumour cell cytostasis (Hibbs et al. 1987b; Tibbs et al. 1987a), a 
variety of N“-substituted-L-arginine derivatives have been investigated as potential 
inhibitors of NOS. cNOS and iNOS also show some differences ii their affinity for N“- 
monosubstituted arginine analogs, which compete with L-arginine or binding sites in the 
NO synthase enzymes and inhibit their activity (Gross et al. 199; Gross et al. 1990). 
Thus, N“ -nitro-L-arginine (L-NNA) and N® -amino-L-arginine (LNAA) are more potent 
inhibitors of cNOS and iNOS, respectively, while N“ -moncnethyl-L-arginine (L- 
NMMA) was found to be an effective inhibitor of both NOS ypes. The L-arginine 
analogues are selective inhibitors of NOS activity, in compaison to other known 
inhibitors (Knowles & Moncada, 1994). The human iNOS isoform ias been cloned and its 
expression and activity has been induced in human hepatocytes (Geller et al. 1993), 
mesangial cells (Nicolson et al. 1993), lung epithelial cells (Robbins t  al. 1994; Asano et al.
1994), monocytes/macrophages (Reiling et al. 1994), colonocytes Sherman et al. 1993), 
astrocytes (Lee et al. 1993), chondrocytes (Palmer et al. 1993; Chrles et al. 1993) and 
smooth muscle cells (Junquero et al. 1992; Nakayama et al. 194) stimulated with a 
"cocktail" of cytokines.
NO has numerous physiological and pathophysiological action, having both anti­
inflammatory and proinflammatory properties depending on the Vpe and phase of the 
inflammatory reaction (Moilanen & Vapaatalo, 1995). In mammls, it is a recognised 
mediator of blood vessel relaxation that helps to maintain blood jressure (Welch et al.
1995) and vascular integrity (Cosentino & Luscher, 1995). In the entral nervous system 
NO acts as a non-conventional neurotransmitter and participates ii the establishment of 
long-term plasticity required for memory formation. This moleule is an important
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regulator of cerebral vascular tone. Tonic production of NO maintains the cerebral 
vasculature in a dilated state. NO appears to be an important vasodilator during activation 
of neurons by excitatory amino acids, somatosensory stimulation and cortical spreading 
depression. Tonic production of NO appears to be critical in vasodilatation during 
hypercapnia, although NO may not directly mediate vasodilatation (Brian et al 1996).
Induction of NO synthesis in many cell types as part of the host response to sepsis and 
inflammation. Induced NO can have a variety of effects which may be detrimental or 
beneficial during sepsis or inflammation, depending on amount, duration, and anatomic 
site of synthesis. As arginine is the only physiological nitrogen donor for NO synthesis, 
metabolism of this amino acid may play an important role in regulation of NO synthesis 
during sepsis (Morris & Billiar, 1994). NO is believed to play a role in various pulmonary 
physiological processes, such as bronchodilation (Jorens et al. 1993). In addition, NO is 
responsible for mediation of macrophage cytotoxicity (Jorens et al. 1995), inhibition of 
platelet aggregation, and for some parts of the host response to sepsis and inflammation 
and contributes to certain disease states (Moncada et al. 1991; Kuo & Schroeder, 1995). 
The mechanism for these diverse effects involves the local diffusion of NO from generator 
to target cells, which represents a novel singal transduction mechanism between cells.
Production of NO in large amounts by iNOS activity can inhibit key enzymes by 
nitrosylation of reactive groups, such as iron-sulphur centres (Fe-S) and thiol groups (- 
SH), which are essential for enzyme catalytic function (Molina Y Vedia et al. 1992; 
Cattell & Cook, 1993). The anti-proliferative effects of NO may be due to inhibition of 
DNA synthesis via inactivation of the ribonucleotide reductase enzyme. NO can also 
inhibit enzymes in the mitochondrial electron transport chain and citric acid cycle, which 
may account for the cytotoxic and cytostatic effects of macrophage-derived NO on tumour 
cells and micro-organisms. The cytotoxic activity of NO may play a role in tissue injury 
during inflammatory diseases, and the production of NO can lead to the generation of
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more toxic radicals through its reaction with superoxide, forming peroxynitrite, which 
degrades to form hydroxyl radicals (Beckman et al. 1990). Peroxynitrite is considered a 
potent oxidant that reacts with proteins, lipids, and DNA, and it is a potent initiator of 
DNA strand breakage, which is an obligatory stimulus for the activation of the nuclear 
enzyme poly ADP ribosyl synthetase (PARS). The peroxynitrite-PARS pathway, by 
leading to cell necrosis or apoptosis, contributes to cellular injury in a number of 
pathophysiological conditions including shock and inflammation, pancreatic islet cell 
destruction, and diabetes, stroke, and neurodegenerative disorders, as well as the toxic 
effects of various environmental oxidants or cytotoxic drugs (Szabo, 1996). The body can 
protect against NO-mediated tissue damage by producing corticosteroids, growth factors 
and cytokines that are potent inhibitors of nitric oxide production (Laskin et al. 1994; 
Liew, 1995).
A number of strategies have emerged with regard to a pharmacological control of 
pathological NO production and new therapeutic approaches are studied, that may provide 
new means for clinical medicine (Pfeilschifter et al. 1996). Since the various isoforms of 
NOS are distributed in cells and tissues according to their function, there is the possibility 
that manipulation of NO levels can be accomplished by designing specific 
pharmacological agents targeted at a single NOS isoform (Fukuto & Chaudhuri, 1995).
1.4.1 The role of nitric oxide (NO) in inflammatory bowel disease
Nitric oxide (NO) is produced at many sites in the gastrointestinal tract and it is believed 
to take a part in physiological and pathological events (Whittle, 1994; Kubes & Wallace,
1995). Increasing evidence, which is based on studies in animal models as well as in man, 
indicates that NO may be involved in gastrointestinal inflammation and it has a 
pathogenetic role in IBD (Boughton-Smith, 1994). Recent studies in a number of 
inflammatory disease patients have shown a marked increase in NO synthase activity in
Introduction 40
the inflamed mucosa from patients with active UC compared to uninflamed control tissue. 
The concentrations of citrulline, the co-product of NO synthase, were found higher in 
rectal biopsy specimens from patients with active UC than in those from patients with 
quiescent disease or normal histology. Citrulline concentrations were significantly lower in 
biopsy specimens incubated with L-NMMA than in those incubated with D-NMMA. 
These results suggest that the increased citrulline biosynthesis must be a consequence of 
NO synthase activity, which simultaneously produces NO (Middleton et al. 1993a). 
Studies of the activity of both cNOS and iNOS in colonic mucosa and muscle tissue from 
patients with active UC and CD compared to control uninflamed tissue revealed a 
substantial increase of Ca2+-independent NO synthase activity in UC, characteristic of the 
inducible form of the enzyme. iNOS activity in colonic mucosa of UC patients was about 
8 -fold higher than the value in control mucosa, with no individual overlap. In CD patients 
mucosal NOS activity did not differ from control values. Finally there was no difference in 
NOS activity in colonic muscle between UC patients and controls (Boughton-Smith et al.
1993). Measuring serum nitrate levels they found that nitric oxide production was 
increased in both active UC and CD (Pool et al. 1995). Luminal gas sampled from the 
colons of patients with active UC and controls was analysed, using a chemiluminescence 
technique and NO concentrations were found more than 100 times higher in the patients 
than in the controls (Lundberg et al. 1994). Reynolds et al, 1995 (Reynolds et al. 1995a), 
using another molecule-specific technique had similar results with increased luminal NO 
concentrations in ulcerative colitis patients but not in controls. UC patients with blood 
visible in the rectum were negative for NO and they suspected that NO, which is avidly 
bound by haemoglobulin, was trapped in the lumen by the blood (Reynolds et al. 1995a). 
Luminal NO measurements may reflect NO production only in the superficial parts of the 
mucosa, since NO production in deeper mucosal layers is bound, e.g. by haemoglobulin in 
blood vessels, and therefore will not reach the lumen. These results suggest that the excess 
NO production in UC mainly occurs in very superficial mucosal layers (Lundberg et al.
1994).
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The cellular source of NO and iNOS in models of IBD has received little attention to date 
(Alican & Kubes, 1996). Boughton-Smith et al., 1993 have found enhanced activity of the 
inducible form of nitric oxide synthase in the mucosa of patients with UC, but not CD and 
they suggested that this iNOS expression is responsible for the increased NO production in 
UC. However, the definition of iNOS, which based on the lack of Ca++ dependency, was 
not confirmed by either mRNA or protein data. Other studies using immunostaining and in 
situ hybridisation demonstrated high expression of iNOS localised to the surface 
epithelium and crypts in the mucosa from patients with UC (Reynolds et al. 1995b). 
Recently this enzyme was detected in colonic tissue including the epithelium from patients 
with active UC (Godkin et al. 1996), while Singer et al., 1996, using immunostaining, 
were found focal iNOS labelling localised in inflamed colonic mucosa in UC, CD, and 
diverticulitis, suggesting that iNOS expression is a feature of intestinal inflammation. 
There was also a similar, but not identical, distribution of nitrosylated protein.
Excess NO produced by the inducible enzyme may theoretically exacerbate the 
clinicopathological features of UC by direct cytotoxicity, activation of neutrophils 
(Ribbons et al. 1995), vasodilatation, reduced smooth muscle tone (Middleton et al. 
1993b), increased production of nitrosamines (to cause cancer) (Ohshima & Bartsch,
1994), and interaction with superoxide to form the highly toxic peroxynitrite radical 
(Singer et al. 1996). In contrast, cNOS activity may have a protective role through 
vasodilatation, reduced platelet aggregation and inhibition of fluid secretion 
(MacNaughton, 1993). There is growing evidence that endogenous NO regulates mucosal 
barrier integrity under physiological conditions and counters the increase in mucosal 
permeability associated with acute pathophysiological states. The potential mechanisms of 
action for the protective effects of NO include maintenance of blood flow (Kubes & 
Wallace, 1995), inhibition of platelet and leukocyte adhesion and/or aggregation within 
the vasculature, modulation of mast cell reactivity, and scavenging of reactive oxygen
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metabolites such as superoxide (Alican & Kubes, 1996). In experimental models, the 
protective effect of L-NAME indicates that NO contributes to tissue injury and that its 
modulation may be a novel approach to treat IBD (Rachmilewitz et al. 1995a). 
Methylprednisolone was found to decrease NO generation by cultured colonic mucosa and 
it has been suggested that NO synthase activity is induced during the culture and this 
steroid effect may relate to its therapeutic effect. (Rachmilewitz et al. 1995c). Inhibition of 
NO synthesis by an L-arginine analogue significantly ameliorated the extent of tissue 
injury in two models of experimental (Rachmilewitz et al. 1995b). The further study of the 
cellular source of NO in colonic mucosa and the development of selective inhibitors of 
NO synthase isoforms will provide more information on the complex role of NO in 
physiology and pathophysiology of intestinal mucosa and should reveal novel targets for 
therapeutic intervention of intestinal inflammation.
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1.5 AIM OF THE STUDY
Our study is based on the hypothesis that the intestinal epithelial cells constitute an interface 
between the host and the environment and they have a crucial role as an outpost of the 
immune system located in the underlying gut mucosa. In this study we explore their 
involvement in immune and inflammatory reactions via the release of inflammatory 
mediators.
The objectives of the investigation were:
1. To explore the potential of human colonic epithelial cells to express inflammatory 
mediators, such as chemokines and nitric oxide.
2. To investigate the mechanisms involved in nitric oxide production and regulation in 
human colonic epithelial cells.
3. To characterise the spectrum of chemokine production by human colonic epithelial 
cells and to determine which factors can modulate this generation.
2. To explore the effects of T cell-derived cytokines on nitric oxide and chemokine 
production in human colonic epithelial cells.
The elucidation of the role of the colonic epithelial cells in inflammatory process could 
offer a novel approach in the development of new diagnostic tests and potential new 
therapeutic strategies for the effective treatment of intestinal inflammation.
Materials and Methods 44
2. MATERIALS AND METHODS
2.1 MATERIALS
Human recombinant IL-la (specific activity 5xl07 U/mg), a generous gifts from Glaxo 
(Greenford, UK) was diluted in sterile PBS + 0.25% (w/v) bovine serum albumin (BSA, 
low endotoxin) (Sigma) and stored in aliquots at -70° C.
Human recombinant TNF-a (specific activity 6xl07 U/mg), a generous gifts from Bayer 
(Slough, UK) was diluted in sterile PBS + 0.1% (w/v) bovine serum albumin (BSA, low 
endotoxin) (Sigma) and stored in aliquots at -70° C.
Human recombinant IFN-y (specific activity > 2.0xl07 U/mg) was purchased from 
Boehringer Mannheim, U.K and stored in aliquots at -70° C.
Human recombinant IL-10 (specific activity lxlO7 U/mg), kindly donated by Dr K.W. 
Moore (DNAX Palo Alto, California U.S.A.) was diluted in sterile PBS + 0.1% (w/v) 
bovine serum albumin (BSA, low endotoxin) (Sigma) and stored in aliquots at -70° C. 
Human recombinant IL-4 (specificity > lxlO7 U/mg) was purchased from Genzyme and 
stored in aliquots at -70° C.
Human recombinant IL-13 was purified from culture supernatants of stable transfected 
CHO cells (Minty et al. 1993) and generously provided by Dr A. Minty (Sanofi, Recherche, 
Labege, France). IL-13 was diluted in sterile PBS + 0.25% (w/v) bovine serum albumin 
(BSA, low endotoxin) (Sigma) and stored in aliquots at -70° C.
All cell culture plastics were purchased from Nunc.
Materials and Methods 45
2,3-Diaminonaphthalene (DAN) was purchased from Lancaster Synthesis Ltd. 
Cycloheximide, Sodium nitrite, Actinomycin-D, and Dimethyl-sulphoxide (DMSO)
were purchased from Sigma Chemical, UK.
The Digoxigenin (DIG) chemiluminescent detection kit for Northern blotting was from 
Boehringer Mannheim (Lewes, U.K.).
5'Digoxigenin labelled probe for iNOS was cocktail containing 3 antisense 30-mer 
oligonucleotides purchased from R & D Systems (Abingdon, U.K.).
5'Digoxigenin labelled probes for IL-8, MCP-1, and RANTES were cocktails containing 3 
and 4 antisense 30-mer oligonucleotides, respectively, purchased from R & D Systems 
(Abingdon, U.K.).
5'Digoxigenin labelled probes for p-actin was cocktail containing 4 antisense 30-mer 
oligonucleotides, purchased from R & D Systems (Abingdon, U.K.).
Antibodies for IL-8 (anti-human IL-8 mouse monoclonal antibody, alkaline phosphatase 
conjugated anti-human IL-8 goat polyclonal antibody and human recombinant IL-8 
standard) enzyme-linked immunosorbent assay (ELISA) were a generous gift from Dr I.J.D. 
Lindley (Sandoz Forschungsinstitut, Vienna, Austria) (Ceska et al., 1989).
Antibodies for RANTES (anti-human RANTES mouse monoclonal antibody and anti­
human RANTES goat polyclonal antibody) were purchased from R & D Systems 
(Abingdon, UK). In ELISA, this antibody does not cross-react with other chemokines 
tested (R & D Systems).
Antibodies for MCP-1 (anti-human MCP-1 mouse monoclonal antibody and polyclonal 
rabbit aMCP-1), were a gift from Dr. T. Yoshimura (NIH) (Yoshimura et al., 1991).
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Dr J.R. Weinder and colleagues at Merck Research Laboratories, Rahway, New Jersey, 
U.S.A, characterised and generously provided a rabbit anti-iNOS affinity purified IgG 
designated NO-53, which was raised against the last seven carboxy terminal amino acids of 
human iNOS and does not cross react with the constitutive NOS isoform (Singer et al 
1996) and the immunogenic peptide (lUN-Tyr-Arg-Ala-Ser-Leu-Glu-Met-Ser-Ala-Leu- 
Ser-COOH), as specificity control.
Mouse monoclonal anti-human IL-8 for immunostaining was a generous gift from Dr 
I.J.D. Lindley (Sandoz Forschungsinstitut, Vienna, Austria).
The ABC complex and the DAB (3,3'-Diaminobenzidine) peroxidase substrate tablets set 
were from DACO and Sigma, respectively.
2.2 CELL CULTURE CONDITIONS
2.2.1 HT-29 colon adenocarcinoma cell One
The human colon epithelial cell line HT-29 was obtained from the European Collection of 
Animal Cell Cultures (ECACC). HT-29 cells are human colon adenocarcinoma grade II 
cells isolated from a primary tumour in a 44 year old Caucasian female (ECACC). They are 
a well characterised epithelial cell line and have characteristics of normal intestinal 
epithelium such as epithelial polarity, presence of the actin-biding protein villin and the 
occurrence of an enterocytic differentiation (Chantret et al 1988).
2.2.2 Cell culture
HT-29 cells were routinely cultured in 80 cm2 tissue culture flasks in McCoy’s medium 
supplemented with penicillin (lOu/ml), streptomycin (10|ig/ml), fungizone (0.5|Xg/ml), 
and 10 % (v/v) FCS (referred to as complete medium). Cultures were maintained at 37° C
Materials and Methods 47
in an atmosphere of 5 % CO2 . The medium was changed every 3 days. To subculture 
confluent monolayers, the medium was removed and the cells were washed 3 x with PBS 
(w/o Ca2+ and Mg2+). Cells were then washed (IX) with a 3ml Trypsin-EDTA mixture of 
0.05% (w/v) Trypsin and 0.02% (w/v) EDTA. The excess solution was removed and the 
cells were incubated for approximately 5 mins at 37° C until the cells had detached from 
the flask. The action of trypsin/EDTA was inhibited by adding 10ml of complete 
McCoy’s medium and the cell suspension was centrifuged at 200 g for 5 min. The cell 
pellet was resuspended in complete medium and cell counting and viability were checked 
in a Neubauer haematocytometer after mixing with Trypan Blue (Sigma). Dead cells 
stained blue, due to the uptake of Trypan Blue. Cell viability was always greater than 
95%. Cells were counted and then seeded at 2-3 X 104 / ml of McCoy’s complete 
medium, into 80 cm2 tissue culture flasks for further culture, or into 6-well plates for 
experimental protocols. Flasks and plates reached confluency after approximately 6 days. 
For storage, cells were resuspended at 4 X 106 cells /ml of freeze medium. The freeze 
medium contained 10% of dimethylsulphoxide (DMSO) (Sigma), 40% FCS, and 50% 
McCoy’s medium. The cell suspension was transferred to cryotubes (Nunc) at 1 ml / tube, 
gradually cooled in vapour phase of liquid nitrogen overnight and tubes were stored in 
liquid nitrogen tanks. For resuscitation of cells from liquid nitrogen, cells were rapidly 
defrosted at 37° C in a water bath, washed in McCoy’s medium, resuspened in complete 
medium and cells from 1 cryotube were seeded into 80 cm2 tissue culture flasks in 
McCoy’s medium, continuing as above.
2.2.3 Mycoplasma assay
HT-29 cells were tested for contamination with the 4 common mycoplasma species (M. 
arginini, M. hyorhinis, A. laidlawii, M.orale) using an enzyme immunoassay kit
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(Boehringer Mannheim). The protocol recommended by the manufacturers was followed 
and 4 day old culture supernatants were routinely screened. The protocol was used as 
follows. 96 well microtitre plates (Nunc Immuno maxisorb plates) were coated with 125 
|xl of four different antibody solutions directed against the four mycoplasma species. 
Plates were incubated for 2 hours at 37° C. Antibody solutions were removed and non 
specific binding sites blocked with 125 j l l I  of blocking solution for 30 minutes at 37° C. 
Plates were washed 3 x and incubated with 100 |X l  of either cell culture supernatant, or 
positive control solutions, or medium alone, at 4° C overnight. Plates were washed 3 x 
and incubated with 100 jxl of the four corresponding detecting biotin-labelled antibodies 
for 2 hours at 37° C. Plates were washed 3 x and incubated with 100 fxl of streptavidin- 
alkaline phosphatase for 1 hour at 37° C. Washed plates were incubated with 100 jxl of 
substrate solution for 1 hour at room temperature. Results were evaluated visually and 
confirmed by reading optical densities at 405 nm. All cultures tested during the study 
were negative for all four mycoplasma species were examined.
2.3 EXPERIMENTAL PROTOCOL
HT- 29 cells were grown in 6-well plates until confluent. Twenty-four hours prior to the 
experiment the confluent monolayers were washed and cultured in FCS-free McCoy’s 
medium. Growth arrested cultures were then treated with fresh FCS-free medium and 
stimulated with the appropriate doses of either drugs, or cytokines, or vehicle controls for 
the times described in the results section. Supernatants were collected, centrifuged to 
remove cellular debris and stored at -70° C until assayed for extracellular chemokines or 
nitrite. Total RNA and cellular proteins were extracted as described below. Cell counting 
and viability was routinely checked at the beginning and the end of the experiment, by
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phase microscopy and by trypan blue exclusion, using representative wells. Cell viability 
was always greater than 95%.
2.4 COLONIC BIOPSY CULTURES
2.4.1 Patients
Colonic biopsies were selected from patients who had undergone colonoscopy at the Royal 
United Hospital, Bath. The patient group (n=8, 3 men and 5 women, median age 55.6 years, 
range 42-74) included patients with diverticular disease (n=3), colon adenocarcinoma (n=2), 
and normal individuals (n=3). These samples in routine histology had normal morphology 
and number of glands, normal numbers of goblet cells and did not show inflammatory 
infiltration of the lamina propria. Patients consent was obtained and the local Research 
Ethics Committee granted approval for this study.
2.4.2 Biopsy culture
Human colonic biopsies, after removal from patient, were immediately placed in transport 
medium, Hanks’ balanced salts solution (HBSS) pH 7.4, supplemented with antibiotics 
(penicillin lOOU/ml, streptomycin 100 pg/ml, gentamycin 50 pg/ml, and fungizone 2.5 
pg/ml), transferred to the laboratory, and gently washed 3 X of 15 minutes in the 
transport medium. Mucosal biopsy specimens were then placed in a six-well plate 
(Gibco), containing 2 ml of Trowell’s-T8 65% (v/v) / RPMI-1640 25% (v/v) / foetal calf 
serum 10% (v/v) medium (supplemented with Hepes buffer 10 mM, glutamine 2 mM, 
penicillin lOOU/ml, streptomycin 100 pg/ml, gentamycin 50 |ig/ml, and fungizone 2.5 
pg/ml) per well. Colonic biopsies were incubated at 37° C in an atmosphere of 5% CO2  in 
the presence of appropriate stimuli and were cultured for 30 hours. Supernatants were
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then collected for nitrite measurement and colonic specimens were used for total protein 
estimation of each well.
2.4.3 Protein assay
After 30 hours culture with appropriate stimuli culture supernatants removed for nitrite 
measurement and colonic biopsy specimens were used for estimation of total protein per 
well, using the Bio-Rad Protein microassay. The protein assay was based on the Bradford 
dye-binding procedure (Bradford, 1976). Known concentrations of bovine serum albumin 
(BSA) (Sigma) diluted in phosphate buffered saline (PBS), pH 7.4 were used as a 
standard curve. Colonic specimens were homogenised in PBS, pH 7.4, using an ultrasonic 
homogeniser and solubilised tissue was diluted in various dilutions (1:10-1:200). 200 |il 
of sample or standard and 50 pi of Bio-Rad protein Assay (Bio-Rad) were added per well 
in a 96-well microtiter plate and protein was measured with a microplate reader. Nitrite 
production was expressed as pmol/mg of protein.
2.5 ENZYME-LINKED IMMUNOSORBENT ASSAYS (ELISA)
Extracellular chemokine activity of culture supernatants was measured by double ligand 
ELISA (Brown et al 1994). All ELISA samples were measured in duplicate
2.5.1 IL-8 ELISA
96 well microtitre plates (Nunc immuno maxisorb plates) were coated with 100 pl/well of 
monoclonal anti-IL-8 antibody (5 |Xg/ml) in carbonate coating buffer. Plates were covered 
and incubated overnight at 4° C. Plates were washed 3 x with wash buffer, followed by 
addition in duplicate of 100 pi IL-8 standard (0.05 to 2 ng/ml) or culture supernatant
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appropriately diluted in wash buffer + 2%  (v/v) FCS, and incubated for 2 hours at 37° C. 
Plates were washed 3 x and 50 pi alkaline phosphatase-conjugated goat anti-IL-8 
antibody (5 pg/ml) in wash buffer + 2%  FCS was added for 2 hours at 37° C. Following 
3 washes, plates were incubated with 100 |xl of 1 mg/ml /7-nitrophenyl phosphate in 
warmed diethanolamine buffer at room temperature, until the top standard read -1 .5  OD. 
The reaction was terminated with 50 pi / well 3M NaOH, and the OD measured at 
405nm. The assay was linear between 0.2-2 ng/ml.
2.5.2 RANTES ELISA
96 well microtitre plates (Nunc immuno maxisorb plates) were coated with 50 pl/well of 
anti-RANTES monoclonal antibody (1 pg/ml) in carbonate coating buffer, pH 9.6. The 
plates were covered and incubated overnight at 4° C. Plates washed 3 x with wash buffer, 
followed by the addition in duplicate of 50 pi of RANTES standard (0.1 to 6 ng/ml) or 
culture supernatant diluted in wash buffer + 2%  FCS, and incubated for 2 hours at 37° C. 
Plates were washed 3 x and 50 pi biotynolated anti-RANTES polyclonal antibody (1 
pg/ml) in wash buffer + 2%  FCS added for 2 hours at 37° C. Plates were washed 3 x and 
incubated with 50 pi streptavidin-peroxidase (0.5 mg/ml) in wash buffer + 2 % FCS for 
30 minutes. Following 3 washes, 100 pi of 0.2 mg/ml OPD dissolved in warm 0.1 M 
citric acid-phosphate buffer containing 0.4 pl/ml 30 % (v/v) H2O2 was added. After a 20 
minutes incubation in the dark, at room temperature, the reaction was quenched with 150 
pi 1 HSO and optical densities (OD) at 492 nm were determined. The assay was linear 
between 0.2-4 ng/ml.
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2.5.3 MCP-1 ELISA
96 well microtitre plates (Nunc immuno maxisorb plates) were coated with 100 p.l/well of 
monoclonal anti-MCP-1 antibody (4.5 pg/ml) in coating buffer. Plates were covered and 
incubated overnight at 4° C. Vacant sites on the plastic were blocked with 0.3 ml/well of 
0.2% BSA in coating buffer and plates were incubated at least for 30 min at 37° C. Plates 
were then washed 3X with wash buffer, followed by addition in duplicate of 100 pi of 
serially diluted MCP-1 standard (0.05 to 10 ng/ml) or culture supernatant appropriately 
diluted in TBS-Tween-0.2% BSA, and incubated for 90min at 37° C. Plates were washed 
3X with wash buffer and 100 pl/well of polyclonal rabbit anti-MCP-1, diluted in TBS- 
Tween-0.2% BSA was added for 90 min at 37° C. Following 3 washes, plates were 
incubated with 100 |xl/well of alkaline phosphate labelled anti-rabbit IgG in TBS-Tween 
for 90 min at 37° C. Plates were washed 3X with TBS w/o Tween and followed by 
addition of substrate solution (5mg Sigma 104 phosphate in 5ml substrate buffer) and 
after 20 min at room temperature the reaction was stopped with O.lml/well of 3N NaOH. 
The OD measured at 405nm. The assay was sensitive down to 0.2ng/ml.
2.6 NORTHERN ANALYSIS
Total cellular RNA was isolated from HT-29 colon adenocarcinoma cells using a 
modification of the method of Strieter et al, 1989. Buffers used for northern analysis are 
detailed below, and all solvents were “analytical reagent” grade.
2.6.1 RNA isolation
HT-29 cells, in six well plates, were scraped into 1.5 ml nucleic acid extraction buffer and 
frozen at -70° C in 15 ml sterile polypropylene conical tubes (Falcon) for at least 1 hour,
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preferably overnight. For extraction the cell mixture was defrosted and homogenised by 
pipeting up and down 25 x using a sterile pastette. 1.5 ml of phenol extraction buffer and
1.5 ml of an 1:1 solution of water-saturated phenol (Rathbum Chemicals Ltd, 
Walkerbum, UK) : chloroform was added and each tube vortexed vigorously for 2 
minutes. Tubes were centrifuged at 3,000 g for 10 minutes at 4° C. Using a sterile glass 
pipette, the upper aqueous layer was transferred to a fresh 15 ml tube and 1.5 ml phenol: 
chloroform (1:1) added. The tubes were vortexed and centrifuged as before. The upper 
aqueous layer was transferred to a fresh 15 ml tube and 2.5 ml of 1:25 solution of isoamyl 
alcohol : chloroform added. The tubes were vortexed and centrifuged at 3,000 g for 7 
minutes. The upper aqueous layer was transferred to a fresh 15 ml tube and mixed with 
300 pi 3M sodium acetate and 3 ml of isopropyl alcohol (Fisons propan-2-ol, HPLC 
grade). Tubes were kept at -70° C for at least 1 hour to allow RNA to precipitate. The 
contents were then transferred to a 16 x 16 mm polyallomar ultra centrifuge tube 
(Beckman Instruments Ltd, Buckinghamshire, UK), which had been DEPC-treated and 
autoclaved. The tubes were centrifuged at 30,000 g for 75 minutes at 4° C. The 
supernatants was removed and RNA pellet transferred to an Eppendorf tube in 1.5 ml 75 
% ethanol solution. The Eppendorfs were frozen at -70° C for at least 1 hour, or until 
ready to run gels.
2.6.2. Sample preparation
Eppendorfs containing the RNA samples were defrosted and centrifuged at 12,000 g for 
15 minutes at 4° C. The supernatant was removed and 1.5 ml 75 % ethanol added to the 
RNA pellet. The samples were centrifuged and the wash step repeated twice. The 
supernatant was removed and the pellets air dried in a fume cupboard for 1 hour. RNA 
pellets were resuspended in 50 jxl DEPC-treated water and kept on ice. RNA was
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quantitated by measuring absorbance of 2 |xl RNA in 1 ml 0.1 M NaOH at 260 nm. The 
amount of RNA present in the samples (in pg) was calculated by:
A260 x dilution factor (500) x 40 x volume of remaining RNA solution in ml (0.048) 
ODs were also read at 280 nm and 230 nm to assess the purity of RNA. A value of less 
than 2 for the OD2 6 0  : OD280 ratio indicated protein contamination. A low OD26 0  • OD230 
ratio indicated guanidine contamination. 30 |il of RNA sample buffer was added to 10 fig 
RNA and the samples were vortex mixed and heated for 15-30 minutes at 80° C. The 
samples were cooled on ice and 2.5 pi of bromophenol blue solution were added. 
Samples were mixed and briefly centrifuged (5 secs) prior to loading on agarose gels.
2.6.3. Gel preparation and transblotting
1 % agarose gel was prepared by dissolving 3 g agarose (Boehringer Mannheim) in 230 
ml DEPC-treated water and the solution was heated in microwave oven until the agarose 
dissolved. 15 ml 20 x MOPS buffer and 54 ml formaldehyde were added and the gel 
solution allowed to cool to ~ 60° C before pouring. The gel was set with two 15 lane 
combs using tanks purchased from Hoefer Scientific Instruments (Newcastle, UK). After 
40 minutes, the gel was transferred to a submarine tank (Hoefer), which was surrounded 
with ice, and covered with cold IX MOPS running buffer. 10 pg RNA per lane was 
loaded and the gel run at constant current of 100 mA, until the bromophenol blue band 
had migrated 1.5 inches (~ 2 hours). The gel was placed under a UV light and the 
ethidium-bromide stained 18S and 28S ribosomal RNA bands observed to assess equal 
loading. The gel was photographed using a polaroid CU5 88-46 land camera (Genetic 
research instrumentation Ltd) and type 55 polaroid film (Sigma). The gel was agitated 
gently in DEPC-treated water for 30-60 minutes to remove formaldehyde, prior to 
transblotting. The blotting tank consisted of a glass plate suspended in a sandwich box,
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which was half filled with 20 x SSC buffer. A wide strip of filter paper placed over the 
glass plate and reaching down into the buffer solution at each end acted as a wick. The 
gel was placed upside down on the filter paper and covered with a piece of positively 
charged nylon membrane (Boehringer Mannheim), which had been briefly soaked in 20 x 
SSC. All air bubbles were removed by rolling with a sterile glass pipette, before covering 
the membrane with 3 pieces of similar size paper and a stack of paper towels. A 500 g 
weight was placed on top and left overnight to allow the RNA to transfer by capillary 
action. The RNA was fixed onto the nylon membrane by baking in an vacuum oven 
(Jouen) at 120° C for 20 minutes. The membrane was sealed in a plastic bag and stored at 
room temperature prior to hybridisation.
2.6.4. Hybridisation with DIG-labelled oligonucleotides
Hybridisation of membranes and detection of bound probes was performed essentially as 
described in the Digoxigenin (DIG) chemiluminescent detection kit for Northern blotting of 
Boehringer Manheim. The DIG detection system is based on the labelling of nucleid acid 
probes with a steroid hapten, digoxigenin. The DIG-labelled probes are hybridised to 
membrane-bound RNA. Specific hybridisation is immuno-detected with an alkaline 
phosphatase conjugated anti-digoxigenin antibody and visualised with the 
chemiluminescent substrate, CSPD, using X-ray film. Hybridisation temperature was 
optimised for each probe. IL-8, MCP-1, RANTES, and P-actin probes were all hybridised 
at 42° C, while the iNOS probe was used at 60° C. All probes were used at a final 
concentration of 10 ng/ml. The volumes specified are for a 100 cm2 membrane and pre­
hybridisation, hybridisation and wash steps were all performed at the appropriate 
hybridisation temperature. The membrane was prehybridized by incubating with 20 ml 
hybridisation solution for 1 hour in a sealed bag. The hybridisation solution was
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discarded and 2.5 ml of probe diluted to 10 ng/ml in hybridisation solution was added. 
All air bubbles were removed and the bag resealed and incubated overnight. The 
membrane was transferred to a small sandwich box and washed for 2X of 5 min in 2 x 
SSC, 0.1 % SDS solution followed by 2X of 5 minutes in 0.1 x SSC, 0.1 % SDS solution 
at hybridisation temperature. The following steps were then performed at room 
temperature on a shaking water bath. Membranes were washed for 5 minutes in wash 
buffer, prior to blocking for 30 minutes with 100 ml buffer 2. Membranes were incubated 
for 30 minutes with 20 ml alkaline phosphatase conjugated anti-DIG antibody diluted 1 : 
10,000 in buffer 2. Membranes were washed 2X of 15 min in wash buffer and 
equilibrated for 2-5 min in buffer 3. The membrane was drained and incubated for 5 min 
between 2 plastic sheets with 1 ml of lumigen PPD substrate diluted in 1 : 100 in buffer 3. 
The membrane was drained again, sealed in a plastic bag and incubated for 15 min at 37° 
C in a dark place. The membrane was then exposed to Kodak omat AR5 X-ray film 
(Sigma) for appropriate time at room temperature.
2.7 FLUOROMETRIC NITRITE ASSAY
Nitric oxide (NO) was determined by measuring in culture supernatants the stable-end 
product nitrite. Nitrite was measured using a fluorometric assay based upon the reaction 
of 2,3- diaminonaphthalene (DAN) (Lancaster, Morecambe, UK) with nitrite under acidic 
conditions to form the fluorescent product 1-(H)- naphthotriazole. The assay was 
modified for use on a Photon Technology International (PTI) spectrofluorimeter from the 
method of Misko et al (Misko et al. 1993), which employed a 96 well plate format for a 
fluorescent plate reader. In contrast to the plate reader, the optimum excitation and
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emission wavelengths for the assay could be set on the fluorimeter, thus improving 
sensitivity. Fluorescent excitation and emission spectra for 1-(H)- naphthotriazole were 
obtained as previously described (Misko et al. 1993) and optimum wavelengths were 
determined. An excitation wavelength of 365 nm and emission wavelength of 405 nm 
were found to be optimum, which was consistent with previous findings (Misko et al. 
1993). A standard curve of sodium nitrite in McCoy’s medium ranging from 100 nM to 2 
pM was prepared. 2 ml of standard or culture supernatant was mixed in a bijoux with 200 
pi of freshly prepared DAN reagent ( 0.05 mg/ml DAN in 0.62 M HC1) and incubated at 
room temperature in the dark. After 10 minutes the reaction was stopped by the addition 
of 100 pi 2.8 N NaOH. Fluorescent intensity of 2 ml volumes of standards and samples 
was measured on the fluorimeter using an excitation wavelength of 365 nm and an 
emission wavelength of 405 nm. Phenol red present in McCoy’s medium did not interfere 
with the assay. The sensitivity of the assay was lOnM.
2.8 WESTERN BLOT ANALYSIS
2.8.1 Collecting samples
HT-29 cells, after incubation with appropriate stimuli, were extracted for iNOS protein by 
scraping the cell monolayer into 0.3 ml of IX sample buffer. 1 pi of 5 pg/ml 
carboxypeptidase inhibitor (Sigma) was added per ml of sample buffer. Samples were 
immediately boiled for 5 minutes (100° C), and then stored in 100 pi aliquots at -20° C, 
until required. Before use samples were centrifuged at 12,000 x g for 2 min.
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2.8.2 Separation of cell proteins for iNOS detection
Proteins were analysed by one dimensional gel electrophoresis, which under reducing 
conditions separates proteins based on molecule size. Sodium Dodecyl Sulphate - 
Polyacrylamide Gel Electrophoresis (SDS-PAGE) was carried out essentially as described 
by Laemmli (Laemmli, 1970). Proteins were separated by SDS-PAGE using the Protean 
II xi gel system (Bio-Rad).
Minigels (5 % (w/v) acrylamide stacking gel and 7 % (w/v) acrylamide running gel) were 
prepared as described in buffers and solutions section.
The running gel was poured into the gel equipment and overlaid with a layer of 50% 
methanol in distilled water. After 1 hour the methanol was removed the top of the gel was 
rinsed with distilled water and the stacking gel was poured on the top of the running gel 
and set with a 15 lane comb. Samples were thawed and centrifuged at 12,000 g for 2 
minutes prior to loading. When stacking gel was set the comb was removed and 20 pi of 
sample was loaded per lane (~ 20 pg) of stacking gel and a prestained molecular weight 
marker was included on each gel. Gels were run at room temperature at 100 volts, until 
the bromophenol blue tracking dye entered the running gel. The voltage was then 
increased to 150 volts. Gels were run until the bromophenol blue band had reached the 
bottom of the resolving gel. Gels were then placed into transfer buffer in preparation for 
Western blotting.
2.8.3 Electrophoretic transfer of proteins to nitro-cellulose
Solubilized roteins after separation on 7 % polyacrylamide gels were transferred to nitro­
cellulose paper, using a transblot electrophoretic apparatus (Bio-Rad). The 
polyacrylamide gel was soaked for 15 minutes in transfer buffer and the lanes of the 
stacking gel removed. Two pieces of filter paper, a piece of nitro-cellulose paper, just
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slightly larger than the gel and two nylon pads were also soaked in transfer buffer. A 
sandwich was constructed in which the gel was overlaid with a piece of wet nitro­
cellulose membrane (Protein BA 85, Schleicher and Schuell, Dassel, Germany), taking 
care to remove all air bubbles and both were surrounded on each side by a layer of filter 
paper and a nylon pad. The sandwich was enclosed in a cassette and placed in the transfer 
tank (Bio-Rad) with the nitro-cellulose nearest the anode. The tank was filled with cold 
(4° C) transfer buffer and placed on a magnetic stirrer. Electrophoretic transfer was 
carried out for 35 minutes at 75 volts.
2.8.4 Immunoblotting of nitro-cellulose-bound protein
Western blot analysis of iNOS protein was performed according to the method of Dr J. 
Weinder, MERCK research laboratories, Rahway, NJ (personal communication). N053 
rabbit antisera directed against the C-terminal sequence of human iNOS and control 
N054 blocking peptide were gifts from MERCK. Antisera were diluted 1 : 1 in glycerol 
and stored at -20° C for daily use. Non specific binding sites on the nitrocellulose were 
blocked for 30 min with 3% non fat-dried milk protein reconstituted in deionized water. 
After washing the nitrocellulose membrane for 10 min in PBS-T (PBS w/o Ca** and Mg++ 
containing 0.05% Tween-20) the membranes were incubated for 1 hour with rabbit anti­
human iNOS antibody (NO-53) diluted 1:40,000 in PBS-T. The membranes were then 
washed (3 x 10 min) in PBS-T before incubation for 1 hour with sheep anti-rabbit IgG 
conjugated to alkaline phosphatase. After further washing in PBS (3 x 10 min) iNOS 
protein was detected using 5-bromo-4-chloro-3-indolyl phosphate substrate solution 
(Sigma). The reaction was terminated with 4 mM EDTA in PBS. To avoid carryover, all 
incubations except the wash steps were performed in separate containers. To establish the 
specificity of anti-iNOS antibody (NO-53) additional Western blots were probed with NO-
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53 IgG in the presence of the immunogenic peptide (H2N-Tyr-Arg-Ala-Ser-Leu-Glu-Met- 
Ser-Ala-Leu-Ser-COOH) at concentrations 50 nM. All incubations and washes were carried 
out at room temperature with gentle shaking.
2.9 IMMUNOHISTOCHEMICAL STUDY OF COLONIC MUCOSA
2.9.1 Patients
Colonic biopsies were selected from patients who had been diagnosed at the Royal United 
Hospital, Bath. The patient groups included active ulcerative colitis (n=12, 9 men and 3 
women, median age 42 years, range 24-59), infectious colitis (n=3, 3 men, median age 41 
years, range 29-56), and controls (n=10, 6 men and 4 women, median age 64 years, range 
26-84). All ulcerative colitis patients were newly diagnosed with moderate to severe disease 
activity at the time of colonoscopy. All patients were examined before treatment and biopsy 
samples were taken from the areas of greatest involvement of the inflammatory process. 
Routine histology of these specimens demonstrated ulceration, mucin depletion, 
deformation of the glands, crypt abscesses, and inflammatory cell infiltration of the lamina 
propria. Patients with infectious colitis, due to salmonellosis were examined and biopsies 
were taken before treatment and in total remission after treatment. Biopsies of normal bowel 
mucosa from patients with diverticular disease (n=2), colon adenocarcinoma (n=6), and 
normal individuals (n=2) were used as controls. These samples in routine histology had 
normal morphology and number of glands, normal numbers of goblet cells and did not 
show inflammatory infiltration of the lamina propria. Patients consent was obtained and the 
local Research Ethics Committee granted approval for this study.
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2.9.2 Immunohistochemistry for iNOS
Polyclonal rabbit antibody against the C-terminal sequence of human iNOS was used in an 
avidin-biotin method to demonstrate the presence of iNOS. Colonic biopsies which had 
been fixed in formalin and embedded in paraffin were mounted on APES coated slides. The 
mounted slides were deparaffinized with xylene. Endogenous peroxidase was blocked in 
2.5% hydrogen peroxide in methanol for 10 min and rehydrated in distilled water for 5 min. 
The slides were then washed with Tris buffered saline, pH 7.6 (TBS), treated with 5 % 
normal swine serum for 5 min, and exposed to rabbit anti-human iNOS (NO-53), diluted 
1:1000. After an 1 hour incubation at room temperature the sections were rinsed with TBS, 
incubated for 40 min in swine anti-rabbit biotynolated secondary antibody, diluted 1:500, 
and washed in two changes of TBS. Slides were then treated with avidin-biotin complex for 
40 min, rinsed twice in TBS, overlaid with 3,3'-diaminobenzidine (DAB) peroxidase 
substrate and incubated for 10 min at room temperature to allow for colour development. 
Gills haematoxylin was used as a counterstain. Blocking experiments were carried out by 
adding 150 nM of the immunogenic peptide (H2N-Tyr-Arg-Ala-S er-Leu-Glu-Met-S er-Ala- 
Leu-Ser-COOH) to the working dilution of anti-iNOS antibody.
2.9.3 Immunostaining for IL-8
Mouse monoclonal antibody against the human IL-8 was used in an avidin-biotin method to 
demonstrate the presence of IL-8. Colonic biopsies which had been fixed in formalin and 
embedded in paraffin were mounted on APES coated slides. The mounted slides were 
deparaffinized with xylene. Endogenous peroxidase was blocked in 2.5% hydrogen 
peroxide in methanol for 10 min and rehydrated in distilled water for 5 min. The slides were 
then washed with TBS, treated with 5 % normal rabbit serum for 5 min, and exposed to 
mouse anti-human IL-8, diluted 1:100. After an 1 hour incubation at room temperature the
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sections were rinsed with TBS, incubated for 40 min in rabbit anti-mouse biotynolated 
secondary antibody, diluted 1:400, and washed in two changes of TBS. Slides were then 
treated with avidin-biotin complex for 40 min, rinsed twice in TBS, overlaid with DAB 
peroxidase substrate and incubated for 10 min at room temperature to allow for colour 
development. Gills haematoxylin was used as a counterstain.
2.10 STATISTICAL ANALYSIS
Triplicate determinations were performed in each experiment. The (n) number of each 
experiment is given in the respective figure legend. Data were analysed by two-way analysis 
of variance (ANOVA) to determine if any statistical significance existed within the data 
groups. ANOVA was followed by Dunnett's test for the comparison of multiple groups to 
controls. This latter test identified which treatments within the group were significantly 
different from the control. Data were expressed as means ± SEM of (n) experiments. A 
probability value of p < 0.05 was taken as the criterion for a significant difference.
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2.11 BUFFERS AND SOLUTIONS
2.11.1 Solutions and reagents for cell and tissue culture
Tissue culture reagents were used for cell and tissue cultures and all solution were 
prepared using sterile, pyrogen-free distilled water (Steripak Ltd, Cheshire,UK).





Hanks’ Balanced Salts Solutions (HBSS), pH 7.4 
100 ml 10X Hanks’ balanced salts (Gibco)
6 ml 7.5 % (w/v) sodium bicarbonate (Gibco)
20 ml 1M HEPES buffer solution (Gibco)
200 pi 40% (w/v) NaOH
Make up to 1L with distilled water. No need to pH.
McCoy’s medium 5A (Gibco)
Supplemented with penicillin (lOu/ml, Gibco), streptomycin (10 pg/ml) (Gibco), and 
fungizone (0.5 |ig/ml) (Gibco) before use.
Trowell’s T8 / RPMI-1640 medium
65% Trowell’s T8 (Gibco)
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25% RPMI-1640 (Gibco)
10% Foetal Calf Serum (FCS) (Gibco)
10 mM HEPES buffer solution (Gibco)
2 mM Glutamine (Gibco)
Supplemented with penicillin (lOU/ml) (Gibco), streptomycin (10 fxg/ml) (Gibco), and 
fungizone (0.5 pg/ml) (Gibco) before use.
Foetal Calf Serum (FCS)
FCS (Gibco) was heat-inactivated at 56° C for 30 minutes and stored at -20° C.
2.11.2 Solutions and buffers for Nitrite assay
HC1 solution
0.62 M HC1 
in Milli-Q water.
NaOH solution
2.8 M NaOH 
in Milli-Q water.
2.11.3 Solutions and buffers for ELISAs
Coating buffer, pH 9.6 (For IL-8, RANTES, and MCP-1)
15mM Na2C0 3  
35mM NaHC03
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3mM NaN3
Adjust pH to 9.6 with 1 M HC1. Buffer can be kept for 2 weeks.
Wash buffer, pH 7.3 (For IL-8 and RANTES)





Tris Buffered Saline (TBS), pH 7.5 (For MCP-1)
50mM Tris
150mM NaCl
Adjust pH to 7.5 with HC1.
Wash buffer, pH 7.5 (For MCP-1)
0.05% Tween-20 in TBS
Diethanolamine substrate buffer, pH 9.8 (For IL-8)
10% (v/v) diethanolamine (BDH) 
lmM MgCl2
Store in the dark, at 4° C.
0.1M Citric-phosphate substrate buffer, pH 5 (For RANTES)
34mM citric acid
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66mM Na2HP04
Substrate buffer, pH 9.7 (For MCP-1)
1M Tris
300mM MgCl2.6H20  
Adjust pH to 9.7 with IN HC1.
Substrate solution (For MCP-1)
Sigma 104 Phosphate Substrate tablets 5mg (1 tabl)
Substrate buffer 5ml
2.11.4 Solutions and buffers for Northern blot analysis
DEPC-treated water or buffer
Milli-Q water or buffer were treated with 1 ml of diethyl pyrocarbonate (DEPC, Sigma) 
per litre of water, and incubated overnight at 37° C. Autoclave (for 20 minutes at 121° C).
20 % (w/v) SDS solution
20 g SDS diluted in 100 ml of sterile Milli-Q water
0.75M Sodium citrate solution, pH 7.0
0.75M trisodium citrate dihydrate in Milli-Q water. Autoclave.
2M TRIS-HC1 stock solution, pH 8
2M TRIS in Milli-Q water. Autoclave.
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O.SM EDTA stock solution, pH 8
0.5M EDTA in Milli-Q water. Autoclave.
Nucleic acid extraction buffer
4 M Guanidine thiocynate (Fulka, Gillingham, UK) (236.32 g / 500 ml)
25 mM Sodium citrate (17.6 ml of 0.75 M stock / 500 ml)
0.5 % sarcosyl (8.3 ml of 30% stock (BDH)/500 ml)
in Milli-Q water.
Add 0.1M 2-mercaptoethanol (Sigma) prior to use.
Use buffer containing 2-mercaptoethanol within 1 month. Store at 4° C.
Phenol extraction buffer
100 mM Tris 
lOmM EDTA 
1% SDS
in Milli-Q water. Autoclave.
3M Sodium acetate, pH 5.2
3M sodium acetate dissolved in 250 ml Milli-Q water.
Adjust pH to 5.2 using 3M glacial acid. DEPC-treat and autoclave.
75% (v/v) ethanol solution
75 ml absolute ethanol (Hayman Ltd, Witham, UK) in 25 ml DEPC-treated water.
(25ml of 2M stock/500ml) 
(10ml/ of 0.5M stock/500ml) 
(25ml of 20% stock/500ml)
Materials and Methods 68
20X MOPS running buffer
0.4M 3-[N-morpholino]-propane-sulfonic acid (MOPS)
0.02M EDTA (4ml of 0.5M stock/lOOml)
0.2M sodium acetate (6.64ml of 3M stock/100ml)
Adjust volume to 100ml with Milli-Q water and pH with solid NaOH. Filter sterilise.
IX MOPS running buffer
50ml 20X MOPS in 950ml DEPC-treated water.
lmg/ml Ethidium bromide solution
lOmg ethidium bromide (Sigma) in 10 ml DEPC-treated water.
RNA Sample buffer (per sample)
7|_l1 36 % (w/v) formaldehyde (BDH)
4pl 20X MOPS running buffer
2|il lmg/ml ethidium bromide solution
20pl formamide (mol. biol. grade, BDH)
Made up fresh immediately before use.
Bromophenol solution
0.025g bromophenol blue 
3ml glycerol
Adjust volume to 10ml with DEPC-treated water.
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20x SSC, pH 7 
3M NaCl
0.3M trisodium citrate dihydrate 
in Milli-Q water. DEPC-treat and autoclave.
Buffer 1
0.1M maleic acid 
0.15M NaCl
Adjust to pH 7.5 with solid NaOH. DEPC-treat and autoclave.
Blocking stock solution
lOg blocking reagent (Boerhinger Mannheim, Lewes, UK) in 100ml buffer 1. 





1% blocking buffer 
in DEPC-treated water.
(25ml of 20X stock/100ml) 
(0.33ml of 30% stock/lOOml) 
(0.1ml of 20% stock/lOOml) 
(10ml of 10% stock/lOOml)
2X SSC, 0.1% SDS solution
50ml of 20X SSC 
2.5ml of 20% SDS stock
Adjust volume to 500ml with DEPC-treated water.
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0.1X SSC, 0.1% SDS solution
2.5ml of 20X SSC 
2.5ml of 20% SDS stock
Adjust volume to 500ml with DEPC-treated water.
Washing buffer
0.3% (v/v) Tween-20 (Sigma) in buffer 1.
Buffer 2
10% (v/v) blocking stock solution in buffer 1.
Buffer 3, pH 9.5
0.1MTRIS
O.lMNaCl
in sterile Milli-Q water.
2.11.5 Solutions and buffers for SDS-PAGE and Western blotting
1M TRIS-HC1, pH 8.8
1M TRIS 
in Milli-Q water.
1M TRIS-HC1, pH 6.8
1M TRIS 
in Milli-Q water.
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10% (w/v) SDS solution
5g of SDS in 50ml Milli-Q water.
10% (w/v) Ammonium Persulphate Solution (APS)
O.lg ammonium persulphate (Sigma) in 1ml Milli-Q water. 
Made up fresh on day.
IX Sample buffer
10% SDS 5 ml
glycerol 5 ml




Bromophenol blue (Bio-Rad) O.Olg
7 % (w/v) acrylamide running gel:
Protogel {30 % (w/v) acrylamide, 0.8 % (w/v) bisacrylamide) 3.5 ml
1M Tris-HCl, pH 5.6 5.6 ml
10 % SDS solution 0.15 ml
10 % ammonium persulphate (APS) 0.1ml
Double-distilled water 5.85 ml
N,N,N’,N\tetramethylene-diamine (TEMED) (Sigma) 10 |il
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5 % (w/v) acrylamide stacking gel:
Protogel {30 % (w/v) acrylamide, 0.8 % (w/v) bisacrylamide) 1.67 ml
1M Tris-HCl, pH 5,6 1.25 ml
10 % SDS solution 0.1ml
10 % ammonium persulphate (APS) 0.05 ml
Double-distilled water 6 ml










40% (v/v) methanol 
7% (v/v) acetic acid
0.1% (w/v) coomassie brilliant blue R-250 (Sigma) 
in Milli-Q water.
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Destain solution
40% (v/v) methanol 
7% (v/v) acetic acid 
in Milli-Q water.




Tris Buffered saline (TBS), pH 7.6
50mM Tris
150mM NaCl
Adjust pH to 7.6 with HC1.
Normal Rabbit Serum 5% (For monoclonals)
TBS, pH 7.6 200ml
NaN3 0.2 g
Add normal Rabbit serum 10 ml
Normal Swine Serum 5% (For polyclonals)
TBS, pH 7.6 200ml
NaN3 0.2 g
Add normal Swine serum 10 ml
Avidin-Biotin Complex (ABC) 





















3.1 INDUCIBLE NITRIC OXIDE EXPRESSION AND ACTIVITY BY COLONIC 
EPITHELIAL CELLS
3.1.1 Nitrite generation by HT-29 cells
Growth arrested monolayers of HT-29 cells when stimulated with vehicle produced a small 
constitutive amount of nitrite (Fig. 2). Time course studies revealed a time-dependent increase 
in constitutive nitrite generation of 50 ± 4, 75 ± 8, and 103 ± 8 nM/106 cells (n=3) at 24h, 48h, 
and 72h, respectively (Fig. 3). The pro-inflammatory cytokines IL-la (lOng/ml), TNF-a 
(lOOng/ml), and IFN-y (300U/ml), added alone to HT-29 cells did not induce a significant 
increase in nitrite generation compared to the constitutive nitrite production in vehicle treated 
cells (Fig. 2). The combination IL-lcx/IFN-y was the minimal requirement for enhanced nitrite 
production, while other pairs of cytokines were ineffective. Stimulation with IL-la 
(10ng/ml)/IFN-Y (300U/ml) produced a highly significant (p < 0.001) increase in nitrite 
production o f306 ± 24 nM/106 cells (n=3) at 48 hours, compared to the basal production of 75 
± 8 nM/106 cells (n=3) (Fig. 2). The addition of TNF-a to the combination of IL-la/IFN-y 
produced approximately a three fold enhancement of BL-la/IFN-y-induced nitrite generation 
eg 889 ± 35 nM/106 cells (n=3) compared to 306 ± 24nM/106 cells (n=3) at 48h (Fig 2).
Stimulation of HT-29 cells with IL-la (10ng/ml)/IFN-y (300U/ml) induced a time-dependent 







Nitrite (nM per 10 cells)
Figure 2 Nitrite production by HT-29 colonic epithelial cells following stimulation for 48 
hours incubation at 37° C with vehicle, IL-la (lOng/ml), TNF-a (lOOng/ml), and IFN-y 
(300U/ml) added alone or in combination. Nitrite levels were determined in supernatants, 
using a fluorescent substrate with a 10 nM level of detection. Basal is the amount of nitrite 














Figure 3 Time course of nitrite production by HT-29 cells following stimulation with vehicle 
(open bars) or IL-la (10ng/ml)/IFN-y (300U/ml) (solid bars). Nitrite levels were determined 
in supernatants, after incubation at 37° C, using a fluorescent substrate with a 10 nM level 
of detection. Each bar is the mean ± SE of three experiments.
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values of 50 ± 4, 75 ± 8, and 103 ± 8 nM/106 cells respectively (n=3) (Fig. 3). Stimulation with 
increasing concentrations of IL-la (0-10ng/ml) in the presence of IFN-y (300U/ml) was found 
to produce a concentration dependent generation of nitrite production at 48 hours by HT-29 
cells (Fig. 4a). Similarly, increasing concentrations of IFN-y (0-300U/ml) in the presence of IL- 
la  (lOng/ml) were found to produce a concentration related production of nitrite at 48 hours 
(Fig. 4b). Interestingly different concentrations of TNF-a(0-100ng/ml) in the presence of the 
combination IL-la(10ng/ml)/IFN-y(300U/ml) induced a concentration dependent 
enhancement of nitrite production (Fig. 5). Pre-treatment of HT-29 colonic epithelial cells with 
the protein synthesis inhibitor cycloheximide (5 mg/ml) for 1 hour prior to EL- 
la(10ng/ml)/IFN-y (300U/ml) stimulation reduced the nitrite levels from 306 ± 24 to 80 ± 6 
nM/106 cells (n=3) at 48 hours, which was no different to basal nitrite production of 75 ± 8 
nM/106cells. Finally, treatment of unstimulated cells with cycloheximide (5mg/ml) did not 
affect the basal nitrite production (74 ± 4 vs 75 ± 8 nM/106cells).
To examine the possible modulatory effect of IL-13, IL-4, and IL-10 on the cytokine-induced 
nitrite generation confluent monolayers of HT-29 cells, after lh pre-treatment with various 
concentrations (0.1-30ng/ml) of IL-13, IL-4 or IL-10 were stimulated with either IL-la 
(10ng/ml)/IFN-y (300U/ml) or IL-la (10ng/ml)/IFN-y (300U/ml)/TNF-a (lOOng/ml) 
supernatants were collected and nitrite were determined at 24 and 48 hours. The stimulation of 
HT-29 cells with IL-13, EL-4, and IL-10, added alone, up to 72 hours did not affect the 
constitutive nitrite generation by these cells (Fig 6). At the stimulation with IL-la 
(10ng/ml)/LFN-y (300U/ml)/TNF-a (lOOng/ml) IL-13 (0.3-30ng/ml) and EL-4 (0.3- 30ng/ml) 
produced a significant suppression of nitrite generation (p < 0.01 -p  < 0.001) (Fig 7a,8a). The 

























Figure 4. a) Nitrite production by HT-29 cells after 48h treatment with different 
concentrations of IL-la (0-lOng/ml) in the presence of IFN-y (300U/ml). b) Nitrite 
production by HT-29 cells after 48h treatment with different concentrations of IFN-y (0- 












Figure 5. Effect of TNF-a (0-100ng/ml) on IL-la (10ng/ml)/IFN-y (300U/ml)-induced 
nitrite generation after 48h treatment by HT-29 cells. Nitrite levels were determined in 
supernatants, after incubation at 37° C, using a fluorescent substrate with a 10 nM 
level of detection. Basal is the amount of nitrite produced by HT-29 cells in the 






Figure 6 Nitrite production by HT-29 cells after treatment with cytokines. Confluent 
monolayers of HT-29 cells were treated with IL-13 (lOng/ml), IL-4 (lOng/ml), IL-10 
(lOng/ml), IL-la (10ng/ml)/IFN-y (300U/ml) or IL-la(10ng/ml)/IFN-Y(300U/ml)/TNF- 
a(100ng/ml) and after 48 hours incubation at 37° C nitrite levels were determined in 
supernatants, using a fluorescent substrate with a 10 nM level of detection. Basal is the 
amount of nitrite produced by HT-29 cells in the absence of added cytokines. The result 





















Figure 7. Nitrite production by HT-29 cells after treatment with (a) IL-la(10ng/ml)/IFN- 
y(300U/ml)/TNF-a( 1 OOng/ml) or (b) IL-la(10ng/ml)/IFN-7(300U/ml) in the presence of 
increasing concentrations of IL-13. Each point represent the mean ± SEM of three 

























Figure 8. Nitrite production by HT-29 after treatment with (a) IL-la(10ng/ml)/IFN- 
y(300U/ml)/TNF-a( 1 OOng/ml) or (b) IL-la(10ng/ml)/IFN-y(300U/ml) in the presence of 
increasing concentrations of IL-4. Each point represent the mean ±  SEM of three 
separate experiments (* p  <0.01, * p  <0.001), compared with positive control (0) 
response.
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nitrite generation. Low concentrations (0.3-3ng/ml) of IL-13 but not IL-4 produced a 
significant enhancement (p < 0.01), while doses of IL-13 and IL-4 higher than lOng/ml 
suppressed significantly (p < 0.01 at 30ng/ml) the nitrite generation by HT-29 cells (Fig. 
7b,8b). In marked contrast the same concentration range of IL-10 had no effect on IL-la/EFN- 
y (Fig 9a) or on IL-la/IFN-y/TNF-a-induced nitrite generation by HT-29 cells (Fig 9b).
3.1.2 Inducible NOS mRNA expression by HT-29 cells
To determine whether the inducible generation of nitric oxide by HT-29 epithelial cells was 
due to the induction of iNOS, the iNOS mRNA expression was determined by Northern 
blot analysis. The time course of iNOS mRNA expression in epithelial cells after 
stimulation with IL-la(10ng/ml)/IFN-y(300U/ml) was examined. In unstimulated cells 
iNOS transcripts were not detected at any of the time points. The combination IL-la 
(10ng/ml)/IFN-y(300U/ml) induced iNOS mRNA expression, which was first observed at 
6h, peaked at 24h and was undetectable by 72h (Fig. 10). Increasing concentrations of IL- 
la(0-10ng/ml) in the presence of IFN-y(300U/ml) were found to produce concentration 
related iNOS mRNA expression after 24h treatment (Fig. 11a). Similarly, using different 
concentrations of IFN-y(0-300U/ml) in the presence of IL-la(10ng/ml) we found 
concentration dependent iNOS mRNA expression at 24 hours in HT-29 cells (Fig. lib). 
These results demonstrate that both IL-la and IFN-y produce concentration dependent 
iNOS mRNA expression in HT-29 cells which induces concentration dependent nitrite 
formation by these cells(Fig. 4a, 4b). In marked contrast, experiments using different 
concentrations of TNF-a(3-100ng/ml) in the presence of IL-la (10ng/ml)/IFN-y(300U/ml) 





















Figure 9 Nitrite production by HT-29 cells after treatment with (a) IL-la(10ng/ml)/IFN- 
y (300U/ml)/TNF-a( 1 OOng/ml) or (b) IL-la(10ng/ml)/IFN-y(300U/ml) in the presence of 
increasing concentrations of IL-10. Each point represent the mean ±  SEM of three separate 
experiments.
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Figure 10 Northern blot analysis of time course of iNOS mRNA expression in HT-29 cells 
stimulated with DL-la (10ng/ml)/IFN-Y (300U/ml). The top panel is the northern blot, the 
middle panel is the densitometry analysis of blot and the lower panel is the ethidium bromide 
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Figure 11 a) iNOS mRNA expression in HT-29 cells after 24h treatment with different 
concentrations of IL-la (0-10ng/ml) in the presence of EFN-y (300U/ml). b) iNOS mRNA 
expression in HT-29 cells after 24h treatment with different concentrations of IFN-y (0- 
300U/ml) in the presence of IL-la (lOng/ml). The top panel of each figure is the northern blot, 
the middle panel is the densitometry analysis of blot and the lower panel is the ethidium 
bromide stained 18s and 28s bands indicating equal loading of the lanes. Representative of two 
experiments.
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iNOS expression in HT-29 colonic epithelial cells (Fig. 12). These results suggest that the up- 
regulation by TNF-a of the IL-1 a/IFN-Y-induced nitrite generation by HT-29 cells is at the 
post-transcriptional level.
To determine the effect of IL-13, IL-4 and IL-10 on the cytokine-induced iNOS mRNA 
expression, cells were pretreated for lh with different doses (0.3-30ng/ml) of IL-13, IL-4 or 
IL-10, then L l a  (10ng/ml)/ IFN-y (300U/ml) or IL-la (10ng/ml)/ IFN-y (300U/ml)/ TNF-a 
(lOOng/ml) were added and iNOS mRNA expression was measured at 24h. Low doses (0.3- 
3ng/ml) of IL-13 but not of IL-4 were found to increase the IL-1 a/IFN-y-induced iNOS 
mRNA expression, while high doses (10-30ng/ml) of both IL-13 and IL-4 suppressed 
significantly the iNOS mRNA expression by HT-29 cells, in the same way as they regulated 
the nitrite generation (Fig. 13a, 14a). Similarly, low doses (0.3-3ng/ml) of IL-13 but not IL-4 
were found to increase the IL-1 a/IFN-y/TNF-a-induced iNOS mRNA expression, while 
higher doses of both IL-13 (Fig. 13b) and IL-4 suppressed significantly the iNOS mRNA 
expression by HT-29 cells, likewise they regulated the IL-1 a/IFN-y-induced iNOS mRNA 
expression, and in marked contrast with the regulation by IL-13 and IL-4 of the IL-la/IFN- 
y/TNF-a -induced nitrite generation. These data taken together suggest that IL-13 and IL-4, at 
all concentrations they were examined, down-regulate the post-transcriptional effect of TNF-a 
on the IL-1 a/IFN-y-induced nitrite generation by HT-29 cells, while high concentrations (>10 
ng/ml) in addition blocked iNOS mRNA induced by proinflammatory cytokines.




















Figure 12 Effect of TNF-a (0-100ng/ml) on IL-la (10ng/ml)/IFN-Y (300U/ml)-induced iNOS 
mRNA expression in HT-29 cells after 24h treatment. The top panel is the northern blot, the 
middle panel is the densitometry analysis of blot and the lower panel is the ethidium bromide 
















Figure 13 iNOS mRNA expression by HT-29 cells after treatment with (a) IL- 
1 a( 10ng/ml)/IFN-y(300U/ml) or (b) IL-la(10ng/ml)/IFN-Y(300U/ml)/TNF-a(100ng/ml) 
in the presence of increasing concentrations of IL-13. Pro-inflammatory cytokines were 
added after lh pretreatment with IL-13 and incubated for 12h at 37° C. The top panel is the 
Northern blot hybridized at 60° C overnight with DIG-labelled oligonucleotide probes 
(lOng/ml) for iNOS, the middle panel is the densitometry analysis of blot and the lower 
panel the ethidium bromide stained 18s and 28s bands indicating equal loading of the lanes. 
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Figure 14 iNOS mRNA expression by HT-29 cells after treatment with IL- 
la(10ng/ml)/IFN-y(300U/ml) in the presence of increasing concentrations of IL-4 (a) or IL- 
10 (b). Pro-inflammatory cytokines were added after lh pretreatment with either IL-4 or 
IL-10 and incubated for 12h at 37° C. The top panel is the Northern blot hybridized at 60° 
C overnight with DIG-labelled oligonucleotide probes (lOng/ml) for iNOS, The top panel is 
the Northern blot, the middle panel is the densitometry analysis of blot and the lower panel 
the ethidium bromide stained 18s and 28s bands indicating equal loading of the lanes. 
Representative of three experiments.
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3.1.3 iNOS protein expression
HT-29 cells were treated for 24 hours with the appropriate stimuli, then the iNOS protein 
expression was determined by Western analysis. The minimal requirement for iNOS protein 
expression is the combination of IL-la/IFN-y, while the iNOS protein expression is greatly 
enhanced by the addition of TNF-a, in parallel to the 3 fold increase of nitrite generation. 
Unstimulated cells did not express iNOS protein. Pre-treatment of HT-29 cells for 1 hour with 
low concentrations of IL-13 (0.3 - 30 ng/ml) slightly increased, while higher concentrations (10 
- 30 ng/ml) suppressed iNOS protein expression induced by the minimal cytokine requirement 
of IL-la (10ng/ml)/ IFN-y (300U/ml) combination (Fig. 15a). In contrast, pretreatment for 1 h 
with IL-13 (0.3 -30 ng/ml) produced a concentration dependent inhibition of iNOS protein 
expression induced by the optimal cytokine "cocktail" of IL-la (10ng/ml)/ IFN-y (300U/ml)/ 
TNF-a (lOOng/ml) (Fig. 15b).
3.1.4 Nitrite generation in human colonic biopsies
To examine similar effect of cytokines on the nitrite production by human colonic biopsies 
and whether they can be modulated by IL-13 colonic biopsies were cultured with the same 
combination of cytokines under similar conditions. IL-13 added alone did not modulate the 
constitutive production on either HT-29 cells or colonic biopsy cultures. Mucosal biopsy 
specimens of each patient were placed in three wells of a six-well plate containing 2 ml of 
culture medium with the appropriate concentrations of stimuli per well. Colonic biopsies from 
each patient were then cultured for 30 hours in the presence of either a) vehicle, or b) 
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Figure 15. iNOS protein expression by HT-29 cells after stimulation with a): IL-la 
(lOng/ml) / IFN-y (300U/ml) and b): IL-la (lOng/ml) / IFN-y (300U/ml) / TNF-a 
(lOOng/ml) in the presence of increasing concentrations of IL-13. HT-29 cells were 
pretreated for lh with IL-13, then pro-inflammatory cytokines were added. HT-29 
monolayers were scraped after 12h incubation at 37° C and total protein was 
extracted. iNOS protein expression was determined by Western blot analysis, using an 
anti-human iNOS antibody. Representative of three experiments.
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(100 ng/ml) + IFN-y (300 U/ml) added after 1 h pre-treatment with vehicle, or c) 
combination of IL-la (10 ng/ml) + TNF-a (100 ng/ml) + IFN-y (300 U/ml) added after 1 
hour pre-treatment with IL-13 (30 ng/ml). After treatment, total protein were estimated per 
well and individual nitrite content of each well was measured and expressed as pmol mg'1 of 
total protein (Table 4). Unstimulated colonic biopsies produced a constitutive amount of 
nitrite (225 ± 14 pmol/mg of protein of tissue, n=8). Stimulation with IL-la+TNF-a+IFN-y 
produced a highly significant (p < 0.001) increase in nitrite production of 784 ± 58 pmol/mg 
of protein (n=8). Following stimulation with IL-la+TNF-a+IFN-y, IL-13 produced a highly 
significant (p < 0.001) suppression of nitrite generation by the cultured colonic biopsies, to 422 
± 39 pmol/mg of protein, at 30ng/ml of IL-13 (n=8) (Fig. 16).
3.1.5 Immunohistochemical study of colonic biopsies
Colonic biopsies of normal, non inflamed mucosa (10 out of 10 cases), derived from patients 
with diverticular disease, colon adenocarcinoma and healthy individuals were found negative 
for iNOS expression (Fig. 17A). In 11 out of 12 cases of ulcerative colitis the epithelial cells 
markedly expressed iNOS always at the superficial part of the crypt and the surface of the 
mucosa, while no other positive cells were found in lamina propria (Fig. 17B). 
Characteristically the iNOS expression was located in the most cases at the apical part of 
epithelial cells and it was in close association with the neutrophil infiltration of lamina propria 
and epithelium (Fig. 17C). Similar results were seen in all cases of infectious colitis examined 
(Fig. 17D). Colonic biopsies from infectious colitis patients, positive for iNOS in the acute 
phase of the disease, when re-examined in total remission did not express detectable iNOS
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Patient (No) Basal IL-1 a/IFN-y/TNF-a Presence of IL-13
P1 236 758 314
P2 190 612 384
P3 262 782 348
P4 164 985 462
P5 254 646 516
P6 184 914 390
P7 248 582 326
P8 266 995 638
Table 4. Nitrite production by cultures of human colonic mucosa after stimulation with
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Figure 16. Nitrite production by human colonic biopsies after treatment with (3C), IL-la 
(10ng/ml)/IFN-y(300U/ml)/TNF-a(100ng/ml) in the presence of 30 ng/ml of IL-13. Pro- 
inflammatory cytokines were added after lhour pre-treatment with vehicle (3C) or IL-13 
(3C+IL-13) and nitrite levels were determined in supernatants after 24h incubation at 37° C.
Data are individual datapoint and bars indicate the mean ± SEM of eight samples (n=8).
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Figure 17A Normal colonic bowel mucosa with no detection of iNOS. Immunostaining 
with anti-human iNOS (NO-53) using avidin-biotin peroxidase. Original magnification X 
100.
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Figure 17B Ulcerative colitis with staining of superficial section of crypt and surface 
epithelium, while no other positive cells were found in lamina propria. Immunostaining with 
anti-human iNOS (NO-53) using avidin-biotin peroxidase. Original magnification X 100.
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Figure 17C Another ulcerative colitis case showing similar staining; iNOS labelling is 
located at the apical part of epithelial cells in close association with the neutrophil infiltration 
of lamina propria and epithelium. Immunostaining with anti-human iNOS (NO-53) using 
avidin-biotin peroxidase. Original magnification X 100.
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Figure 17D Acute infectious colitis with staining of superficial section of crypt and surface 
epithelium. Immunostaining with anti-human iNOS (NO-53) using avidin-biotin peroxidase. 
Original magnification X 100.
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Figure 17E The patient of figure 17D, in total remission, with resolution of iNOS 
expression. Immunostaining with anti-human iNOS (NO-53) using avidin-biotin peroxidase. 
Original magnification X 50.
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Figure 17F Same section as figure 17D using primary antibody preabsorbed after 
incubation with the immunogenic peptide. The staining was dramatically reduced. 
Immunostaining with anti-human iNOS (NO-53) using avidin-biotin peroxidase. Original 
magnification X 250.
Results 103
staining (Fig. 17E). No staining was seen in the negative controls, when the primary antibody 
(NO-53) was omitted, and staining was dramatically reduced when the NO-53 IgG was 
incubated with the immunogenic peptide (Fig. 17F).
3.1.6 Discussion
NO is produced at many sites of the gastrointestinal tract and it is considered as an important 
mediator in physiological and pathological events (Whittle, 1994). At the beginning of this 
study, NO synthesis (Middleton et al, 1993; Lundberg et a l, 1994) and NOS activity 
(Boughton-Smith et al, 1993) had been reported increased in the inflamed mucosa from 
patients with IBD compared to the uninflamed controls, but the type of cells responsible for 
this production was unknown. We have examined the source of NO generation in colonic 
mucosa using immunohistochemical analysis of human large bowel biopsies, cultures of 
the colonic adenocarcinoma cell line HT-29 and cultures of human colonic biopsies.
We have clearly shown iNOS protein expression via immunohistochemistry in the epithelial 
cells of the colonic mucosa of patients with active ulcerative colitis and infectious colitis. This 
iNOS protein expression is absent from the mucosa of biopsies derived from patients in 
remission, uninvolved mucosa of colon adenocarcinoma, diverticular disease, as well as healthy 
individuals. The iNOS was heavily expressed on the apical surface of the epithelium at the top 
of the crypts with less expression in deeper epithelial cells of the crypts, while iNOS expression 
was not detectable in the lamina propria or in the inflammatory leukocytes closely associated 
with the epithelial cells. Similarly, Reynolds et al (Reynolds et al, 1995), using in situ
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hybridisation and immunohistochemistry have demonstrated high expression of iNOS 
localised to the surface epithelium and crypts in the mucosa from patients with ulcerative 
colitis. These results strongly suggest that the colonic epithelial cells are the major source of 
NO production and NOS activity that is increased in the mucosa from patients with ulcerative 
colitis (Middleton et al 1993; Lundberg et al 1994; Boughton-Smith et al 1993) and this NO 
generation is in close association with, and probably contributory to, the inflammatory 
process. Our results with biopsies derived from newly diagnosed ulcerative colitis and 
infectious colitis patients extend and complement a parallel study by Singer et al. (1996) in 
which resected colon from patients with long standing intractable ulcerative colitis were 
examined. The similarity in these two studies is the heavy iNOS staining in the apical region 
of the superficial region of crypts in close association to areas of intense neutrophil infiltration 
of lamina propria and epithelium. In addition Singer et al. (1996) have noted iNOS expression 
in the deeper epithelial cells of the crypts as well as the occasional iNOS expression by the 
infiltrating mononuclear and polymorphonuclear cells within the lamina propria. Whether this 
increased pattern of iNOS distribution reflects the chronicity and untreatable nature of the 
ulcerative colitis in the Singer et al. study compared to our own remains to be determined. 
However, another complementary observation between the two studies is that we noted an 
absence of iNOS expression by the epithelial cells in the non-inflamed mucosa of patients 
with diverticular disease, while Singer et al. observed iNOS expression in inflamed mucosa of 
patients with diverticulitis and that iNOS expression was not present in colonic biopsies from 
patients with infectious colitis in total remission after treatment. Taking these results together 
it is clear that iNOS expression by colonic epithelial cells is only present when there is an 
underlying inflammatory component within the colonic mucosa.
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In support of our immunohistochemical findings, we have demonstrated that human HT-29 
colonic epithelial cells in response to specific combinations of cytokines express iNOS 
mRNA and produce large quantities of nitrite. The expression of iNOS activity in cells and 
tissues is thought to be controlled by a combination of cytokines and the profile of cytokine 
responsiveness varies with the cell type. In our study unstimulated HT-29 cells produced a 
small amount of nitrite in a time dependent manner, which appeared to be due to constitutive 
NOS as no iNOS mRNA expression was detected and the production of nitrite was unaffected 
by the protein synthesis inhibitor cycloheximide. None of cytokines added alone increased the 
nitrite generation. These results are similar with that found in cultured human hepatocytes 
(Nussler et al. 1992; Geller et al 1993), lung epithelial cells (Asano et al. 1994; Robbins et al. 
1994), and mesangial cells (Nicolson et al. 1993). In contrast, treatment of either human 
vascular smooth muscle cells (Junquero et al. 1992) with IL-lp, or human chondrocytes 
(Charles et al. 1993; Maier et al. 1994) with single proinflammatory cytokines IL-lp, IFN-y, 
or TNF-a caused a marked increase in iNOS mRNA, iNOS protein, and nitrite generation. 
The combination of IL-la and IFN-y was the minimal stimulation required, while no other 
pair of cytokines was effective, for iNOS mRNA expression or significant increase of nitrite 
generation in HT-29 cells. Similar results were also obtained with human mesangial cells 
(Nicolson et al. 1993). Combinations of IL-la and IFN-y induced a concentration dependent 
nitrite generation and iNOS mRNA expression. Treatment of HT-29 cells with IL-la/IFN-y
induced up to a 4 fold increase in nitrite generation, which is in contrast with human 
hepatocytes as the same combination of cytokines induced only 5% increase in nitrite 
generation (Nussler et al. 1992). The combination TNF-a/IL-la/IFN-y was most effective 
with nitrite levels increasing 12 fold compared to constitutive values.
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The presence of these three signals produced the same high increase of nitrite production in 
human hepatocytes, lung epithelial cells, and mesangial cells. Studies of iNOS mRNA 
expression revealed that the TNF-a up-regulation of IL-la/IFN-y induced nitrite generation 
by HT-29 cells was at the post-transcriptional level. Cycloheximide, a protein synthesis 
inhibitor, has been reported to inhibit the nitrite generation in human cells treated with 
cytokines (Junquero et al. 1992; Nicolson et al. 1993; Palmer et al. 1993). Similarly in our 
study pretreatment with cycloheximide reduced the nitrite production to constitutive levels, 
regardless of maximal stimulation with IL-la/IFN-Y, suggesting that the nitrite evoked by 
these cytokines is dependent on de novo protein synthesis, probably the iNOS enzyme and/or 
essential peptide co-factors.
We believe that the increased nitrite generation is due to iNOS enzyme activity because this 
production was induced by a combination of cytokines and blocked by cycloheximide, a 
protein synthesis inhibitor. However more importantly, we have only detected increased nitrite 
generation with those treatments which induce the expression of iNOS mRNA. Time course 
studies with the combination of IL-la and IFN-y demonstrated that the nitrite generation 
peaked at 72h, while peak ratio of nitrite production occurs between 24-48h and slows 
between 48-72h. The different ratio of nitrite generation could represent peak protein 
translation or co-factors generation at 24-48h, which is necessary for optimum enzyme 
activity. Furthermore Northern analysis demonstrated that iNOS mRNA peaks at 24h and is 
undetectable by 72h, indicating a loss of iNOS mRNA from 24h onwards available for protein 
synthesis. These results are consistent with the findings from human hepatocytes (Geller et al. 
1993; Nussler et al. 1992) in which the iNOS mRNA peaked at 8h after stimulation and the
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nitrite generation peaked at 48h. The fact that the maximum nitrite generation occurs more 
than 24h after the peak of mRNA indicates that iNOS enzyme is stable and active for long 
after its synthesis. The gap between maximum enzyme message expression and maximum 
nitrite generation might suggest the requirement of de novo synthesis of a co-factor, e.g. 
tetrahydrobiopterin (Stuehr & Griffith, 1992; Nussler et al 1992) for maximal activity. These 
data suggest that human colonic epithelial cells must now be considered together with human 
hepatocytes, smooth muscle cells, chondrocytes, lung epithelial cells, and mesangial cells as 
an important source of nitric oxide production.
Since both T-cells and T-cell-derived cytokines including IFN-y, IL-4, and IL-10 have been 
detected in the mucosa of patients with inflammatory bowel disease (Lichtman & Sartor, 
1993; Sartor, 1994; Kolios & Nakos, 1995) we have utilised the human colonic epithelial cell 
line HT-29 as a model to explore the regulation by T-cell derived cytokines of epithelial iNOS 
expression and activity. We have demonstrated for first time that IL-4 and 11^13, but not IL- 
10 produces a concentration related and a marked inhibition of nitrite generation, iNOS 
protein expression and iNOS mRNA induced in a human colonic cell line by the optimal 
cytokine cocktail of IL-1 a/IFN-y/TNF-a. However, it is likely that IL-4 and IL-13 are 
operating via distinct receptors as differential effects of IL-4 and IL-13 were observed (Callard 
et al 1996). Firstly low doses of IL-13, but not IL-4 produced an enhanced nitrite generation 
when the sub-optimal stimuli of IL-lot/IFN-y combination was used, although higher 
concentrations of IL-4 and 11^13 both inhibited nitrite generation in this system. Secondly, 
this differential effect of IL-4 and IL-13 was observed at the level of iNOS mRNA, namely 
low concentrations of IL-13, but not IL-4, enhanced iNOS mRNA expression, while
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concentrations above 3 ng/ml of IL-4 and IL-13 produced a concentration related and marked 
inhibition of iNOS mRNA transcription. It is clear by taking the iNOS mRNA, iNOS protein 
and nitrite generation data into account that the inhibitory effect of IL-13 and IL-4 observed at 
low concentrations of each of these cytokines is dependent upon the presence of TNF-a, 
acting as a post-transcriptional stimulator of iNOS expression and activity. In contrast, the 
higher concentrations of both IL-4 and IL-13 are potent inhibitors of iNOS mRNA induction, 
which is entirely independent of the presence of TNF-a.
Interleukin-13 has been reported to inhibit nitric oxide production by activated murine 
peritoneal macrophages (Doyle et al 1994) and mouse bone marrow-derived macrophages 
(Doherty et al 1993). Recently Saura et al. (1996), have published that IL-13 inhibits iNOS 
expression in human mesangial cells after stimulation with a "cocktail" of pro-inflammatory 
cytokines and LPS. However, the mechanism responsible for this effect is not known. In our 
study IL-13 was found to have a dual effect on pro-inflammatory-derived iNOS expression 
and activity in HT-29 cells. As we discussed above, it inhibits, at all concentrations examined, 
the postranscriptional effect of TNF-a on IL-1 a/IFN-y-induced nitrite generation and in 
concentrations higher than 3 ng/ml it inhibits the IL-1 a/IFN-y-induced iNOS expression and 
activity, while at lower doses enhances the effect of IL-la/IFN-y on iNOS expression and 
activity by HT-29 cells. Similar up-regulating effect was observed for IL-4, which induces an 
increased secretion of nitrite by IFN-y-activated human monocytes (Kolb et al 1994). IL-4 
has been reported to inhibit NO synthesis in mouse activated macrophages (Oswald et al 
1992), in murine macrophages (Cenci et al 1993; Liew et al 1991), and human mesangial 
cells (Saura et al 1996). IL-4 shares many properties with IL-13 with regard to biological
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activities and signal transduction pathways and in most cell types in which an IL-4 effect was 
seen, subsequent analysis has shown that IL-13 is also effective (Zurawski & De Vries, 1994). 
However these two cytokines have also different biological functions on the same cell lines. It 
has been reported that the binding sites for IL-4 and IL-13 on target cells are slightly different, 
but at least one binding protein is shared by both IL-4 and IL-13 receptors. Some cells, 
however, may express all three subunits for IL-4 and IL-13 receptors, while other cells may 
express different subunits or not all of them (Feng et al 1995).
Interleukin-10 is considered as an anti-inflammatory cytokine, which was originally described 
as Th2-cell-derived cytokine. Recent studies have shown that IL-10 is produced by a variety 
of cells, including Th2 cells, Ly-1 B cells, mast cells and cells of the macrophage lineage 
(Moore et al 1993). This cytokine at concentrations of 10 ng/ml or less is an effective 
inhibitor of cytokine generation by IFN-y and/or LPS stimulated human monocytes (De Waal 
Malefyt et al 1991), prostaglandin E2  production by IL-1 or LPS activated human monocytes 
(Poole et al 1995) and chemokine generation by polymorphonuclear leukocytes treated with 
LPS (Kasama et a l 1994). IL-10 has been found to inhibit NO production by mouse activated 
macrophages (Oswald et al 1992; Cenci et al 1993). However, we found that IL-10 
throughout the concentration range of 0.1 to 10 ng/ml had no effect on pro-inflammatory 
cytokine-induced iNOS expression and activity by the colonic epithelial cell line HT-29. 
Despite the absence of any effect of IL-10 on our cell model, our findings give a strong 
evidence that the T-cell derived cytokines modulate the pro-inflammatory cytokines derived 
iNOS expression and activity in colonic epithelial cells and might be involved in intestinal 
inflammation.
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Although our results were obtained with a colonic epithelial cell line, which has many 
characteristics in common with "normal" colonic epithelial cells (Chantret et al. 1988) the 
possibility exists that "normal" cells may behave differently to tumour cells. Thus, colonic 
biopsies were cultured under similar conditions to explore the ability of normal colonic 
mucosa to produce nitrite and to examine the agents, which regulate this generation. We have 
demonstrated for first time that un-stimulated cultures of colonic biopsies from normal bowel 
mucosa produced a constitutive amount of nitrite. Stimulation with pro-inflammatory 
cytokines induced a 3fold increase of this production. This increase of nitrite generation 
probably might be due to induction of iNOS in colonic epithelial cells , as the increase NO 
production in DBD (Middleton et al. 1993; Lundberg et al. 1994) is in close association with a 
strong iNOS activity mainly in colonic epithelium (Boughton-Smith et al. 1993; Singer et al. 
1996; Kolios et al. 1997). The addition of anti-inflammatory cytokine IL-13 potently inhibited 
the nitrite generation by colonic mucosa in a similar manner to nitrite generation by colonic 
epithelial cells HT-29. Similarly, interleukin-13 has been reported to inhibit nitric oxide 
production by activated murine peritoneal macrophages (Doyle et al. 1994) and mouse bone 
marrow-derived macrophages (Doherty et al. 1993). Saura et al. (1996), have published that 
H^13 inhibits iNOS expression in human mesangial cells after stimulation with a "cocktail" of 
pro-inflammatory cytokines and LPS.
In conclusion, we have demonstrated in this study that colonic epithelial cells HT-29 express 
iNOS and produce nitrite after induction with cytokines, while T-cell derived cytokines down- 
regulate iNOS expression and activity. Furthermore, our immunohistochemical study has 
shown that inflamed colonic mucosa from patients with intestinal inflammation expressed 
iNOS activity and colonic epithelial cells were the main source of this expression. In marked
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contrast, uninflamed epithelium from controls did not express iNOS activity. These data taken 
together with our results from cultures of colonic biopsies from normal bowel mucosa 
indicate the involvement of colonic epithelium in NO production and suggest a crucial role of 
pro-inflammatory and T-cell derived cytokines in iNOS expression and activity in colonic 
mucosa. The stimulation of colonic epithelial cells by inflammatory mediators seem to trigger 
the increased production of NO in colonic mucosa in intestinal inflammation, while the T-cell 
derived cytokines may have a regulatory effect on NO generation (Fig. 18).
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Figure 18 Nitric oxide production by colonic epithelial cells after stimulation with pro- 
inflammatory cytokines. Inhibitory effect by the T cell derived cytokines IL-4 and IL-13.
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3.2 CHEMOKLNE EXPRESSION BY COLONIC EPITHELIAL CELLS
3.2.1 Chemokine secretion from HT-29 cell line in response to cytokines
Confluent monolayers of HT-29 cells were treated with either IL-la (0.1-30 ng/ml) or TNF-a 
(1-100 ng/ml) or IFN-y (10-300 U/ml) or IL-13 (0.1-10 ng/ml) or IL-4 (0.1-10 ng/ml) or IL-10 
(0.1-10 ng/ml) for 24 hours. Supernatants were collected and IL-8, MCP-1 and RANTES 
secretion was measured by ELISA. Un-stimulated cells did not produce detectable levels of 
chemokines (below 200 pg/ml).
The generation of IL-8 was found to be markedly up-regulated in a concentration dependent 
manner by either the IL-la or TNF-a (Fig. 19a, 19b). Interestingly, maximal concentration of 
TNF-a produced twice as much IL-8 (164.4 ± 6.9 ng/ml) as was induced by maximal 
concentration of IL-la (79.6 ± 8.4 ng/ml). Furthermore, neither IFN-y nor IL-13 nor IL-4 nor 
IL-10 stimulated IL-8 generation, when added alone to HT-29 cells. Finally, both IL-la (30 
ng/ml) and TNF-a (100 ng/ml) induced a time dependent generation of IL-8 with significant 
amounts detected by 4 hours and peak production with each cytokine was at 24 hours (Fig. 
20).
Pro-inflammatory cytokines and T cell derived cytokines added alone did not induce MCP-1 or 
RANTES secretion by HT-29 cells. The combination of TNF-a/IFN-y was the minimal 
stimulation for MCP-1 an RANTES generation while no other pair of cytokines was effective. 
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Figure 19 Production of IL-8 by HT-29 cells following stimulation for 24h with IL-la (a), 










Figure 20 The time course of IL-8 production by HT-29 cells following stimulation 
with IL-la (■, 30 ng/ml), or TNF-a ( • ,  100 ng/ml),. Each point is the mean ± 
SEM of three experiments.
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peak production of 8.09 ± 0.55 ng/ml and 19.63 ±1.4 ng/ml, respectively, after a maximal 
stimulation with TNF-a (lOOng/ml) / IFN-y (300U/ml) at 48 h. The same stimulation induced 
a stronger IL-8 mRNA expression and higher levels of IL-8 secretion (e.g. 283 ±18 ng/ml 
of IL-8) (Fig. 21).
3.2.2 Chemokine mRNA expression by HT-29 cells
Chemokine mRNA expression in epithelial cells was examined. In un-stimulated cells no 
chemokine transcripts were detected. IL-la induced IL-8 mRNA expression peaked at lh and 
declined rapidly to a very low expression by 24h (Fig. 22). In contrast, TNF-a-induced IL-8 
mRNA peaked at the same time, but remained high for at least 12h (Fig. 23). No single 
cytokine was capable of inducing MCP-1 or RANTES mRNA expression. The combination of 
TNF-a/EFN-y was the minimal stimulation for MCP-1 and RANTES mRNA expression, while 
no other pair of cytokines was effective. The same stimuli induced a strong EL-8 mRNA 
expression. Characteristically HT-29 cells showed a delayed MCP-1 mRNA expression, which 
started at 6 h and peaked at 12 h and a later on RANTES mRNA expression, which started at 
12 h and peaked at 24 h in comparison with the early IL-8 mRNA at 1 h (Fig 24).
3.2.3 Synergistic effect of Hi-13 and IL-la on IL-8 secretion
Possible modulatory effects of IL-10 and IL-13 on IL-la or TNF-a-induced EL-8 production 
were examined. Confluent monolayers of HT-29 cells, after 1 hour pre-treatment with either 














Figure 21 Chemokine secretion by HT-29 cells after 48 hours incubation at 37° C in the 
presence of the proinflammatory cytokines TNF-a and IFN-y. Each bar is the mean ±  
SEM of three experiments.
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Figure 22 Northern blot analysis of time course of IL-8 mRNA expression in HT-29 
cells stimulated with IL -la (3 ng/ml). The top panel of each figure is the northern 
blot, middle panel is densitometry analysis of blot and lower panel is the ethidium 
bromide stained 18s and 28s bands indicating equal loading of the lanes. 
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Figure 23 Northern blot analysis of time course of IL-8 mRNA expression in HT-29 
cells stimulated with TNF-a (30 ng/ml). The top panel of each figure is the northern 
blot, middle panel is densitometry analysis of blot and lower panel is the ethidium 
bromide stained 18s and 28s bands indicating equal loading of the lanes. 
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Figure 24 Northern blot analysis of time course of chemokine mRNA expression in 
HT-29 cells stimulated up to 72 hours with the combination IFN-y (300U/ml) + 
TNF-a (100 ng/ml). Representative of three experiments.
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were incubated for 24 hours and then IL-8 secretion was measured in supernatants by ELISA. 
At all concentrations of IL-la examined, IL-13 (l-10ng/ml) produced a significant 
enhancement of IL-8 generation (p<0.05 -p<0.01) (Fig. 25), for example the presence of EL-13 
(lOng/ml) induced approximately twice as much IL-8 (91.5 ± 3.5 ng/ml) compared to that 
produced by IL-la (3 ng/ml) alone (57.1 ±1.8 ng/ml, /?<0.01) (Fig. 19a). In marked contrast 
the same concentration range of IL-13 had no effect on TNF-a induced EL-8 generation (Fig. 
26). Furthermore, EL-10 (0.1-10 ng/ml, n=3) was found to have no effect on either EL-la or 
TNF-a induced IL-8 production (data not shown). Synergistic effect of IL-4 and IL-la on IL-8 
secretion by HT-29 cells was subsequently examined by Dr Adrian Minty, Sanofi Recherche, 
France, and it was found similar to the effect of EL-13 (personal communication).
To determine whether the synergistic effect of EL-13 with EL-la on EL-8 generation was at the 
mRNA level, cells were pre-treated for lh with EL-13 (5 ng/ ml), then EL-la (3 ng/ml) was 
added and mRNA expression was measured from 1 to 12h post EL-la addition. IL-13 was 
found to prolong the EL-la-induced mRNA expression in HT-29 cells (Fig. 22, 27), while it 
was without effect on TNF-a-induced IL-8 mRNA expression (Fig. 23,28).
Experiments using the protein synthesis inhibitor cycloheximide were then conducted to 
determine whether the EL-13-induced prolongation of EL-8 mRNA was due to de novo protein 
synthesis. HT-29 monolayers were treated with cycloheximide (5 mg/ml) for 2 hours and then 
EL-la (3 ng/ml) was added alone or after 1 hour pre-treatment with EL-13 (5 ng/ml), then total 
RNA was extracted at 1, 2, 4, 6 and 12h post IL-la addition. The addition of cycloheximide 
was without effect on the IL-13-induced prolongation of IL-la stimulated IL-8 mRNA
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Figure 25 Effect of IL-13 (0.1-10 ng/ml) on IL -la  (# , 3 ng/ml) induced IL-8 generation by 









Figure 26 Effect of IL-13 (0.1-10 ng/ml) on TNF-a (# , 30 ng/ml) induced IL-8 
generation by HT-29 cells after 24h treatment. Each point is the mean ±  SEM of 
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Figure 27 Effect of IL-13 on IL -la induced IL-8 mRNA expression by HT-29 cell 
line. Cells were pretreated for 1 hour with IL-13 (5 ng/ml) and then IL -la  (3 ng/ml) 
was added. The top panel is the northern blot, middle panel is densitometry analysis 
of blot and lower panel is the ethidium bromide stained 18s and 28s bands indicating 
equal loading of the lanes. Representative of three experiments.
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Figure 28 Effect of IL-13 on TNF-a induced IL-8 mRNA expression by HT-29 cell 
line. Cells were pretreated for 1 hour with IL-13 (5 ng/ml) and then TNF-a (30 
ng/ml) was added. The top panel is the northern blot, middle panel is densitometry 
analysis of blot and lower panel is the ethidium bromide stained 18s and 28s bands 
indicating equal loading of the lanes. Representative of three experiments.
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expression (compare Fig. 27 and Fig. 29). Although a small prolongation of IL-la-induced 
EL-8 mRNA was produced by cycloheximide (compare Fig. 22 and Fig. 30), this 
prolongation was much weaker compared to that induced by EL-13 (Fig. 27).
The above findings demonstrate that EL-13 potentiates the EL-la-derived IL-8 expression in 
colonic epithelial cells. The expression of most cytokine mRNA is regulated at the 
transcriptional or at the mRNA stability level. To determine the mechanism of EL-13-induced 
regulation, we examined the effect of EL-13 on the t,/2 of IL-8 mRNA derived from EL-la 
stimulated HT-29. After 1 hour incubation with EL-la (3 ng/ml) in the presence (lh pre­
treatment) of IL-13 (5 ng/ml) or vehicle, actinomycin-D (5 mg/ml) was added to the cultures 
to block further transcription and total RNA was extracted at specific time points. The 
expression of B-actin mRNA is constitutive, thus its expression is not blocked by 
actinomycin-D. Analysis of the time course of the IL-8 mRNA / p-actin mRNA ratios in the 
presence of actinomycin-D provides a measure of the stability (t1/2) of EL-la-induced EL-8 
mRNA independent of transcription. Comparison of the EL-8 mRNA / P-actin mRNA ratio 
in the presence or absence of IL-13 followed by the addition of actinomycin-D demonstrated 
that EL-13 did not affect EL-8 mRNA t1/2 (Fig. 31). Therefore the site of increased EL-la- 
induced EL-8 mRNA expression in the presence of IL-13 (Fig. 27) is at the level of 
transcription.
3.2.4 Differential effect of T cell derived cytokines on C-X-C and C-C chemokines by 
HT-29 cells
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Figure 29 Effect of IL-13 on IL-la induced IL-8 mRNA expression in HT-29 cells in the 
presence of cycloheximide. After 1 hour pretreatment with cycloheximide (5 pg/ml), IL- 
13 (5 ng/ml) was added and the incubation continued for 1 hour. Then IL -la  (3 ng/ml) 
was added. The top panel is the northern blot, middle panel is densitometry analysis of 
blot and lower panel is the ethidium bromide stained 18s and 28s bands indicating equal 
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Figure 30 Effect of cycloheximide (5 ng/ml) on IL-la induced IL-8 mRNA expression in 
HT-29 cells. Cells were pretreated for 2 hours with cycloheximide (5 pg/ml) and then IL- 
la  (3 ng/ml) was added. Total RNA extracted at 1, 2, 4, 6 and 12 h and IL-8 mRNA was 
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Figure 31 The t1/2 of IL-8 mRNA determined at 1 hour after stimulation with IL -la . Cells 
were stimulated for 1 hour with IL -la  (3 ng/ml) in the presence or absence of IL-13 (5 
ng/ml). Then, actinomycin-D (5 pg/ml) was added and the decay of IL-8 mRNA was 
assessed by Northern blot analysis. The t1/2 of IL-la-induced IL-8 mRNA in the presence 
or absence of IL-13 were 1.05 h and 0.9 h, respectively. Representative of two 
experiments.
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HT-29 cells growth arrested cultures were treated with proinflammatory cytokines added 
after lh pre-treatment with various concentrations (0-30 ng/ml) of IL-13, IL-4 or IL-10. Pre­
treatment with IL-13 reduced the TNF-a/TFN-y-induced C-C chemokine mRNA expression 
and secretion. The presence of IL-13 reduced the MCP-1 production from 8.09 ± 0.55 ng/ml 
to 3.40 ± 0.39 ng/ml (Fig. 32) and the RANTES production from 19.63 ng/ml ± 1.44 ng/ml 
to 9.89 ± 0.59 ng/ml (Fig. 33). In marked contrast IL-13 had no effect on TNF-a/IFN-y- 
induced IL-8 production by HT-29 cells induced by the same stimuli (Fig. 34). Examining 
the effect of IL-13 in the TNF-a/EFN-y-induced chemokine mRNA expression we found 
similar inhibitory effect of IL-13 on C-C chemokine expression (Fig. 35,36), but not on 
TNF-a/EFN-y-induced IL-8 expression by HT-29 cells (Fig. 37). IL-4 was found to share the 
same properties with IL-13 on chemokine mRNA expression and production by the HT-29 
colonic epithelial cells (Fig. 38,39). Finally IL-10 was no effective on either C-C or C-X-C 
chemokine expression and secretion (Fig. 40).
3.2.5 Immunohistochemical study of colonic biopsies
Colonic biopsies of normal, non inflamed mucosa (8 out of 8 cases), derived from patients with 
diverticular disease, colon adenocarcinoma and healthy individuals were found negative for EL- 
8 expression (Fig. 41 A). In all cases (n=15) of intestinal inflammation (ulcerative colitis, n=12 
and infectious colitis, n=3) the epithelial cells markedly expressed IL-8, while a number of 
positive cells were found in lamina propria (Fig. 4IB, 41C). Characteristically the IL-8 
expression was located in the basal part of epithelial cells and it was in close association with 






Figure 32 The effect of increasing concentrations of IL-13 (0.1-30 ng/ml) on IFN- 
y(300U/ml)/TNF-a(100ng/ml)-induced MCP-1 generation by HT-29 cells after 24 h 






















Figure 33 The effect of increasing concentrations of IL-13 (0.1-30 ng/ml) on IFN- 
y(300U/ml)/TNF-a(100ng/ml)-induced RANTES generation by HT-29 cells after 24 h 







Figure 34 The effect of increasing concentrations of IL-13 (0.1-30 ng/ml) on IFN- 
y(300U/ml)/TNF-a(100ng/ml)-induced IL-8 generation by HT-29 cells after 24 h treatment. 
Each point is the mean + SEM of three experiments.
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Figure 35 Effect of increasing concentrations of IL-13 on TNF-a/IFN-y induced MCP-1 
mRNA expression by HT-29 cell line. Cells were pretreated for 1 hour with IL-13 and then 
TNF-a(100ng/ml)/dFN-y(300 U/ml) were added. The top panel is the northern blot, middle 
panel is densitometry analysis of blot and lower panel is the ethidium bromide stained 18s and 
28s bands indicating equal loading of the lanes. Representative of three experiments.
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Figure 36 Effect of increasing concentrations of IL-13 on TNF-a/IFN-y induced RANTES 
mRNA expression by HT-29 cell line. Cells were pretreated for 1 hour with IL-13 and then 
TNF-a (100ng/ml)/IFN-y (300 U/ml) were added. The top panel is the northern blot, 
middle panel is densitometry analysis of blot and lower panel is the ethidium bromide 
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Figure 37 Effect of increasing concentrations of IL-13 on TNF-a/TFN-y induced IL-8 mRNA 
expression by HT-29 cell line. Cells were pretreated for 1 hour with IL-13 and then TNF-a 
(100ng/ml)/IFN-Y (300 U/ml) were added. The top panel is the northern blot, middle panel is 
densitometry analysis of blot and lower panel is the ethidium bromide stained 18s and 28s 
bands indicating equal loading of the lanes. Representative of three experiments.
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Figure 38 Effect of increasing concentrations of IL-4 on TNF-o(/IFN-y induced chemokine 
mRNA expression by HT-29 cell line. Cells were pretreated for 1 hour with IL-4 and then 
TNF-a (100ng/ml)/IFN-Y (300 U/ml) were added. The top panel is the northern blot, middle 
panel is densitometry analysis of blot and lower panel is the ethidium bromide stained 18s and 
28s bands indicating equal loading of the lanes. Representative of three experiments.
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Figure 39 Effect of increasing concentrations of IL-4 on TNF-a/IFN-y induced chemokine 
secretion by HT-29 cell line. Cells were pretreated for 1 hour with IL-13 and then TNF- 
a(100ng/ml)/IFN-y(300 U/ml) were added. Each bar is the mean ± SEM of three 
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Figure 40 Effect of increasing concentrations of IL-10 on TNF-o/IFN-y induced chemokine 
mRNA expression by HT-29 cell line. Cells were pretreated for 1 hour with IL-10 and then 
TNF-a (100ng/ml)/IFN-Y (300 U/ml) were added. The top panel is the northern blot, middle 
panel is densitometry analysis of blot and lower panel is the ethidium bromide stained 18s and 
28s bands indicating equal loading of the lanes. Representative of three experiments.
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from colon adenocarcinoma expressed heavy IL-8 staining in colon adenocarcinoma epithelial 
cells, while normal mucosa from adjacent areas were negative (Fig. 4ID). No staining was 
seen in the negative controls, when the primary antibody was omitted (Fig. 4IE).
3.2.6 Discussion
Intestinal inflammation is characterised by infiltration of lamina propria and epithelium by 
selected populations of leukocytes. The migration of leukocytes from the lumen of the 
microvasculature to distant extravascular sites is a characteristic of inflammatory diseases. A 
large family of target cell specific chemotactic polypeptides, collectively known as 
chemokines, are crucial in the orchestration of this leukocyte migration and activation (Miller 
& Krangel, 1992; Lindley et al. 1993). The study of chemokine expression in intestinal 
inflammation is still in its beginning and at the initiation of this study a small number of 
published information focusing on IL-8 was available.
We have clearly shown IL-8 expression using immunostaining in the colonic mucosa of 
patients with ulcerative colitis and infectious colitis, as well as in biopsies from colon 
adenocarcinoma. IL-8 expression was detected in the basal part of colonic epithelial cells in 
close association with neutrophil infiltration and in cells of the lamina propria. These results 
strongly suggest that the colonic epithelial cells are a major source of IL-8 production and that 
this production is associated with the intestinal inflammation. Similarly, the IL-8 production 
in colonic mucosa has been reported to be related with the grade of the intestinal inflammation 
(Mazzucchelli et al 1994). These findings taken together suggest an involvement of colonic
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Figure 41A Normal colonic bowel mucosa with no detection of IL-8. Immunostaining with 
anti-human EL-8 antibody, using avidin-biotin peroxidase. Original magnification X 100.
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Figure 41B Ulcerative colitis with staining for IL-8. Colonic epithelial cells of superficial 
section of crypt and surface epithelium markedly express IL-8, which is expressed in basal part 
of the epithelium, in close association with the neutrophils of the lamina propria (arrows). 
Immunostaining with anti-human IL-8 antibody, using avidin-biotin peroxidase. Original 
magnification X 100.
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Figure 41C Another ulcerative colitis case showing numerous cells positive for IL-8, located 
at the lamina propria and epithelium (arrows). Immunostaining with anti-human IL-8 antibody, 
using avidin-biotin peroxidase. Original magnification X 250.
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Figure 41D Biopsies from colon adenocarcinoma expressed heavy IL-8 staining in colon 
adenocarcinoma epithelial cells. Immunostaining with anti-human EL-8 antibody, using avidin- 







Figure 41E Ulcerative colitis patient, negative control. No staining was seen, when the primary 
antibody was omitted. Original magnification X 50.
Resultsl46
epithelial cells in leucocyte recruitment during the intestinal inflammation. Interestingly, in our 
study we have demonstrated for first time a heavy staining of colon adenocarcinoma cells in 
biopsies from colon adenocarcinoma. In marked contrast, in the same patients colonic epithelial 
cells from adjacent normal areas were negative for IL-8 expression. The latter observation 
suggest that colonic epithelial cells producing large amounts of IL-8 might be involved in 
tumour angiogenesis. While numerous investigations have shown both in vivo and in vitro 
the importance of IL-8 in acute inflammation, as a chemotactic / activating factor for 
neutrophils, recently has it become apparent that this C-X-C chemokine may be important 
in angiogenesis associated with tumorgenesis. IL-8 was found to be a potent angiogenic 
factor with similar angiogenic activity as basic fibroblast growth factor (bFGF)(Koch et 
al, 1992).
In support of our findings from the immunostaining study of colonic biopsies we have found in 
vitro that the human colonic epithelial cells HT-29 in response to pro-inflammatory cytokines 
express IL-8 mRNA and produce large amounts of IL-8. Furthermore, we have demonstrated 
that these cells after induction with specific combinations of cytokines produce MCP-1 and 
RANTES, two members of C-C chemokine family. These results are in agreement with results 
published during the course of my work, demonstrating C-C chemokine expression in colonic 
mucosa during the intestinal inflammation (Reinecker et al, 1995; Grimm et al, 1996; 
Mazzucchelli et al, 1996) and support the concept that colonic epithelial cells are involved in 
leukocyte migration. In our study IL-8 mRNA expression was observed as early as 1 hour, 
peaked at 4 hours and then rapidly declined. MCP-1 and RANTES mRNA expression showed 
a delay with a peak at 12 h and 24 h respectively. These finding are in step with the 
histopathology of colonic mucosa in the early acute phase of ulcerative colitis, which is
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characterised by the presence of numerous neutrophils either infiltrating lamina propria or 
forming crypt abscesses and in the latter chronic phase, which is characterised by infiltration 
of the lamina propria with lymphocytes, plasma cells and eosinophils without neutrophils 
(Nostrant et al 1987).
Examining the role of T cell derived cytokines on chemokine expression by colonic epithelial 
cells, we have demonstrated that IL-13 modulates chemokine expression by HT-29 cells. Thus 
epithelial cells must now be considered together with monocytes, endothelial cells, 
polymorphonuclear granulocytes and keratinocytes as targets for IL-13 (Zurawski & De Vries, 
1994; Herbert et al 1993; Derocq et al 1994; Sironi et al 1994; Colotta et al 1994). This 
cytokine produced a doubling in the IL-8 secreted by epithelial cells that were stimulated by 
IL-la, but was without effect on IL-8 generation in cells stimulated by TNF-a or TNF- 
a/IFN-y. It was apparent at both the level of mRNA and peptide that the effect of IL-13 on 
chemokine production was restricted to IL-la stimulated cells, as it was without effect on 
other cytokine stimulated cells. In addressing this unique action of IL-13 a number of 
observations are worth noting. Firstly, IL-8 production by HT-29 cells by supra-maximal 
concentrations of TNF-a or TNF-a/IFN-y was approximately twice and three times, 
respectively, as much as that produced by supra-maximal concentrations of IL-la, results 
similar to those reported previously (Schuerer-Maly et al 1994). The relative potencies of EL- 
la  and TNF-a is the reverse of the pattern found in other cells and cell lines (Watson et al 
1988; Brown et al 1991; Brown et al 1994; Jordan et al 1996). Secondly, the differential 
action of IL-la and TNF-a or TNF-a/IFN-y on chemokine production was also reflected at 
the level of IL-8 mRNA. Induction of IL-8 mRNA with IL-la peaked at lh, then rapidly 
subsided, in contrast, TNF-a or TNF-a/IFN-y induced EL-8 mRNA expression similarly 
peaked by lh, but was maintained for at least 12h. Thirdly, IL-13 caused a prolongation of IL-
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la  induced IL-8 mRNA expression that was similar to that present in TNF-a or TNF-a/IFN-y 
stimulated cells. Fourthly, experiments with cycloheximide, a protein synthesis inhibitor, 
demonstrated that the effect of IL-13 on IL-8 mRNA expression did not depend upon protein 
synthesis. Thus the action of IL-13 on epithelial cells is unlikely to involve IL-lra because this 
would produce an inhibition of IL-la action not an enhancement, and the involvement of IL- 
lra is not consistent with the lack of effect of cycloheximide on IL-8 mRNA. Finally, 
experiments with actinomycin-D indicate that EL-13 is producing an enhanced IL-la-induced 
IL-8 mRNA via an increase at transcription rather than mRNA stability.
Furthermore, we found that IL-13 in same concentrations had an inhibitory effect on MCP-1 
and RANTES expression and secretion. This action of IL-13 on HT-29 epithelial cells is in 
marked contrast to the effect of IL-13 on monocytes, in which it is a potent inhibitor of 
cytokine and chemokine production (Minty et al 1993; McKenzie et al 1993; Zurawski & 
De Vries, 1994; De Waal Malefyt et al 1993). The inhibitory effect of EL-13 on stimulated 
chemokine production by monocytes is probably via both the enhanced production of EL-Ira 
and soluble receptors, as well as a direct inhibition of chemokine transcription (Muzio et al 
1994). Similar results we found examining the effect of IL-4, which share many properties 
with IL-13 (Zurawski & De Vries, 1994). Both, IL-4 and IL-13 were found to have a 
differential effect on chemokine expression by colonic epithelial cells with an inhibitory effect 
on C-C chemokine expression, but an inflammatory effect inducing IL-8 production. Thus, 
when considering cytokine networks, particularly with respect to chemokine production, T 
cell derived cytokines can have a bifunctional role, depending upon the stimulus and the 
cellular source of chemokines. Finally, we found that IL-10 throughout the concentration 
range of 0.1 to 30 ng/ml had no effect on pro-inflammatory cytokine-induced chemokine 
production by the colonic epithelial cell line HT-29. Therefore the expression of "chronic
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enterocolitis" phenotype in IL-10 deficient mice (Kahn et al 1993) is probably not via a direct 
suppressive action of IL-10 on colonic epithelial cells.
Thus, this capacity of colonic epithelial cells to secrete chemokines, might be important in the 
inflammatory response, as leukocyte infiltration of the intestinal mucosa is a characteristic 
feature of the intestinal inflammation and an increased production of chemokines has been 
reported in colonic mucosa from patients with IBD (Mahida et al. 1992; Mitsuyama et al 
1994; Grimm et al 1996; Mazzucchelli et al 1996; Kolios et al 1997). In addition, the 
findings that pro-inflammatory cytokines released by activated macrophages during an acute 
inflammatory response, induce chemokine production by colonic epithelial cells suggest a 
communication between these cells and immune cells located in the underlying intestinal 
mucosa. Production of the potent neutrophil and T-lymphocyte chemoattractant cytokines IL- 
8, MCP-1, and RANTES from intestinal epithelial cells may have a crucial effect on intra- 
epithelial and lamina propria neutrophils and lymphocytes during the intestinal inflammation. 
The infiltration of T-cells induced by chemokines could be particularly relevant to the role of 
colonic epithelial cells as antigen presenting cells (Mayer et al 1991). Furthermore, our 
results that T-lymphocyte-derived cytokines IL-13 and EL-4 have a synergism with IL-la in 
IL-8 secretion and expression by colonic epithelial cells support the view that there is an 




The aetiology and pathogenesis of ulcerative colitis (UC) and Crohn’s disease (CD), despite 
extensive investigations, is unclear and an abundance of data and theories implicate genetic 
predisposition, infectious agents or other environmental factors, and immunologic 
alterations, but the primary events, which initiate the inflammatory response remain 
unknown. Over the last years a great advance has been made in the understanding of the 
inflammatory process. Previously our knowledge was limited to a simple three-stage process. 
First, an irritant, immune or infectious agent activates leukocytes; second, these cells release 
enzymes and inflammatory mediators; and finally, these products cause pain, heat, oedema 
and loss of function (Zipser, 1988). We now know that the inflammatory process is more 
complicated and it is clear that mediators of inflammation also arise from cells other than 
leukocytes. Some of these mediators are involved in cell-cell communications, affecting the 
immune response, the synthesis and release of enzyme, and the cell proliferation and healing 
phase during the inflammation. The intestinal mucosal system depends on the co-operation 
of epithelial cells and lymphoid components to initiate and maintain an immunological 
response (Schmucker et al. 1996). In inflammatory bowel disease (IBD) the inflammation 
may be triggered by the entry of bacterial products or dietary antigens into the lamina 
propria through an epithelium with abnormal permeability, while environmental factors, such 
as infectious agents, may further stimulate the mucosal immune process, which is probably 
modified and propagated by a genetic predisposition. Regardless of the aetiology and the 
initiating event, the inflammatory response will be amplified through the release of soluble
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mediators as well as the recruitment of cellular components of the immune system (Nielsen 
& Rask-Madsen, 1996).
During the last decade the traditional view of epithelial function has been expanded by the 
realisation that intestinal epithelium has a dual role in the control of intestinal physiology; the 
ability to serve simultaneously as both an absorptive surface and a barrier. Attention has been 
focused on the role of the epithelium in the initiation of chronic intestinal inflammation and 
two models have been proposed. First, a consistent deficiency in structural integrity may permit 
recognition of antigens, not normally encountered below the epithelium, which in the 
genetically susceptible host leads to inflammation; or second, epithelial elements, acting as 
transducers of normally non-pathogenic stimuli, promote and amplify inflammation, regardless 
of maintenance of normal structural integrity (Sands & Podolsky, 1996). The second model 
reflects the role of epithelial cells as an active participant in the immune response. Intestinal 
epithelial cells represent an important interface between the environment and the host tissue 
and in addition to their role as a selective barrier to prevent the entry of antigenic or infectious 
material into the body, they are involved in many inflammatory and immune reactions (McKay 
& Perdue, 1993a; McKay & Perdue, 1993b). Several observations suggest that the intestinal 
epithelial cells may serve as signal transducers, recognising antigens within the lumen and 
presenting information to underlying cell population within the lamina propria (Greenewald & 
James, 1995). Recently, it has been clear that colonic epithelial cells participate in the immune 
process producing a number of soluble inflammatory mediators. These cells present antigens 
via class II molecule expression (Mayer et al. 1991; Lowes et al. 1992), express adhesion 
proteins such as intercellular adhesion molecule-1 (Kaiserlian et al. 1991) and generate soluble
Discussionl52
inflammatory mediators e.g. arachidonic acid derivatives (Gustafson & Tagesson, 1990; Dias et 
al. 1992), platelet activating factor (Ferraris et al. 1993), and cytokines (Hedges et al. 1992; 
Eckmann et al. 1993; Schuerer-Maly et al. 1994; Gross et al. 1995; Jung et al. 1995), all of 
which contribute to the communication between inflammatory cells and cells of the immune 
system (Sartor, 1994). The purpose of our study was to examine the role of colonic epithelial 
cells in the production and release of inflammatory mediators during the intestinal 
inflammation and to define which agents modulate this process. To attain these goals our study 
has focused on the production of nitric oxide (NO) via the expression and activation of the 
inducible nitric oxide synthase (iNOS) and the involvement of the colonic epithelial cells in 
leukocyte recruitment in the site of the inflammation via the expression and secretion of 
chemokines.
In our study, we have demonstrated that human HT-29 colonic epithelial cells in response to 
specific combinations of cytokines express iNOS mRNA and produce large quantities of 
nitrite. Tissue-derived cytokines are known to be potent inducers of NO synthase in 
macrophages, neutrophils and endothelial cells but the demonstration of such activity in human 
colonic epithelial cells is potentially of great importance in colonic inflammation. Pro- 
inflammatory cytokines were found increased in intestinal inflammation and a crucial role of 
these mediators has been proposed in IBD (Kolios & Nakos, 1995; Sartor, 1994; Radford- 
Smith & Jewell, 1996). The observation that these cytokines stimulate HT-29 cells to produce 
large amounts of NO suggests an implication of colonic epithelial cells in immune reactions 
during the intestinal inflammation. Although our results were obtained with a colonic epithelial 
cell line, which has many characteristics in common with "normal" colonic epithelial cells
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(Chantret et al 1988) the possibility exists that "normal" cells may behave differently to 
tumour cells. Studies in patients with UC have shown a remarkable increase in NO synthase 
activity in the inflamed mucosa compared to the uninflamed controls (Middleton et al 1993a; 
Boughton-Smith et al 1993). Nitrite, the stable end product of NO production was found in 
measurable amounts in rectal dialycates from patients with active UC (Eckmann et al 1993) 
and luminal NO was greatly increased in UC patients (Lundberg et al 1994a). They proposed 
that luminal NO measurement may reflect NO production in the most superficial parts of the 
mucosa, since NO produced in deeper mucosal layers is probably trapped (e.g., by 
haemoglobulin in mucosal blood vessels) and therefore will not reach the lumen, suggesting 
that the excess NO production in UC mainly occurs in veiy superficial mucosal layers 
(Lundberg et a l 1994a). However, the cellular source of NO in the intestinal mucosa was not 
identified.
To support our in vitro findings, an immunohistochemical study of colonic biopsies was 
performed, which demonstrated intense iNOS staining in the inflamed colonic epithelium of 
patients with UC and infectious colitis. The colonic epithelial cells that expressed iNOS 
occurred in sites of inflammation and were associated with areas of intense neutrophil 
infiltration of lamina propria and epithelium. Uninflamed mucosa was negative for iNOS 
labelling. Singer et al. working in parallel, using the same antibodies found similar results. 
Furthermore, in the same cases which expressed iNOS, they found that nitrotyrosine, the stable 
product of the action of peroxynitrite on tyrosine-containing proteins, was also localised in 
colonic epithelial cells in areas of inflammation, both in the surface epithelium and crypts 
(Singer et al 1996). These findings suggest that some components of the inflammatory
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response induces iNOS expression in colonic epithelial cells and that NO generated by these 
cells reacts with superoxide to produce peroxynitrite, which nitrates cellular proteins and forms 
nitrotyrosine. Whether the nitration of tyrosine is associated with functional impairment of the 
colonic epithelium is not known, but these findings suggest an implication of colonic epithelial 
cells in the NO-dependent nitrosation reactions during the intestinal inflammation. 
Aminosalicylates, which are widely used to treat IBD, inhibit these nitrosation reactions; 
(Grisham & Miles, 1994) this activity may account for their therapeutic effects in intestinal 
inflammation.
The production of NO by colonic epithelial cells is also supported by similar results in other 
studies. Calcium-dependent NO synthase activity was previously shown to be present in gastric 
epithelial cells (Brown et al. 1992), and also in epithelial cells isolated from rat proximal small 
intestine (Tepperman et al. 1993). Using in situ hybridisation and immunohistochemistry to 
detect iNOS, they have demonstrated high expression of iNOS localised to the surface 
epithelium and crypts in the mucosa from patients with UC (Reynolds et al 1995). iNOS was 
immunolocalised in ileal epithelial cells of lipopolysaccharide treated rats but not in controls 
(Cook et al. 1994), in addition rat intestinal epithelial cells in culture when stimulated with 
cytokines and lipopolysaccharide were found to produce NO (Grisham, 1993). NO synthesis 
has also been found in epithelial cells in rhesus monkeys with idiopathic colitis, but not in 
control monkeys (Ribbons et al. 1995). Induction of iNOS expression is not limited to 
intestinal epithelial cells as it has been identified in rodent and human epithelial cells in vivo 
and in vitro (Robbins et al. 1994b; Robbins et al. 1994a; Gutierrez et al. 1995). Although in
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our study iNOS expression was absent in normal mucosa, they have detected iNOS mRNA in 
normal human airway epithelium (Guo et al. 1995).
The functional role of the NO production by the colonic epithelial cells is not clear. Increased 
expression and production of NO may explain some of the pathophysiological features of 
active IBD. UC and CD are associated with mucosal vasodilation and increased vascular 
permeability, which result in mucosal erythema and oedema. IBD is also associated with 
enhanced epithelial permeability (Bjamason et al. 1995). NO is a potent vasodilator and it is 
known that during active episodes of colonic inflammation blood flow to the mucosa and 
submucosa of the colon is increased between to 2 and 6 fold (Hulten et al. 1977). NO may be 
an important pathway whereby inflammation induces hyperaemia, mucosal vasodilatation and 
increased vascular permeability (Middleton et al. 1993a). While an increase in blood flow 
alone would not cause an increase in vascular permeability, it would enhance the actions of 
other inflammatory mediators, which have a direct injurious action on the microvascular 
endothelium (Whittle, 1995). Diarrhoea is a main symptom of patients with IBD; this symptom 
is multifactorial, but usually has a secretory component. NO is important in the control of 
absorption from intestine. At physiological concentrations NO promotes absorption but at 
higher levels may produce secretory effects in the colon (MacNaughton, 1993). Furthermore, 
NO is capable of affecting alterations in intestinal motility in IBD by mediating the effects of 
gastrointestinal hormones and non-adrenergic and non-cholinergic mediated relaxation of 
colonic smooth muscle (Hata et al. 1990). In addition, NO relaxes colonic circular smooth 
muscle even in low concentrations (Middleton et al. 1993b). In active UC this can contribute to 
diarrhoea by depressing segmentation in the colon and in fulminant colitis impaired colonic
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motility is associated with toxic megacolon, which may lead to perforation (Boughton-Smith, 
1994). It has been shown that NO relaxes the human internal anal sphincter (Burleigh, 1992). 
Sufficient amounts of NO released by colonic epithelial cells may diffuse to the underlying 
muscle layer, in a similar way to the diffusion of NO from endothelium to the vascular smooth 
muscle (Moncada et al 1991), and hence could affect the sphincter function and contribute to 
the urgency to stool, a frequent symptom in patients with UC. NO produced by colonic 
epithelial cells may therefore contribute to all these symptoms of IBD through a local action to 
colonic epithelium and affecting simultaneously the deeper layers of the bowel.
It is not clear whether the increased NO production in patients with IBD is beneficial or 
destructive for the tissue. Although NO or subsequent reactive products can contribute to 
cytopathology against host cells when produced in excess (Tepperman et al 1994), some data 
suggest that NO may diminish epithelial damage. NO can scavenge oxygen radicals reducing 
their harmful effects (Grisham, 1994) and inhibition of NO synthesis promotes damage induced 
by HC1, ethanol, and lipopolysaccharide (Kitagawa et al 1990; MacNaughton et al 1989; 
Hutcheson et al 1990) suggesting that NO has a protective effect on the gut. Epithelial iNOS 
expression could provide an oxidative barrier to bacterial invasion. This idea is supported by 
the findings that patients with active UC have lower numbers of bacteria in the rectal mucosa 
than patients in remission or normal controls (Hartley et al 1992). Furthermore, large 
concentrations of NO are normally present in the nasal airways and the stomach without 
causing local tissue damage (Lundberg et al 1994c; Lundberg et al 1994b). These results 
suggest that NO production may contribute to repair of the epithelial barrier in some acute 
conditions. On the other hand, enhanced NO release via the induction and activation of iNOS
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in the colon may contribute directly to the mucosal damage by cytotoxic activity by a variety of 
mechanisms including inhibition of DNA synthesis, inhibition of mitochondrial function and 
intracellular iron release (Kwon et al 1991; Drapier & Hibbs, 1986). NO may cause tissue 
damage (McCall et al. 1989), freely interact with oxygen metabolites to yield nitrosating 
species and the formation of carcinogenic nitrosamines, shown to be generated by neutrophils 
during intestinal inflammation (Grisham et al 1992), may be the link with the increased 
frequency of colorectal cancer in UC. High levels of nitrosamines have been demonstrated in 
rectal dialysates of patients with active IBD (MacNaughton, 1993). In our study unstimulated 
HT-29 colonic epithelial cells were found to produce a basal amount of constitutive NO, while 
stimulation with cytokines induced a large amount of NO via iNOS expression. It is possible 
that small amounts of NO produced in colonic epithelial cells by constitutive NOS may act to 
preserve intestinal integrity, while the large amounts of NO produced via iNOS induction have 
a proinflammatory effect causing tissue injury.
In conclusion we have shown that human colonic epithelial cells express iNOS activity during 
the intestinal inflammation. This expression of human iNOS mRNA and nitrite generation in 
colonic epithelial cells, in vitro, is differently regulated by combinations of cytokines. If these 
results can be extrapolated to primary colonic epithelial cells then the hypothesis that NO and 
its metabolites are derived from epithelial cells may be of central pathogenic significance in 
intestinal inflammation. These results have stimulated us to search for naturally occurring 
agents, such as asymmetrical dimethylarginine which is found in renal failure (Vallance et al 
1992) and pharmacological agents that might inhibit the production of active nitrogen species 
and prove of value in the treatment of IBD. However, the use of NO generation inhibitors
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should proceed with caution. In UC, where increased NO synthase may contribute to 
vasodilatation, increase vascular permeability and damage of mucosal integrity, inhibitors of 
NO synthesis may be beneficial. In contrast, induction of NO in intestinal inflammation may in 
part serve to maintain colonic microvascular perfusion and may counteract the increased 
synthesis of vasoconstrictors and prevent microvascular coagulation by inhibiting platelet 
aggregation and adhesion (Boughton-Smith, 1994). Therefore, the use of NOS inhibitors could 
produce a NO deficiency in IBD causing a change in the pathophysiology of the disease. 
Whether the inhibition of NO production will be of therapeutic value in intestinal inflammation 
awaits further investigation of NO synthase isoforms and their differential induction, and 
probably the development of selective NOS inhibitors in order to inhibit the excessive NO 
production by the inducible NOS, without changing the physiological control of vascular tone 
and cellular integrity by the constitutive enzyme (Whittle, 1994).
The transmigration of selected populations of leukocytes is a multiple-step process and 
requires a series of co-ordinated signals, which include the expression and activation of 
adhesion molecules as well as the generation of a leukocyte specific chemotactic gradient by 
the cells of the extravascular component (Carlos & Harlan, 1994). However, the nature of the 
stimulus and the subsequent spectrum of chemotactic factors produced, determine the specific 
leukocyte population elicited to the inflammatory site (Baggiolini et al 1994). This hypothesis 
is supported by the characterisation of a large family of target cells specific chemotactic 
polypeptides, now collectively known as chemokines (Lindley et al 1993a; Lindley et al 
1993b). The IBD is characterised by the accumulation of inflammatory cells in the lamina 
propria and the infiltrate is composed predominantly of neutrophils, lymphocytes,
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monocytes/macrophages, and plasma cells. Several studies have documented the recruitment of 
neutrophils (Saverymuttu et al. 1986) and monocytes (Grimm et al. 1995) from the circulation 
to the sites of active intestinal inflammation. Leukocyte adhesion, migration and tissue 
infiltration is critical to the development of intestinal inflammation, thus an increasing interest 
exists in understanding the precise mechanisms involving chemokines, epithelial cells, and 
circulating leukocytes that are implicated in this process (Kam et al. 1995). To contribute to 
this hypothesis we examined the expression of chemokines in colonic epithelial cells and their 
modulation by cytokines. In immunohistochemical studies of colonic biopsies from patients 
with UC and infectious colitis we have clearly shown IL- 8  labelling in colonic epithelial cells 
in close association with sites of inflammation. In the same study H^ 8  expression was detected 
in colon adenocarcinoma cells from colon adenocarcinoma biopsies. In vitro, the study of 
chemokine expression by colonic epithelial cells revealed a marked production of IL- 8  after 
stimulation with pro-inflammatory cytokines, added alone or in combination. In contrast, the 
minimal requirement for the induction of the C-C chemokines, MCP-1 and RANTES was the 
combination of TNF-a and IFN-y, while no other cytokine or pair of cytokines were capable of 
producing these monocyte chemoattractant cytokines.
Similar results from other studies support our findings that colonic epithelial cells express 
chemokines and they are involved in the leucocyte recruitment during the inflammatory 
process. Elevated IL- 8  levels in inflamed mucosa from IBD patients were found in colonic 
biopsy specimens and this increased was correlated with grade of inflammation, number of 
neutrophils, tissue levels of IL-la and TNF-a (Mitsuyama et al. 1994; Mazzucchelli et al. 
1994), and macroscopic inflammation (Daig et al. 1996). IL- 8  has been recognised as an
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important chemoattractant for neutrophils in UC and CD (Raab et al. 1993; Mitsuyama et al. 
1994). Several studies have strongly implicated the colonic epithelium as an important source 
of IL- 8  in gut mucosa (Gibson & Rosella, 1995). Colonic epithelial cell lines and freshly 
isolated human intestinal epithelial cells were found to express IL- 8  following stimulation by 
inflammatory cytokines and LPS (Eckmann et al. 1993; Schuerer-Maly et al. 1994). This IL- 8  
induction by cytokines was independent from protein kinase A, did not require protein kinase 
C, but involved protein tyrosine kinase activity (Gross et al. 1995). Our results from the 
immunostaining study of colonic biopsies that colonic epithelial cells from uninvolved and 
normal bowel mucosa did not expressed IL 8 , while specimens from inflamed mucosa of UC 
and infectious colitis were positive for IL-8 , are in parallel with observation from other studies 
(Mazzucchelli et al. 1994), suggesting an important but not specific role for this chemokine in 
D3D.
In addition, in biopsies from patients with colon carcinoma we detected IL- 8  expression in 
colonic adenocarcinoma cells. IL- 8  was found to stimulate proliferation and it has been 
suggested that, while IL- 8  may have a role in attracting tumour-infiltrating leukocytes, colonic 
epithelial tumours may also derive a proliferative advantage from the capacity to generate IL 8  
(Schuerer-Maly et al. 1994). The capacity of colonic epithelial cells to secrete IL- 8  may be 
important in several respects. Firstly Strieter et al. in a series of papers have demonstrated that 
ELR expressing CXC chemokines are potent angiongenic factors expressed by tumour cells 
and that inhibition of these leads to suppression of tumour growth, conversely non ELR 
expressing CXC chemokines are angiostatic and inhibition of these leads to increased tumour 
growth (Strieter et al. 1995b; Strieter et al. 1995a; Koch et al. 1992). They are the first host
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cells that come in contact with luminal bacteria and therefore they function as an early host 
signalling system to the immune cells located in the underlying intestinal mucosa. Bacterial 
invasion of intestinal epithelial cells has been found to induce IL- 8  secretion by these cells 
(Eckmann et al 1993). Colonic epithelial cell-derived IL- 8  could initiate events recruiting 
leukocytes and leading to acute inflammation, in response to invasion by luminal pathogens. In 
addition, secretion of inflammatory cytokines and EL- 8  by other cell types, including 
macrophages (Friedland et al. 1992; Koch et al 1992) and neutrophils (McCain et al 1993), 
could amplify an ongoing acute immune response leading to chronicity. This hypothesis is 
consistent with our findings that DMa and TNF-a, cytokines predominantly released by 
activated macrophages during an acute inflammatory response, increase significantly IL- 8  
production by colonic epithelial cells. Intestinal epithelial cells have the capacity to express, in 
addition to IL-8 , a number of important mediators of an acute inflammatory response, including 
IL-la, IL-ip, and TNF-a (Eckmann et al 1993). These cytokines are also known to be 
produced by macrophages following LPS activation or active phagocytosis (Friedland et al
1992). The similarity of cytokines that can be expressed by colonic epithelial cells and 
macrophages suggests that they may share common functions and it may be that both cell types 
are a part of a non antigen specific immune system that can recognise and respond to a limited 
but important number of signals (Eckmann et al 1993; Friedland et al 1992).
Other chemokines that have been studied in IBD include gro-a, MCP-1, RANTES, MUM a  
and eotaxin. Gro-a levels were found significantly raised in active UC both compared to the 
normal control group and to active CD (Isaacs et al 1992). MCP-1 was detected elevated in 
macrophages, smooth muscle cells and endothelial cells, but not in epithelial cells in active
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IBD and they demonstrated that therapeutic agents, as 5-aminosalysilic acid and cyclosporin A, 
reduced MCP-1 production (Grimm et al. 1996). In contrast, other studies have revealed MCP- 
1 expression in human colonic epithelial cells (Franci et al. 1995; Jung et al. 1995; Rogler et al. 
1997; Kucharzik et al. 1997). Reinecker et al (1995) detected that intestinal epithelial cells also 
express MCP-1 constituitively and that this chemokine expression is increased by IL-lp 
stimulation. Constituitively MCP-1 expression could contribute to the attraction of lamina 
propria macrophages, which are commonly found in high numbers just beneath the epithelial 
layer (Mahida et al. 1989). Increased MCP-1 expression by epithelial cells may not only lead to 
the increased migration of macrophages into the lamina propria, but could also result in the 
activation of resident macrophages (Rollins et al. 1991). The secretion of a variety of injurious 
molecules from activated macrophages could cause epithelial cells damage. MCP-1 could also 
stimulate increased IL-ip production by monocytes (Jiang et al. 1992), which could create a 
circuit that would lead to a chronicity of inflammation within the intestinal mucosa. RANTES, 
another monocyte chemoattractant cytokine was found expressed in human intestinal mucosa 
in IBD (Mazzucchelli et al. 1996) and rotavirus infection induced increased RANTES 
production in intestinal epithelial cells (Casola et al. 1997). The increased RANTES expression 
in the intestinal mucosa of patients with IBD is of special interest, since the RANTES-mediated 
chemotactic activity for CD4+ “memory” T-lymphocytes (Schall et al. 1990; Proost et al. 
1996) may lead to up-regulation of mucosal immune responses and may exacerbate chronic 
inflammation. Data that have shown MCP-1 and RANTES mRNA expression in intestinal 
mucosa of control patients indicate that local expression of these two chemokines is not 
specific for IBD, but may allow the continued recruitment of immune cells responsible for an 
efficient immunological defence system in an anatomical site with a high antigenic presence
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(Mazzucchelli et al. 1996). The CC chemokines are not only involved in recruitment of T cells, 
but are also activators of T cells e.g. EL-2 receptor expression (Taub et al. 1995b; Turner et al. 
1996). Finally, intestinal epithelial cells were also found to express eotaxin (Lu et al. 1997), 
M IP-la (Rogler et al. 1997), and gro- a  (Casola et al. 1997).
Furthermore, epithelial cells from other organs, including skin (Barker et al. 1991; Gillitzer et 
al. 1991), lung (Standiford et al. 1990), kidney (Schmouder et al. 1992), and bladder were 
found to produce JL-S. Gro and MCP-1 is induced by inflammatory cytokines in human retinal 
pigmented epithelium (Stadnyk, 1994), and human renal cortical epithelial cells are a source of 
MCP-1 production (Schmouder et al. 1993). It is now clear that epithelial cells respond to 
infection or injury with chemokine secretion and serve as an early signal in immune and 
inflammatory reactions. These data suggest that a bi-directional communication exists between 
colonic epithelial cells and mucosal immune and inflammatory cells, which may be of 
paramount importance in gut mucosal defence.
There is a strong evidence that intestinal T-lymphocytes play crucial regulatory role in local 
mucosal immunity. Once absorbed, luminal antigens are processed and presented on the 
surface of antigen presenting cells in association with histocompatibility leukocyte antigen 
(HLA) class II molecules. Then, the processed antigen is recognized by antigen sensitive CD4+ 
cells resulting in their immune-activation and secretion of IL-2 and IFN-y, which induce CD4 
cells to undergo clonal expansion into memory and effector cells. Furthermore, IFN-y induces 
MHC class II expression on antigen presenting cells (APCs) and cytokine secretion from 
macrophages that continues to amplify the immune response (Przemioslo & Ciclitira, 1996).
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T(helper)-cells have been designated Thl and Th2 according to the pattern of cytokines they 
secrete (Mosmann & Coffman, 1989). Gross regulation of Thl and Th2 lymphocyte subsets 
may provide a basis for the mutually exclusive humoral and cell mediated response to antigen 
and cytokines released by one sub-group of T cells can down-regulate the secretion of 
cytokines from the other (Fiorentino et al 1989). A balance between the predominantly 
inflammatory Thl cytokine response and the more protective or humoral Th2 response is 
thought to play an important role in gut immune responses (Godkin et al. 1996). Recent data by 
Lukacs et al. indicate that CC chemokines may regulate the Thl/Th2 balance and thus regulate 
the immune responce (Karpus et al 1997). Some differences observed in the repertoire of T 
lymphocytes in gut of UC and CD patients suggest that they play a role controlling immunity 
into the intestinal mucosa in IBD (Greenewald & James, 1995). The concept that IBD is 
mediated by Thl and Th2 lymphokines is further supported by observations of increased tissue 
concentrations of IL-4 and IL-10 in UC but not in patients with CD (Sartor, 1994; Kolios & 
Nakos, 1995).
Intra-epithelial leukocytes have been reported in intestinal mucosa and these are a prominent 
characteristic of intestinal inflammation. Although their role remains uncertain it is probable 
that they are involved in a spectrum of immunological events within intestinal mucosa 
(Croitoru & Ernest, 1992; Cerf-Benussan & Gay-Grand, 1991). T-lymphocyte accumulation in 
lamina propria and infiltration of the colonic epithelium by these cells is a characteristic feature 
of the intestinal inflammation (Croitoru & Ernest, 1992; Cerf-Benussan & Gay-Grand, 1991). 
Intestinal epithelial cells take part in the mucosal immune response and play a role in antigen 
presentation to mucosal T cells (Shanahan, 1993; Greenewald & James, 1995) through their
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capacity to express HLA class II antigens (Mayer et al 1991). Expression of class II molecules 
was found increased on epithelial cells located near lymphoid follicles, which are increased in 
IBD (Chiba et al. 1994) and a disturbance in lymphoepithelial communication has been 
proposed in IBD (Shanahan, 1993).
To explore the role of T-cell derived cytokines in the regulation of the production of 
inflammatory mediators by colonic epithelial cells we studied three Th2 derived cytokines, 
namely E^13, IL-4 and IL-10, that have been proposed as anti-inflammatory agents (Minty et 
al 1993; Zurawski & De Vries, 1994; Moore et al 1993). In our study we examined, in vitro, 
the regulatory effect of Th2 derived cytokines on the iNOS and chemokine expression and 
activity induced by pro-inflammatory cytokine in the colonic epithelial cells HT-29. In addition 
we studied the effect of IL-13 on the cytokine induced nitrite production in cultures of human 
colonic mucosa biopsies. IL-13 and IL-4 were found to modulate iNOS as well as chemokine 
expression and activity in colonic epithelial cells. In marked contrast IL-10 had no any effect. 
IL-13 was found to inhibit significantly the IL-la/IFN-y and IL-1 a/IFN-y/TNF-a induced 
iNOS expression and activity by HT-29 cells. In addition IL-13 significantly reduced the nitrite 
production in cultures of colonic biopsies treated with “cocktail” of cytokines. IL-4 shared with 
IL-13 the inhibitory effect on iNOS expression and activity by activated HT-29 cells, but in 
marked contrast, it was not found to have the up-regulating effect of IL-13 on IL-loc/IFN-y- 
induced iNOS expression and activity. Similar, but independent biological functions of IL-4 
and IL13 suggest that IL-4 and IL-13 receptors are closely related but distinct (Callard et al 
1996). Interestingly, the latter observation in our present study suggest that these two cytokines 
share some, but not all, of their biological activities in the same type of cells. Differences have
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been reported in signal transduction by IL-4 and IL-13 (Keegan et al 1995) that could explain 
our findings. Both IL-4 and IL-13 markedly inhibited MCP-1 and RANTES expression and 
secretion by HT-29 cells, but they had no effect on IL- 8  production by colonic epithelial 
cytokines treated with combination of pro-inflammatory cytokines. Similarly in other studies, 
IL-4 and IL-13 were found to down-regulate MCP-1 expression in activated intestinal epithelial 
cells (Kucharzik et al 1997), while lack of inhibition of IL- 8  production in epithelial cell lines 
was detected after stimulation with the T cell derived cytokines IL-4 and IL-10 (Schuerer-Maly 
e ta l 1994).
The inhibitory effect of Th2 cell derived cytokines IL4 and IL-13, we found, is in parallel with 
findings from other studies. For example IL-13 is a potent suppressor of cytokine and 
chemokine expression by activated monocytes and macrophages (Minty et al 1993; McKenzie 
et a l 1993; Zurawski & De Vries, 1994; De Waal Malefyt et al 1993), and endothelial cells 
(Marfaing-Koka et al 1995). In addition IL-13 and IL-4 inhibit iNOS expression in human 
messangial cells, but IL-13 was suggested as a potential therapeutic tool, because it shows a 
wider temporal window of intervention (Saura et al 1996). Indeed, we have recently 
demonstrated that the mechanism of IL-13-induced inhibition of iNOS is via the activation of 
phosphatidylinositol 3-kinase (Wright et al 1997). Both IL-4 and IL-13 are considered as anti­
inflammatory cytokines. However, both of these cytokines also have a pro-inflammatory effect 
because each enhances B cell production of IgE (Defrance et al 1994). In our study, for first 
time IL-13 was found to express a new inflammatory property. It was found to enhance the IL- 
la-induced IL- 8  expression and secretion in HT-29 cells, and IL-4 was detected to have the
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same effect on HT-29 cells (Dr Adrian Minty, personal communication), suggesting a 
bifunctional effect of these cytokines on the colonic epithelial cells.
Interleukin-10 is a 35 kDa homodimeric cytokine, which was originally described as Th2-cell- 
derived cytokine. Recent studies have shown that IL-10 is produced by a variety of cells, 
including Th2 cells, Ly-1 B cells, mast cells and cells of the macrophage lineage (Moore et al.
1993). This cytokine at concentrations of 10 ng/ml or less is an effective inhibitor of cytokine 
generation by IFN-y and/or LPS stimulated human monocytes (De Waal Malefyt et al. 1991), 
prostaglandin E2 production by IL-1 or LPS activated human monocytes (Poole et al. 1995) and 
chemokine generation by polymorphonuclear leukocytes treated with LPS (Kasama et al.
1994). IL-10 has been found to inhibit NO production by mouse activated macrophages 
(Oswald et al. 1992; Cenci et al. 1993). Thus IL-10 is considered to be a modulator of the 
inflammatory response. However, we found that IL10 throughout the concentration range of
0.1 to 30 ng/ml had no effect on pro-inflammatory cytokine-induced iNOS expression and 
activity by the colonic epithelial cell line HT-29. Similarly, IL-10 had no any effect on 
chemokine generation by HT-29 cells, in marked contrast with the other T cell derived 
cytokines, IL-4 and IL-10. Thus, the expression of "chronic enterocolitis" phenotype in IL-10 
deficient mice (Kahn et al. 1993) is probably not via the loss of a direct suppressive action of 
IL-10 on colonic epithelial cells, but is probably due to the loss of the suppresive action of ILr 
10 on T cells and monocytes. IL-10 was found to down regulate effectively the enhanced 
secretion as well as mRNA levels of IL-1 p and TNF-a by IBD peripheral monocytes and 
intestinal lamina propria mononuclear cells. In addition, IL-10 was capable of inducing IL-lra 
secretion in both peripheral monocytes and intestinal lamina propria mononuclear cells and
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restoring the decreased IL-1 ra/IL-1 (3 ratio in IBD to normal levels (Schreiber et al. 1995b). This 
protective effect of IL-10 was found transitory, suggesting that IL-10 was able to down-regulate 
the local inflammatory reactions by inhibiting the synthesis if inflammatory cytokines, but did 
not reverse the inflammatory potential of the immune cells (Goldman et al. 1997). Therefore, 
primary defect in IL-10 expression may be a failure to control normal intestinal immune 
responses, leading to chronic inflammation via continuous overproduction of pro-inflammatory 
cytokines such as IL-1 and TNF-a (Kahn et al. 1993). These findings propose that H^IO, 
because of its ability to inhibit monocyte/macrophage activation it may be a useful therapy in 
IBD (Schreiber et al. 1995b; Duchmann et al. 1996).
In conclusion we found, that colonic epithelial cells produce a spectrum of inflammatory 
mediators, depending on the stimuli and the duration of the stimulation, as they expressed for 
example an early signal for IL- 8  and a delay expression of C-C chemokines and NO 
production. In addition T cell derived cytokines were found to have a differential effect on the 
colonic epithelial cells activation. Taken together our results suggest that T cell derived 
cytokines can have a bifunctional role in the regulation of inflammatory mediators by colonic 
epithelial cells, depending upon the stimulus and probably the phase of the disease. This 
differential effect of T cells on the colonic epithelial cell inflammatory response, via a cytokine 
network, could play an important role in the inflammatory process and define the remission or 
the chronicity of the intestinal inflammation.
Studies of the migration of human intestinal intraepithelial lymphocytes (IEL) have shown that 
IELs first are attracted by chemokines in the lamina propria and then by chemokines in the
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epithelium (Ebert, 1995). Colonic epithelial cells producing chemokines, as MCP-1, RANTES, 
and IL 8 , in response to cytokine activation and bacterial invasion are capable of drawing IELs 
to the epithelium. RANTES with its chemotactic activity for CD4+/CD45RO+ ‘memory’ T- 
lymphocytes (Schall et al 1990) and MCP-1 with its property of T lymphocyte chemoattraction 
(Carr et a l 1994; Taub et al 1995a) contribute in T lymphocyte migration into the epithelium. 
In addition, IL-8 , originally described as a neutrophil chemoattractant cytokine, has been shown 
to attract T lymphocytes (Larsen et al 1989). IL- 8  and RANTES were found to be the most 
attracting cytokines in intestinal epithelium, attracting large fractions of IELs, mainly because 
of chemotaxis rather than chemokinesis (Ebert, 1995). Thus, our in vitro results suggest that 
colonic epithelial cells producing chemokines are involved in T cells recruitment and 
participate in a bi-directional communication with T lymphocytes. An imbalance in this 
communication has been suggested to be implicated in pathogenesis of IBD (Schreiber et al 
1995a; West et al 1996). For example, differences of IL-4 and IL-10 production in CD 
compared to UC have been considered responsible for the failure to detect induction of iNOS 
in CD (Boughton-Smith et al 1993; Boughton-Smith, 1994) and therapeutic approach with T 
cell derived cytokines has been proposed (Kucharzik et al 1996). It will be important to 
determine whether colonic epithelial cells from normal individuals and from patients with IBD 
also respond to the same stimuli. This might provide useful information on the leukocyte 
recruitment in the colonic epithelium during intestinal inflammation and help with the 
understanding of the pathogenesis of IBD. In vivo it is likely that the optimal cocktail of 
inflammatory cytokines is present in gut epithelium and capable of inducing chemokine and 
iNOS activity by colonic epithelial cells. Strategies to increase apical epithelial concentrations 
of T cell derived cytokines could provide an anti-inflammatory approach to intestinal
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inflammation. Alternatively identification of IL-4, IL-10, and TL-13 signal transduction system 
responsible for the common inhibitory effect of these cytokines on inflammatory mediators 
expression should reveal novel targets for therapeutic intervention of IBD.
The mechanisms of inflammation represent an obscure network of cytokine-immune cell 
interactions, which are under a constant regulation, and a dynamic balance must exist in order 
to maintain an harmony between the ability to respond to noxious antigens or stimuli, while at 
the same time to limit and down-regulate this cascade of reactions to prevent it from producing 
excessive injury (McCarthy, 1994). Recent studies support the hypothesis that the 
pathogenesis of IBD involves a dysfunction of the intestinal immune system due to an 
imbalance between activating and suppressing cellular mediators, which results in a chronic 
inflammation (Kam et al 1995). The intestinal mucosa is composed of several cell 
population, among them epithelial cells, immune cell populations and fibroblasts. It is 
presumed that complex mechanisms exist to maintain an homeostasis and simultaneously to 
co-ordinate an interaction between these cell populations. Nevetherless, it is clear that a 
intricate network of soluble mediators is essential in regulating the cascade of reactions from 
the recognition of the stimuli to the inflammatory process. The intestinal epithelial cells 
constitute a barrier between the environment and the host tissue and they are the first cells to 
come in contact with many pathogens, thus when invaded by external antigens can function as 
an early warning system to cells in the underlying mucosa, indicating to the host that the 
mucosal barrier has been penetrated. From this position intestinal epithelial cells might play a 
crucial role as an outpost of the immune system located in the underlying intestinal mucosa and 
soluble mediators produced by these cells might function as an early signal to neighbouring
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immune cells and are involved in the recruitment of cells during the inflammatoiy response. 
Intestinal epithelium is, however, more than a physical barrier and the front of the immune 
system. An emerging role for the constitutive secretion of cytokines by colonic epithelial cells 
is to support the growth and development of non epithelial cells in the microenvironment, in 
particular, lymphocytes (Stadnyk, 1994). It is involved in the maintenance of homeostasis 
secreting effector molecules, as NO, which for example serves to maintain the colonic mucosal 
vascular perfusion (Boughton-Smith, 1994). Finally, it participates in repair and healing 
mechanisms producing chemokines that are necessary for the repair of tissue damage (Miller & 
Krangel, 1992).
The elucidation of immunoinflammatory process in colonic epithelium combining basic 
research and pharmacokinetic studies in patients could offer the best approach in the 
development of new diagnostic test and potential new therapeutic strategies for the effective 
treatment of IBD. Interrupting or inhibiting the secondary amplification of inflammatory 
response with selective interventions that target the intestinal cytokine network or other 
mediators of inflammation will prove of value in the manipulation of intestinal inflammation.
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5. CONCLUSIONS
In this study human colonic epithelial cells were found to produce important 
inflammatory mediators, such as nitric oxide and members of the recently identified 
chemokine superfamily. These findings provide support for the suggestion that the 
colonic epithelial cells must be considered as a potentially important source of soluble 
mediators in intestinal inflammation. Several conclusions can be drawn from this study. 
Particularly:
1. Colonic epithelial cells have functional receptors for pro-inflammatory and T cell- 
derived cytokines, which are coupled to a regulation of inflammatory mediators 
generation, probably contributing to the perpetuation and/or the initiation of the 
intestinal inflammation.
2. The large amounts of NO that produced from stimulated colonic epithelial cells and 
the iNOS immunostaining of the epithelial cells in colonic biopsies suggest that these 
cells but not mononuclear and polymorphonuclear leukocytes may be the major source 
of NO production in UC. In addition, the basal constitutive production of NO by 
unstimulated colonic epithelial cells indicates that these cells might participate in the 
homeostatic role of NO in the intestinal physiology.
3. The production of chemokines by intestinal epithelial cells might be important in the 
inflammatory process. In this study colonic epithelial cells did not express chemokines 
unless challenged with cytokines and in addition IL- 8  was found to be expressed in 
inflamed but not normal colonic mucosa. This capacity of colonic epithelial cells to 
secrete chemokines in response to inflammatory stimuli may be important in the intra- 
epithelial and lamina propria infiltration by neutrophils and lymphocytes during the 
intestinal inflammation and indicates a communication between the colonic cells and 
the immune cells located in the underlying intestinal mucosa.
4. The inhibitory effect of IL-13 and IL-4, on chemokine and nitric oxide production by 
colonic epithelial cells proposes an anti-inflammatory role of T cell derived cytokines
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in the intestinal inflammation. Interestingly, the differential effect of IL-13 and IL-4 on 
chemokine expression by HT-29 cells suggests that, when considering cytokine 
network, T cell derived anti-inflammatory cytokines may have a bi-functional role, 
depending upon the stimulus and the cellular source of chemokines. This dual effect of 
IL-13 and IL-4 on chemokine expression by colonic epithelial cells may play a crucial 
role in different stages of the inflammatory process in IBD and contribute to the 
continuation or the remission of inflammation.
Accepting the above data there is a strong evidence that colonic epithelial cells may play 
an active role in the inflammatory response, via the generation of inflammatory mediators 
and T-cell derived cytokines may modulate this process and have a crucial role in the 
pathogenesis of IBD. These observations suggest a further comprehensive study in order 
to characterise the spectrum of chemokine and chemokine receptor expression in normal 
and IBD colonic mucosa and to determine the modulatory effect of T cell derived 
cytokines and the mechanistic pathway of this modulation of chemokine expression on 
colonic epithelium.
In addition, we have shown that human colonic epithelial cells express iNOS activity during 
the intestinal inflammation, which is differently regulated by combinations of cytokines. If 
these results can be extrapolated in vivo then the hypothesis that NO and its metabolites are 
derived from epithelial cells may be of central pathogenic significance in intestinal 
inflammation. These results propose further search for naturally occurring and 
pharmacological agents that might inhibit the production of active nitrogen species and 
prove of value in the treatment of IBD. Whether the inhibition of NO production will be of 
therapeutic value in intestinal inflammation awaits further investigation of NO synthase 
isoforms, and probably the development of selective NOS inhibitors in order to inhibit the 
excessive NO production by the inducible NOS, without changing the physiological control 
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